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SUMMARY 
 
Mismatch repair (MMR) evolved to repair mismatches that escaped the proofreading 
activities of replicative DNA polymerases. MMR plays a major role in maintaining 
genomic stability by preventing accumulation of mutations, and contributes to other 
DNA repair pathways such as homologous recombination. It also participates in the 
response to DNA damaging agents. 
The subject of my PhD work was to study the role of MMR as an in vivo coordinator of 
cellular responses to genotoxic treatments, in particular to the methylating agent N-
methyl-N’-nitro-N-nitrosoguanidine (MNNG), a monofunctional alkylating agent that 
methylates many macromolecules inside living cells. At clinically–relevant concentrations, 
the cytotoxicity of MNNG is exerted through the formation of methyl monoadducts on 
DNA bases. Similar to other SN1-type alkylating agents, MNNG modifies predominantly 
the N7 and N3 positions of purine rings. Although N7-methylguanine and N3-
methyladenine are the most abundant adducts, they are efficiently removed by base 
excision repair and, at the concentrations used, do not cause significant cytotoxicity. The 
single adduct responsible for cell killing is O6-methylguanine (6meG), which comprises 
only ∼8% of all methylations in the DNA. Interestingly, the presence of 6meG in the 
DNA is not toxic per se. Under normal conditions, the methyl group at the O6 position 
of guanine is rapidly removed by methylguanine methyl transferase (MGMT), which 
reverts 6meG to G. However, in the absence of MGMT, such as in many tumours, 6meG-
containing DNA persists until replication. When the polymerase encounters a 6meG in the 
template, it preferentially incorporates a thymidine into the nascent strand, thus creating 
a mismatch. It is believed that MMR-mediated processing of such 6meG/T mismatches 
ultimately kills the cell, by an unknown mechanism. 
In an attempt to elucidate the mechanism of MMR-mediated cell killing, I used the 293T 
Lα cell line (Cejka et al., 2003), the MMR status of which can be modulated by 
doxycyclin. In the presence of this drug the cells shut off the expression of hMLH1 and 
become MMR-deficient and resistant to MNNG treatment. Unexpectedly, low levels of 
MLH1 expression restored MMR proficiency as assessed by in vitro repair assays, but not 
MNNG sensitivity. In order to sensitize cells to MNNG, the full complement of MLH1 
was required. After treatment, such cells arrested in the G2/M phase of the cell cycle, 
although the initial levels of DNA damage in both MMR-proficient and -deficient cells 
was identical. 
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In order to study the role of MMR proteins in the activation of the cell cycle checkpoint, 
the 293T Lα cells were treated with MNNG and the subsequent activation of DNA 
damage signalling pathways was assessed. We showed (Stojic et al.) that MNNG 
treatment induced a cell cycle arrest that was absolutely dependent on functional MMR. 
Unusually, the MMR-proficient cells arrested only in the second G2 phase after 
treatment. Downstream targets of both ATM and ATR kinases were modified, but only 
the ablation of ATR, or the inhibition of CHK1, attenuated the arrest. The checkpoint 
activation was accompanied by the formation of nuclear foci containing the signaling and 
repair proteins ATR, the S*/T*Q substrate, γ-H2AX, and replication protein A (RPA). 
The persistence of these foci implied that they might represent sites of irreparable 
damage. 
Analysis of the MMR-dependent signaling pathways activated by MNNG suggested that 
the cell cycle checkpoint was not activated directly. The delay in its activation and the 
appearance of RPA foci suggested that the initial damage was being processed into 
secondary lesions that triggered the checkpoint and caused cytotoxicity. I wanted to 
identify the pathways downstream of the MMR-dependent processing of MNNG 
damage and learn how they contribute to cell death. I was able to show that the initial 
recognition of 6meG-containing mispairs by MMR happened in the first S-phase after 
treatment and this provoked cytologically-visible uncoupling of replication and repair 
foci. Although 6meG is recognized already in the first cell cycle, its presence is required in 
both cell cycles after MNNG treatment for cell cycle checkpoint activation, indicating 
the involvement of another pathway. Activation of the MRN complex was MMR-
dependent, but not necessary for the arrest or overall survival. In vivo activation of 
homologous recombination (HR) depended on MMR status and the sites of ongoing 
recombination contained the ssDNA-binding protein RPA. Lack of HR rendered cells 
extremely sensitive to MNNG. Moreover, the cell cycle arrest in HR-deficient cells was 
activated already in the first cycle after treatment. This finding suggests that progression 
through the first cell cycle requires homologous recombination, possibly to rescue the 
intermediates created by MMR processing of 6meG-containing mismatches that arose 
during the first replication. 
MMR is highly conserved from bacteria to humans and the sensitivity to 6meG –inducing 
agents is its hallmark. The finding that MMR status did not affect the sensitivity of 
Saccharomyces cerevisiae to MNNG was therefore unexpected. One possible explanation for 
this difference was the differential ability of yeast cells to process the secondary lesions 
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created by MMR. As I showed for mammalian cells, homologous recombination 
contributes to cell survival after MNNG treatment. Given that HR is much more 
efficient in yeast as compared to mammalian cells, this difference could account for 
MNNG resistance in yeast. Indeed, HR inactivation sensitized S. cerevisiae to MNNG and, 
as in human cells, defects in MMR rescued this sensitivity. This finding pays witness to 
the importance of secondary pathways involved in MMR-mediated cytotoxicity. 
 
 
 
Summary
6
ZUSAMMENFASSUNG 
 
Die Fehlpaarungs-Reparatur (MMR) erfüllt die Aufgabe, falsch gepaarte Basen, welche 
nicht durch die Korrektur-Lesefunktion der replikativen DNA-Polymerasen erkannt 
werden, zu reparieren. Dieses Reparatur-System spielt eine wichtige Rolle in der 
Aufrechterhaltung der genomischen Stabilität, indem es Ansammlungen von Mutationen 
verhindert und massgeblich an anderen DNA-Reparaturwegen wie homologe 
Rekombination beteiligt ist. Zudem kommt MMR eine grosse Bedeutung in der Antwort 
auf DNA-schädigende Wirkstoffe zu. 
Das Thema meiner Doktorarbeit war es, die Rolle der MMR als in vivo-Koordinator der 
zellulären Antworten auf die genotoxische Behandlung mit dem methylierenden 
Wirkstoff N-methyl-N’-nitro-N-nitrosoguanidin (MNNG) zu studieren. MNNG ist eine 
monofunktionale alkylierende Substanz, welche zahlreiche Makromoleküle in der 
lebenden Zelle methyliert. Die Zell-Toxizität bei der Behandlung mit klinisch relevanten 
MNNG-Konzentrationen wird durch die Bildung von Methyl-Monoaddukten an DNA-
Basen vermittelt. Analog zu anderen SN1-alkylierenden Wirkstoffen modifiziert auch 
MNNG hauptsächlich die N7- und N3-Positionen von Purinringen. N7-Methylguanin 
und N3-Methyladenin sind zwar die häufigsten Addukte, werden aber effizient von der 
Basen-Exzisions-Reparatur repariert und verursachen deshalb keine signifikante Zell-
Toxizität. O6-Methylguanin (6meG) hingegen, welches nur für  ∼8% aller Methylierungen 
in der Zelle verantwortlich ist, besitzt als einziges Addukt die Fähigkeit, die Zelle zu 
töten. Interessanterweise ist die Präsenz von 6meG per se nicht toxisch. Unter normalen 
Bedingungen entfernt Methylguanin-Methyltransferase (MGMT) die Methyl-Gruppe an 
der O6-Position von Guanin rasch und effizient, was eine Revertierung von 6meG zu G 
zur Folge hat. Fehlt MGMT hingegen, was in manchen Tumoren zu beobachten ist, 
persistiert die 6meG-enthaltende DNA bis zur Replikation. Wenn die Polymerase auf ein 
6meG in der Matrize stösst, wird vorzugsweise ein Thymidin in den wachsenden Strang 
eingebaut und somit eine Fehlpaarung verursacht. Es wird angenommen, dass MMR 
solche 6meG/T-Fehlpaarungen prozessiert und die Zelle durch einen bislang unbekannten 
Mechanismus in letzter Konsequenz zu töten vermag. 
Für den Versuch, dem Mechanismus der MMR-abhängigen Zelltötung auf die Spur zu 
kommen, arbeitete ich mit der 293TLα-Zell-Linie (Cejka et al., 2003), in welcher der 
MMR-Status mit Hilfe von Doxyzyklin moduliert werden kann. In Anwesenheit dieser 
Droge wird die Expression von hMLH1 ausgeschaltet, die Zellen werden MMR-defizient 
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und gleichzeitig resistent gegenüber MNNG. In in vitro Reparatur-Versuchen konnte 
gezeigt werden, dass ein niedriger MLH1-Pegel zwar ausreicht, um die MMR-Kapazität 
wieder herzustellen, nicht aber um die Empfindlichkeit gegenüber MNNG auszubilden. 
Um die Zellen wieder MNNG-sensitiv zu machen benötigen diese das ganze 
Komplement an MLH1. 
MMR-profiziente Zellen mit dem vollen Komplement an MLH1, nicht aber MMR-
defiziente Zellen, arretieren nach MNNG-Behandlung in der G2/M-Phase des 
Zellzyklus, obgleich der induzierte DNA-Schaden in MMR-profizienten und MMR-
defizienten Zellen identisch ist. 
Um die Rolle der MMR-Proteine in der Aktivierung des Zellzyklus-Kontrollpunktes zu 
studieren wurden 293TLα-Zellen mit MNNG behandelt und die dadurch induzierte 
Aktivierung des DNA-Schaden-Signalweges beurteilt. Wir konnten zeigen (Stojic et al.), 
dass die Behandlung mit MNNG eine Zellzyklus-Arretierung auslöst, welche aber ein 
voll funktionstüchtiges MMR-System voraussetzt. Interessanterweise arretieren MMR-
profiziente Zellen nur in der zweiten G2-Phase nach der Behandlung. Nachgeordnete 
Ziele der beiden Kinasen ATM und ATR sind dabei modifiziert, wobei nur die Ablation 
von ATR oder die Inhibition von CHK1 die Arretierung abschwächt. Nebst der  
Kontrollpunkt-Aktivierung konnte die Formation von nuklearen Fokussen beobachtet 
werden, welche die Signal- und Reparaturproteine ATR, S*/T*Q-Substrat, γ-H2AX und 
das Replikationsprotein A (RPA) enthalten. Die Persistenz dieser Fokusse deutet an, dass 
es sich hierbei um Orte mit irreparablem Schaden handeln könnte. 
Die Analyse des durch MNNG induzierten MMR-abhängigen Signalweges lässt die 
Vermutung aufkommen, dass der Zellzyklus-Kontrollpunkt nicht direkt aktiviert wurde. 
Der Verzug in der Aktivierung und das Auftreten der RPA-Fokusse deutet an, dass der 
anfängliche Schaden prozessiert und in sekundäre Läsionen umgewandelt wurde, welche 
ihrerseits den Kontrollpunkt auslösten und die Zell-Toxizität verursachten. Ich wollte die 
nachgeordneten Wege der MMR-abhängigen Prozessierung von MNNG-induzierten 
Schäden identifizieren und schlussendlich verstehen, wie dieses Signalnetzwerk den 
Zelltod beeinflusst. Ich konnte zeigen, dass die Ersterkennung von 6meG-enthaltenden 
Fehlpaarungen durch die MMR-Maschinerie in der ersten S-Phase nach der Behandlung 
mit MNNG stattfindet und eine cytologisch sichtbare Abkoppelung der Replikations- 
und Reparaturfokusse provoziert. Obschon 6meG bereits im ersten Zellzyklus erkannt 
wird, muss es während beider Zellzyklen nach MNNG-Behandlung vorhanden sein, um 
den Zellzyklus-Kontrollpunkt aktivieren zu können, was für eine zusätzlich involvierte 
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Signalkaskade spricht. Aktivierung des MRN-Komplexes ist MMR-abhängig, aber weder 
für die Arretierung noch das gesamte Überleben notwendig. In vivo-Aktivierung von 
homologer Rekombination (HR) hängt vom MMR-Status ab und Orte mit aktiver 
Rekombination enthalten das an ssDNA bindende Protein RPA. Zellen ohne 
funktionstüchtige HR sind extrem empfindlich gegenüber MNNG. Zudem ist die 
Zellzyklus-Arretierung in HR-defizienten Zellen bereits im ersten Zellzyklus nach der 
Behandlung aktiviert. Diese Beobachtung lässt vermuten, dass homologe Rekombination 
für die Progression durch den ersten Zellzyklus nötig ist, möglicherweise um 
Zwischenprodukte, welche durch die MMR-Prozessierung von 6meG-enthaltenden 
Fehlpaarungen während der ersten Replikation entstehen, zu retten. 
MMR ist hochkonserviert in Bakterien bis zum Menschen und trägt das Kennzeichen 
hoher Empfindlichkeit gegenüber 6meG-induzierenden Wirkstoffen. Deshalb erstaunt die 
Tatsache, dass in Saccharomyces cerevisiae der MMR-Status keinerlei Einfluss auf die 
MNNG-Sensitivität hat. Eine mögliche Erklärung für diese Diskrepanz ist die 
unterschiedliche Fähigkeit von Hefezellen, sekundäre MMR-Läsionen zu prozessieren. 
Konsistent mit meinen Resultaten in Säugerzellen trägt homologe Rekombination 
massgeblich zum Überleben der Zelle nach Behandlung mit MNNG bei. Da HR in 
Hefezellen verglichen mit Säugerzellen sehr viel effizienter ist, könnte dieser Unterschied 
die MNNG-Resistenz in Hefe erklären. In der Tat reagiert S. cerevisiae mit inaktivierter 
HR sehr empfindlich auf MNNG und – analog zu den menschlichen Zellen – kann diese 
Sensitivität mit einem Defekt im MMR-System gerettet werden. Dieses Resultat zeigt 
deutlich die Wichtigkeit der sekundären Signalwege, welche in die MMR-abhängige Zell-
Toxizität involviert sind. 
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1 INTRODUCTION 
 
 
"The possibility that genes were subject to the hurly-burly of both insult and clumsy efforts to reverse the 
insults was unthinkable." 
Frank Stahl 
(Friedberg, 1997) 
 
 
Since the perception of DNA as a highly stable macromolecule changed, major insights 
into the metabolism of the “molecule of life” have been discovered. Indeed, it became 
apparent that DNA in all living organisms is constantly subjected to alterations by 
endogenous metabolites and exogenous DNA-damaging agents. More interestingly, 
studies of three “R’s” of DNA metabolism – Replication, Recombination and Repair 
revealed the existence of ingenious mechanisms for tolerating and repairing the damage, 
thus making DNA the only biomolecule that is specifically repaired – all others being 
replaced. 
The importance of repair mechanisms becomes evident in multiple human syndromes 
related to inefficient repair of certain types of DNA damage. Failure of these 
mechanisms can lead to serious consequences (Table 1) but also provide valuable insights 
into the detailed mechanisms of their actions. 
DNA damage types include covalent changes of DNA structure and non-covalent 
anomalous structures, including base-pair mismatches, loops and bubbles arising from 
strings of mismatches. Some of these can arise during normal cell growth and replication, 
while others are usually consequences of the action of exogenous agents. During 
replication, recombination and repair, fork structures, bubbles, Holliday structures, 
stalled and collapsed replication forks and other non-duplex DNA forms are generated, 
providing high-affinity sites for repair proteins.  
Oxidation, alkylation, deamination, depurination and depyrimidation of DNA create ∼104 
mutagenic DNA base lesions per day in each human cell (Lindahl, 1993). Damage to 
DNA bases occurs constantly and it can stem from numerous sources: by-products of 
natural aerobic respiration, environmental chemicals or chemotherapeutic drugs, 
ultraviolet (UV) light or ionizing radiation (IR). Besides creating reactive oxygen species, 
UV radiation gives raise to specific products such as cyclobutane pyrimidine dimmers 
and (6-4) photoproducts. Chemicals form various base adducts, either bulky ones, such 
as those generated by reaction with large polycyclic hydrocarbons or simple ones, such as 
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6-methylguanine, 3-methyladenine or 7-methylguanine generated by alkylating agents. 
Large proportion of chemotherapeutic drugs, including cisplatin, mitomycin C, psoralen, 
nitrogen mustard and adriamycin, form base adducts. 
DNA backbone damage includes abasic sites and single and double strand breaks. Abasic 
sites are generated spontaneously, by the formation of unstable base adducts or by base 
excision repair. Single-strand breaks are produced either directly by damaging agents, or 
single-strand breaks and gaps in the range of 1-30 nucleotide are produced as 
intermediates of base- and nucleotide excision repair. Ionizing radiation and other DNA-
damaging agents form double-strand breaks. In addition, double-strand breaks are 
essential intermediates in recombination and perhaps during transposition. 
Bifunctional agents such as cisplatin, nitrogen mustards, mitomycin C, and psoralen form 
interstrand cross-links and DNA-protein cross-links. 
As the molecule that guards the information necessary for the life of the cell, DNA 
undergoes many repair processes, which ensure its integrity. On the other hand, 
evolution requires genetic diversification, so mutations, another important consequence 
of DNA damage, must be promoted at levels that will allow evolutionary changes. DNA 
thus balances between a requirement for genomic stability and a necessity for instability. 
 
In the next paragraphs I will discuss major DNA repair pathways with more detailed 
description of mismatch repair and homologous recombination as the major pathways 
studied during my PhD project. 
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 Table 1. Human syndromes with defective genome maintenance mechanisms.  
(Hoeijmakers, 2001) 
 
SYNDROME 
Affected 
pathway / gene 
Main type of 
genome instability 
Major Cancer 
predisposition 
Xeroderma pigmentosum 
(XP) 
NER, TCR / XPA-
XPG 
Point mutations 
UV-induced skin 
cancer 
Cockayne syndrome (CS) TCR / CSA, CSB Point mutations None 
Trichothiodystrophy 
(TTD) 
NER / TCR Point mutations None 
Ataxia telangiectasia (AT) DSB repair / ATM Chromosome aberrations  Lymphomas 
AT-like disorder (ATLD) 
DSB repair / 
MRE11 
Chromosome aberrations  Lymphomas 
Nijmegen breakage 
syndrome (NBS) 
DSB repair / NBS1 Chromosome aberrations  Lymphomas 
Familial breast cancer 
predisposition 
Recombination, 
DSB repair / 
BRCA1/2 
Chromosome aberrations  
Breast and ovarian 
cancer 
Werner syndrome (WS) DSB repair / WRN Chromosome aberrations  Various cancers 
Bloom syndrome (BS) 
Recombination, 
DSB repair / BLM 
Chromosome aberrations 
/ SCE 
Leukaemia, 
Lymphomas 
Rothmund-Thompson 
syndrome (RTS) 
Recombination, 
DSB repair / 
RECQL4 
Chromosome aberrations  Osteosarcoma 
Ligase IV deficiency 
NHEJ / DNA ligase 
IV 
Recombination fidelity Leukaemia  
Fanconi anaemia (FA) 
DNA cross-link 
repair / FANCA-G 
Chromosome aberrations  Leukaemia 
Seckel syndrome 
DNA damage 
checkpoint / ATR 
 None 
Hereditary non-polyposis 
colon cancer (HNPCC) 
MMR / MSH2/6 
and MLH1/PMS2 
Microsatelite instability 
(MI) 
Colorectal cancer 
Xeroderma pigmentosum 
variant (XPV) 
TLS / DNA 
polymerase η 
 
UV-induced skin 
cancer 
Radiosensitive severe 
combined 
immunodeficiency 
NHEJ / Artemis Chromosome aberrations  Lymphomas 
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1.1 DNA DAMAGE REPAIR PATHWAYS 
 
In order to protect their genomes from the deleterious consequences of DNA damage, 
cells have evolved multiple pathways that help coordinate cell growth, division and 
removal of the damage. General effect and consequence of DNA damage can be 
categorized into four types of responses (Figure 1): DNA repair, DNA damage 
checkpoints, transcriptional response and apoptosis (Sancar et al., 2004). Defects in any 
of these pathways may cause genomic instability. Each of these four pathways should not 
be taken as independent order of events, but rather as interconnected networks.  
 
Figure 1. DNA damage response reactions in mammalian cells. 
The four responses (DNA repair, transcriptional response, DNA damage checkpoints, and apoptosis) may 
function independently, but frequently a protein primarily involved in one response may participate in 
other responses. 
 
In contrast to enzymes with simple substrates, proteins that bind to a specific sequence 
or structure in DNA, must recognize their targets in a vast excess of related structures. 
Damage sensors not only bind undamaged DNA in search of damage, but they also 
contact undamaged DNA during specific binding. Therefore, they generally have non-
negligible affinity for undamaged DNA. Since the amount of undamaged DNA vastly 
exceeds that of damaged DNA, DNA damage sensors spend far more time associated 
with undamaged DNA than with damaged DNA. Yet, these sensors carry out their 
specific functions in the presence of high concentrations of non-specific DNA, because 
damage recognition is usually a multistep reaction. There is thus a low probability that all 
of the steps will occur subsequent to the initial contact with undamaged DNA. However, 
even with multistep recognition, the discrimination between undamaged and damaged 
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DNA is not absolute, so that neither DNA repair nor the DNA damage checkpoints 
should be envisioned as operated by molecular switches. Rather, both processes are 
operative at all times, but the magnitudes of the repair or checkpoint reactions are 
amplified by the presence of DNA damage (Sancar et al., 2004). 
Depending on the type of DNA damage, different repair pathways are activated. 
Examples of abnormal DNA structures that induce such responses are shown in Figure 
2. 
 
 
Figure 2. DNA lesions and structures that elicit DNA response reactions 
 
Repair mechanisms can be grouped into five categories: direct repair of damage, Base 
Excision Repair (BER), Nucleotide Excision repair (NER), Mismatch Repair (MMR), 
double-strand break repair and although not repair per se, DNA damage bypass. 
In some cases, certain types of adducts can be addressed by more than one repair 
pathway and sometimes two different pathways might be necessary to fully repair the 
damage. Repair reactions in vivo are usually multistep processes with highly 
interconnected pathways. 
Direct repair  Direct repair 
Nucleotide Excision  
Repair (NER)  
Base Excision  
Repair (BER)  
Recombinational Repair  
(HR, NHEJ)  
Cross-link  
Repair  
Mismatch Repair 
(MMR) 
Base mismatches 
Insertions 
Deletions 
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1.1.1 Direct repair 
 
Direct repair, or direct reversal is the simplest mechanism, which involves a single 
enzyme reaction for removal of certain types of DNA damage. Although it might seem 
that reversal of damage would be the easiest way to correct the damage, in most cases the 
reverse reaction is not possible for thermodynamic or kinetic reasons. In addition, direct 
reversal mechanisms of DNA repair require that each type of chemical alteration be 
addressed by a dedicated enzyme. What the cell needs are more general mechanisms 
capable of correcting different sorts of chemical damage with a limited toolbox. This 
requirement is met by the mechanisms of excision repair. 
Maybe that’s the reason why there are only four examples of the direct repair enzymes: 
photoreactivation by photolyases, alkyl transfer by DNA methyl transferases, oxidative 
demethylation and ligation. Photolyase is not present in many species, including humans, 
whereas methylguanine DNA methyltransferase has nearly universal distribution. 
The third example of direct damage reversal is provided by AlkB, a protein that is found 
in most living organisms, including humans. This protein is a member of the class of 
enzymes called alpha-keto-glutarate-dependent and iron-dependent oxygenases (aKG-
Fe(II)-oxygenases), which use iron-oxo intermediates to oxidize chemically inert 
compounds. In the process, alpha-keto-glutarate is converted to succinate and CO2. AlkB 
is capable of reversing methylation at the 1 position of adenine and the structurally 
similar 3 position of cytosine. The reaction catalyzed by AlkB couples the oxidative 
decarboxylation of alpha-keto-glutaric acid to the hydroxylation of the methyl group. The 
methyl group then spontaneously decomposes to formaldehyde, restoring the original 
base (Begley and Samson, 2003). 
A final example of direct damage reversal is the sealing of a subset of nicks in DNA by 
DNA ligases. Of course, DNA ligases can only seal nicks having 5'-phosphates and 3'-
hydroxyls. Nicks with other configurations, or nicks accompanied by additional 
backbone or base damage, require more complicated processing prior to repair and 
would not be classified as direct damage reversal mechanisms. 
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Photoreactivation 
 
Many species from each of the three kingdoms of life and even some viruses have 
photolyases, whereas other species do not (Sancar, 2003). There are two types of 
photolyases, one that repairs cyclobutane pyrimidine dymers (photolyase) and the other 
that repairs (6-4) photoproducts (6-4 photolyase ). CPD photolyases are found in 
bacteria, fungi, plants and many vertebrates, but not in placental mammals. In addition, 
6-4 photolyases (which repair 6-4PPs) have been found in insects, reptiles and 
amphibians, but not in E. coli, yeast or mammals.  
The reaction catalyzed by CPD photolyases was the first DNA repair process to be 
discovered (Dulbecco, 1949; Kelner, 1949), well before the double-helical structure of 
DNA was described in 1953.  
CPD photolyase contains two chromophores responsible for absorbing light energy. In 
all such photolyases, one of the chromophores is FADH- and the other is either 
methenyl-tetrahydrofolate (MTHF) or 8-hydroxy-5-deazaflavin (8-HDF) (Thompson and 
Sancar, 2002). MTHF and 8-HDF act as primary light gatherers, transferring energy to 
FADH-. The energy from FADH- is then used to split the dimer (Figure 3). Placental 
mammals lack photolyases but contain two proteins with high sequence and structural 
similarities to photolyases, but no repair function. These proteins, named cryptochromes, 
function as photoreceptors for setting the circadian clock (Sancar, 2003). 
 
 
 
Figure 3. Photoreactivation reverses 
DNA damage. DNA exposed to 
ultraviolet (UV) radiation results in 
covalent dimerization of adjacent 
pyrimidines, typically thymine residues 
(thymine dimers). These lesions are 
recognized by a photoreactivating enzyme, 
which absorbs light at wavelengths 
>300nm (such as fluorescent light or 
sunlight) and facilitates a series of 
photochemical reactions that monomerize 
the dimerized pyrimidines, restoring them 
to their native conformation 
 
 
 
 
Introduction
16
Alkyl transfer 
 
Another example of direct damage reversal is repair of O6-alkyl guanine by transfer of 
the methyl group from the DNA to a cysteine in a protein, an O6-alkylguanine-DNA 
alkyltransferase. This is a small protein of ∼20 kDa that does not contain a cofactor and 
is ubiquitous in nature. Like photolyases, it is presumed to recognize damage by three-
dimensional diffusion and, after forming a low-stability complex with the DNA 
backbone at the damage site, it is thought to flip-out the 6-methylguanine base into the 
active site cavity (Daniels and Tainer, 2000), wherein the methyl group is transferred to 
an active site cysteine (Lindahl et al., 1988). The protein then dissociates from the 
repaired DNA, but the C-S bond of methylcysteine is stable and therefore, after one 
catalytic event, the enzyme becomes inactivated and is accordingly referred to as a suicide 
enzyme (Figure 4).  
 
 
Figure 4. MGMT mechanism.  
Transfer of an alkyl group from an O-6 position of guanine to an internal cysteine permanently inactivates 
the enzyme and targets it for proteosomal degradation. 
S-methylcysteine in 
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1.1.2 Base excision repair 
 
Base excision repair (BER) works mainly on DNA damage that arises spontaneously in a 
cell as a result of hydrolytic events such as deamination or bases loss, fragmentation of 
bases by ionizing radiation and oxidative damage or methylation of ring nitrogens by 
endogenous agents. The BER pathway is the most important cellular protection 
mechanism responding to oxidative DNA damage, generated by reactive oxygen species 
formed during normal metabolism or by exogenous agents (Tuteja and Tuteja, 2001). 
Specificity of the repair is determined by the glycosylase employed in the initial step of 
recognition and the hydrolysis of the N-glycosyl bond linking the modified or damaged 
base to the deoxyribose-phosphate chain (Table 2). Nevertheless, all of the variant 
pathways have features in common and each of the pathways can be considered to 
consist of 3 steps: 
• Removal of the aberrant base by an appropriate DNA N-glycosylase to create an 
AP site 
• Nicking of the damaged DNA strand by AP endonuclease upstream of the AP site, 
thus creating a 3'-OH terminus adjacent to the AP site 
• Extension of the 3'-OH terminus by a DNA polymerase, accompanied by excision 
of the deoxyribose-phosphate (dRp) 
 
Table 2. Some of the human DNA glycosylases (Christmann et al., 2003; Schoerer and Jiricny, 
2001) 
Acronym Full Name  AP Lyase Activity  Substrates 
UNG Uracil DNA  N-Glycosylase  No   ssU>U:G>U:A, 5-FU 
TDG Thymine DNA Glycosylase   No   U:G>ethenocytosine:G>T:G 
UDG2 Uracil DNA  Glycoslyase 2  No  U:A 
SMUG1 
Single-strand-selective 
Monofunctional Uracil-
DNA Glycosylase 1  
No   ssU>U:A, U:G 
MBD4 Methyl-CpG-binding Domain 4   No  U or T in U/TpG:5-meCpG  
MPG Methyl Purine DNA Glycosylase  No  3-meA, 7-meA, 3-meG, 7-meG 
MYH MutY Homolog  No  A:G, A:8-oxoG 
OGG1 8-Oxo-Guanine Glycosylase 1    Yes  8-oxoG:C 
NTH1 Endonuclease Three Homolog 1    Yes  
T-glycol, C-glycol, 
formamidopyrimidine 
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In addition to removing altered bases, some DNA glycosylases also possess an AP lyase 
activity, which allows them to cleave the DNA backbone on the 3' side of the AP site 
(Figure 5). The cleavage is between C and O, not between O and P, thus, regardless of 
whether the DNA glycosylase possesses a lyase activity, the next step in BER is catalyzed 
by an AP endonuclease, which cleaves the DNA backbone on the 5' side of the AP site. 
The insertion of the first nucleotide is not dependent on the chemical structure of the 
AP site. During short-patch BER, the 5’-dRP is displaced by DNA polymerase β (Polβ), 
which inserts a single nucleotide. The critical step in the decision between short- and 
long-patch BER is the removal of the 5’-dRP upon the insertion of the first nucleotide. 
Besides polymerisation activity, Polβ also possesses a lyase activity and is thereby able to 
catalyze the release of the hemiacetal form of 5’-dRP residues from incised AP sites by β-
elimination. In contrast, oxidised or reduced AP sites, 3’-unsaturated aldehydes or 3’-
phosphates are resistant to β-elimination by Polβ. Upon dissociation of Polβ from the 
DNA, the repair process is completed by DNA-Ligase, which seals the remaining nick. 
During long-patch BER, strand displacement and further DNA synthesis is 
accomplished after dissociation of Polβ by Polε or Polδ together with PCNA and RF-C, 
resulting in repair patches of up to 10 nucleotides. The removal of the 
deoxyribosephosphate flap structure (5’-dRPflap) is executed by the flap endonuclease 
FEN1, which is stimulated by PCNA. Ligase I interacts with PCNA and Polβ and 
participates mainly in long-patch BER. DNA ligase III interacts with XRCC1, Polβ and 
PARP-1 (poly(ADP-ribose) polymerase-1) and is involved only in short-patch BER 
(Christmann et al., 2003; Huffman et al., 2005) 
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Figure 5. Mechanism of base excision repair (BER). 
Recognition of the DNA lesion occurs by a specific DNA glycosylase, which removes the damaged base 
by hydrolyzing the N-glycosidic bond. The remaining AP site is processed by APE. Depending on the 
cleavability of the resulting 5’-dRP by Polβ, repair is accomplished by the short or long patch BER 
pathway. Modified from Christmann et al., 2003. 
unsaturated 
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1.1.3 Nucleotide Excision Repair 
 
Nucleotide excision repair (NER) is the major repair system for removing bulky DNA 
lesions formed by exposure to radiation or chemicals, or by protein addition to DNA. 
The main function of the nucleotide excision repair pathway is the removal of UV-
induced lesions. The damaged bases are removed by the "excision nuclease," a 
multisubunit enzyme system that makes dual incisions bracketing the lesion in the 
damaged strand (Figure 6). Because of the wide substrate range, excision repair cannot 
recognize the specific chemical groups that make up the lesion, but is thought to 
recognize the phosphodiester backbone distortion created by the damage. The basic 
steps of nucleotide excision repair are (a) damage recognition, (b) dual incisions 
bracketing the lesion to form a 12-13-nt oligomer in prokaryotes or a 24-32-nt oligomer 
in eukaryotes, (c) release of the excised oligomer, (d) repair synthesis to fill in the 
resulting gap, and (e) ligation. In humans, excision repair is carried out by 6 repair factors 
(RPA, XPA, XPC, TFIIH, XPG, and XPF/ERCC1) and defects in excision repair cause 
a photosensitivity syndrome called Xeroderma pigmentosum (XP), which is 
characterized by a very high incidence of light-induced skin cancer. 
NER can be subdivided into two distinct pathways termed global genomic repair (GGR) 
and transcription-coupled repair (TCR) (Figure 6). GGR is thought to be largely 
transcription-independent and removes lesions from the non-transcribed domains of the 
genome and the non-transcribed strand of transcribed regions. 6-4PPs, which distort the 
DNA more than CPDs, are removed rapidly and predominantly by GGR. In contrast, 
CPDs are removed very slowly by GGR. Their removal occurs more efficiently by TCR 
from the transcribed strand of expressed genes. Defects in TCR are directly linked to 
Cockayne’s syndrome, which involves two complementation groups: CSA and CSB. CSA 
and CSB, as well as XPB, XPD (as part of TFIIH) and XPG protein are essential for 
TCR (Cleaver, 2005). In contrast to TCR, the mechanism of GGR has been elucidated in 
great detail. 
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Figure 6. Mechanism of nucleotide excision repair (NER). 
During global genomic repair (GGR), recognition of the DNA lesion occurs by XPC–HR23B, RPA–XPA 
or DDB1–DDB2. DNA unwinding is performed by the transcription factor TFIIH and excision of the 
lesion-containing nucleotide by XPG and XPF–ERCC1. Finally, resynthesis occurs by Polδ or Polε and 
ligation by DNA ligase I. During transcription-coupled repair (TCR), the lesion blocks RNA-Polymerase II 
(RNAPII). This leads to assembly of CSA, CSB and/or TFIIS at the site of the lesion, by which RNAPII is 
removed from the DNA or displaced from the lesion, making it accessible to the exonucleases XPF–
ERCC1 and XPG, cleaving the lesion-containing DNA strand. Resynthesis again occurs by Polδ or Polε 
and ligation by DNA ligase I. 
GLOBAL GENOMIC REPAIR TRANSCRIPTION-COUPLED REPAIR 
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1.2 MISMATCH REPAIR 
 
In contrast to lesions produced within the DNA helix by chemical damage, mismatched 
base pairs arise during the course of normal DNA metabolism such as replication or 
recombination. Mismatch repair (MMR) is responsible for correcting base-base 
mismatches as well as insertion-deletion loops (IDLs) that might arise during replication 
due to polymerase slippage, most often on repetitive sequences.  
MMR participates in a wide variety of DNA transactions and tits inactivation can have 
either beneficial or deleterious consequences for the organism. The major consequence 
of defective MMR is an increased rate of point mutations, resulting from unrepaired 
errors of replicative polymareses. Loss of MMR pathway in bacteria favours survival and 
exchange of genetic material under stress conditions (Matic et al., 2003), while in 
mammals MMR deficiency contributes to initiation and promotion of tumours (Loeb et 
al., 2003). The error rate of the replicative polymerase δ is ∼1 misincorporation and 1 -2 
deletions per 105 nucleotides (Kunkel, 2003). When addressed by MMR, replication 
fidelity approaches 1 error per 108 to 109 nucleotides (Sarasin, 2003). In addition to 
recognizing replication-generated mismatches, MMR proteins also recognize mismatches 
in heteroduplex recombination intermediates. These elicit either a repair process that 
leads to a genetically detectable gene conversion event, or trigger an anti-recombination 
activity that prevents the recombination event from going to completion. The anti-
recombination activity of MMR proteins promotes genome stability by inhibiting 
interactions between diverged sequences present in a single genome or derived from 
different organisms. Besides undamaged mismatches, the MMR machinery also 
recognizes certain DNA lesions generated by normal intracellular metabolism such as 
oxidative stress (Colussi et al., 2002) or modifications due to chemical treatments. Some 
chemotherapeutic drugs rely on the activity of MMR proteins for the activation of cell 
cycle checkpoints and apoptosis (Stojic et al., 2004). The role of MMR proteins in 
maintaining genomic stability is highlighted by the finding that mutations in MMR genes 
lead to hereditary non-polyposis colorectal cancer (HNPCC) (Lynch et al., 1993). The 
proteins involved in MMR are listed in Table 3. Besides proteins specific for MMR only, 
there are others, which participate in DNA metabolism required for efficient MMR, such 
as proteins involved in replication and recombination. MMR is greatly conserved 
mechanism, from bacteria to humans, and outlines of the mechanism can be generalized. 
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Two systems will be described, methyl-directed repair in E. coli and human mismatch 
repair. 
  
Table 3. MMR proteins 
Identities and functions of Escherichia coli and eukaryotic proteins involved in MMR of replication errors 
(Kunkel and Erie, 2005) 
E. coli protein Function Homologs Function 
MutS Binds mismatches MSH2-MSH6 
(MutSα) 
Binds single base-base and 1-2 base 
IDL mismatches 
    MSH2-MSH3  
(MutSβ) 
Binds of some single base IDLs and 
IDLs 2 bases  
Partially redundant with Msh2-Msh6 
MutL Matchmaker that 
coordinates multiple 
steps in MMR 
MLH1-PMS2 
(yPms1) 
(MutLα) 
Matchmaker for coordinating events 
from mismatch binding by MutS 
homologs to DNA repair synthesis 
MLH1-MLH2 
(hPMS1) 
(MutLβ) 
Function of human heterodimer 
unknown. Suppresses some IDL 
mutagenesis in yeast 
  
  
  
  MLH1-MLH3  
(MutLγ) 
Suppresses some IDL mutagenesis 
Participates in meiosis 
MutH Nicks nascent 
unmethylated strand at 
hemimethylated GATC 
sites 
None   
γ-δ Complex Loads β-clamp onto 
DNA 
RFC complex Loads PCNA, modulates excision 
polarity 
β-Clamp Interacts with MutS and 
may recruit it to 
mismatches and/or the 
replication fork  
Enhances processivity of 
DNA pol III 
PCNA Interacts with MutS and MutL 
homologs.  
Recruits MMR proteins to 
mismatches. Increases MM binding 
specificity of Msh2-Msh6  
Participates in DNA repair synthesis 
Helicase II Loaded onto DNA at 
nick by MutS and MutL 
Unwinds DNA to allow 
excision of ssDNA 
None   
ExoI ExoX Perform 3' to 5' excision 
of ssDNA 
EXOI (Rth1) Excision of dsDNA 
RecJ ExoVII Perform 5' to 3' excision 
of ssDNA (also 3' to 5' 
excision by ExoVII) 
3' exo of Polδ  Excision of ssDNA Synergistic 
mutator with Exo1 mutant 
DNA pol III Accurate resynthesis of 
DNA 
DNA polδ  Accurate repair synthesis 
SSB Participates in excision 
and repair synthesis 
RPA Participates in excision and in DNA 
synthesis 
DNA ligase Seals nicks after 
completion of repair 
synthesis 
DNA ligase Seals nicks after completion of 
DNA synthesis 
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1.2.1 Methyl-directed mismatch repair in E.coli 
 
The components of bacterial MMR system were documented in 1980 by analysis of 
strains hypersensitive to 2-aminopurine (Glickman and Radman, 1980) although the 
existence of mismatch repair has been known before (Witkin, 1975, Wildenberg, 1975). 
The E. coli MMR system has been completely reconstituted in vitro (Lahue et al., 1989) 
and involves three mismatch proteins: MutS, MutL, and MutH. MutS is an ATPase that 
effects mismatch recognition. MutL is an ATPase that couples mismatch recognition by 
MutS to downstream processing steps, and MutH is a methylation-sensitive endonuclease 
that targets repair to the newly synthesized DNA strand. Inactivation of bacterial MMR 
system results in a strong mutator phenotype, which arises from errors in the newly 
synthesized strand of DNA (Glickman et al., 1978; Herman and Modrich, 1981). 
Strand discrimination in the E. coli MMR system is made possible by the transient 
unmethylation of newly synthesized DNA, which lags behind replication some 2-5 
minutes. Specifically, the MutH protein cleaves the unmethylated strand of a 
hemimethylated GATC dam methylation site, thereby marking the nicked strand for 
exonucleolytic degradation and resynthesis. Incision is mismatch dependent, with the 
MutH endonuclease being activated in vitro by a complex of MutS, MutL and mismatched 
DNA (Au et al., 1992). MutH can nick DNA on either side of a mismatch and, 
depending on which side the cleavage occurs, either a single-strand specific 5'→3' or a 
3'→5' exonuclease degrades the mismatch-containing nicked strand. In the E. coli system, 
there are two 5'→3' exonucleases (exonuclease VII and the RecJ exonuclease) and two 
3'→5' exonucleases (exonuclease I and exonuclease X) that can effect the degradation of 
the nicked strand. Unwinding by the UvrD helicase begins at the nick and proceeds in a 
directional manner toward and past the mismatch. The methyl-directed nature of the E. 
coli MMR system is an efficient way to discriminate template and daughter strands during 
DNA replication. MutL has been speculated to load the UvrD helicase onto the nick in a 
directional manner such that DNA unwinding proceeds toward the mismatch. MutL 
coordinates the mismatch binding activity of MutS with the MutH cleavage and UvrD 
helicase activities, and thereby directs the strand removal process (Harfe and Jinks-
Robertson, 2000). Resynthesis is mediated by the DNA polymerase III holoenzyme with 
the help of single-strand binding protein (SSB). The nick is ligated by DNA ligase (Figure 
7) (Jiricny, 1998; Li, 2003).  
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Figure 7. Mechanism of mismatch correction in E.coli. 
The mispair that arose as an error of a DNA polymerase is present in a DNA heteroduplex, which is 
transiently unmethylated at GATC sequences in the newly replicated strand. Binding of the MutS protein 
to the mismatch initiates ATP-dependent conformational change of MutS, followed by a movement of the 
bound protein away from the mispair, while ATP hydrolysis drives the bi-directional movement of the 
DNA through the bound MutS, thus forming a loop. At the same time, a multiprotein complex containing 
MutS and MutL homodimers and two molecules of the strand specific endonuclease MutH, assembles at 
the base of the looped structure. The assembly of the complex activates the endonucleolytic activity of 
MutH, which cleaves the newly synthesized DNA 5' at the unmethylated GATC sequence. The cleaved 
strand is then degraded from the nick up to and slightly past the mismatch site, either by ExoVII or RecJ 
(in cases where the unmethylated GATC was situated 5' from the mispair), or by ExoI or ExoX (when the 
nick was 3' from the mispair). The single-stranded region thus generated is protected by the single strand-
binding protein Ssb. Polymerase III holoenzyme fills the gap and DNA ligase repairs the nick (Jiricny, 
1998). Figure adopted from Harfe and Jinks-Robertson, 2000. 
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1.2.2 Eukaryotic mismatch repair system 
 
Eukaryotic MMR has features in common with E. coli MMR, but the proteins involved in 
the repair pathway (Table 3) can differ, depending on the nature of the mismatch and the 
substrate for excision. Repair is initiated when complexes of MutS homologs, either 
MSH2-MSH6 (MutSα) or MSH2-MSH3 (MutSβ), bind to a mismatch. The choice of the 
complex binding to the mismatch depends on the structure of the mismatch itself: base-
base mismatches and insertion-deletion loops with 1 or 2 nucleotides are recognized 
primarily by MutSα, while larger insertion-deletion loops, composed of 6-12 nucleotides 
are preferentially bound by MutSβ (Karran, 1995). The relative amounts of these two 
complexes in vivo are balanced in such a way that the amount of MutSβ is 6-8 times lower 
than MutSα. Both MSH6 and MSH3 proteins are stabilised by interaction with MSH2. 
Therefore, deficiency of MSH2 brings about destabilization of both MSH6 and MSH3. 
MutSα not only binds to spontaneously-occurring base mismatches, but also to various 
chemically-induced DNA lesions such as alkylation-induced O6-methylguanine paired 
with cytosine or thymine, 1,2-intrastrand (GpG) cross-links generated by cisplatin, purine 
adducts of benzo  pyrene-7,8-dihydrodiol-9,10-epoxides, 2-aminofluorene or N-acetyl-2-
aminofluorene, and 8-oxoguanine (Christmann et al., 2003). The model of human 
mismatch repair will be described using a base-base mismatch (MutSα system) as an 
example, but the same mechanism is thought to occur in the MutSβ system (Figure 9.) 
The recognition of mismatches or chemically-modified bases is mediated by the MutSα, 
comprised of MSH2 (Fishel et al., 1993) and MSH6 (Palombo et al., 1995), which binds 
to the lesion. It was reported that the binding of MutSα is accompanied and enhanced by 
phosphorylation (Christmann et al., 2002).  
Presently, it is not clear how MMR discriminates between the parental and the newly 
synthesized DNA strand. One possibility could be through recognition of discontinuities 
in the daughter strands, either in the form of gaps between Okazaki fragments or the 3’ 
terminus of the leading strand. In order to couple the mismatch and the nicks, which 
might be some distance apart, the recognition complex of MutSα must translocate along 
the DNA away from the mismatch. There are two models describing the translocation of 
MutSα: the first has been proposed by Modrich (Blackwell et al., 1998a; Blackwell et al., 
1998b) and according to this hydrolysis-driven translocation, MutSα uses the energy 
gained by ATP hydrolysis to translocate actively along the DNA from the site of 
mismatch recognition to a site responsible for signalling the strand specificity (Figure 
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8A). The second, the so called “molecular switch” model has been proposed by Fishel 
and colleagues (Gradia et al., 1997; Gradia et al., 1999) and suggests that MutSα binds 
the mismatch in its ADP form (“active state”). Mismatch triggers an ADP→ATP 
transition, which brings about a conformational change and the formation of hydrolysis-
independent sliding clamp. The hydrolysis of ATP provokes its dissociation from the 
DNA (Fishel, 1999) (Figure 8B) 
 
 
Figure 8. Models of Mutsα  translocation. 
A. In the 'ATP-dependent translocation' model, hMutSα upon mismatch binding moves away from the 
mismatch along the DNA, using the energy of ATP hydrolysis, thus linking mismatch recognition to the 
strand break or DNA terminus that directs excision to the newly-synthesized strand. B. Mismatch binding 
acts as an ADP-ATP exchange factor; the ATP bound MSH2-MSH6 complex becomes a 'sliding clamp' 
that diffuses freely in an ATP-hydrolysis-independent fashion along the DNA, signalling to additional 
components of the MMR machinery. Upon ATP hydrolysis that is perhaps stimulated by MLH1-PMS2, 
the MSH2-MSH6 complex is released from DNA (Bellacosa, 2001). 
 
 
B. HYDROLYSIS INDEPENDENT SLIDING CLAMP 
A. HYDROLYSIS-DEPENDENT TRANSLOCATION 
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Upon binding to the mismatch, MutSα associates with another heterodimeric complex 
(MutLα), consisting of the MutL homologous mismatch repair proteins MLH1 and 
PMS2 (Li and Modrich, 1995). The excision of the DNA strand containing the mispaired 
base is thought to be catalysed by exonuclease I (Genschel et al., 2002) although it’s still 
not clear whether this enzyme performs the excision in vivo. Resynthesis is most likely 
catalysed by Polδ (Longley et al., 1997). 
 
Figure 9. Model of human mismatch repair.  
Recognition of DNA lesions occurs by MutSα (MSH2–MSH6). According to the molecular switch model, 
binding of MutSα–ADP triggers an ADP-ATP transition, stimulates intrinsic ATPase activity and 
provokes the formation of a hydrolysis-independent sliding clamp, followed by binding of the MutLα 
complex (MLH1–PMS2). According to the hydrolysis-driven translocation model, ATP hydrolysis induces 
translocation of MutSα along the DNA. After formation of a complex composed of MutSα and MutLα, 
excision is catalyzed by ExoI and repair synthesis by Polδ. Figure adopted from Christmann et al., 2003. 
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1.3 DOUBLE STRAND BREAK REPAIR 
 
DNA double-strand breaks (DSBs) are highly potent inducers of chromosome 
aberrations and cell death. In higher eukaryotes, a single non-repaired DSB inactivating 
an essential gene can be sufficient for inducing cell death through apoptosis (Rich et al., 
2000). Double-strand breaks are produced by reactive oxygen species, ionizing radiation 
and chemicals that generate reactive oxygen species. They are also a normal result of 
V(D)J recombination and immunoglobulin class-switching processes, but may also arise 
if a replication fork collides with an unrepaired DNA single-strand break (SSB), giving 
rise to a collapsed replication fork. In mammalian cells, these replication-fork-associated 
DSBs also trigger Homologous Recombination Repair (HRR) (Arnaudeau et al., 2001), 
even though they only have one free DNA end to initiate the repair. Recently, 
recombination has been implicated in the repair of stalled replication forks, which may 
also occur in the absence of detectable DSBs (Lundin et al., 2002). In this case, we know 
less about the substrates that initiate Homologous Recombination (HR). However, it has 
been shown in bacteria that nascent DNA strands may anneal and reverse stalled 
replication forks to form chicken-foot structures that may serve as a substrate for HR 
(McGlynn and Lloyd, 2002). Figure 10 shows DNA structures, which are substrates for 
DSB repair pathways in mammalian cells, and Table 4 summarizes products of the most 
common DNA damaging agents and pathways utilized to repair them. 
 
Figure 10. Structure of recombination substrates 
in mammalian cells. 
(a) A classical DSB has two free DNA ends both of 
which may initiate recombination. (b) A persisting 
SSB may be converted into a DSB during replication 
that collapses the replication fork, leaving one free 
DNA end that is a substrate for recombination. (c) 
A replication fork may encounter roadblocks on the 
template DNA that stall the replication fork. Under 
such conditions the replication fork may reverse to 
form a chicken-foot intermediate that may serve as a 
substrate for recombination 
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 Table 4. Summary of recombination substrates and products (Helleday, 2003) 
Agents Recombinogenic lesion 
Recombination 
pathway 
Recombination 
product 
γ-rays, restriction 
endonucleases Two-end DSB NHEJ, HR 
Deletion, gene conversion, 
duplication 
Topoisomerase I 
inhibitors One-end DSB NHEJ, HR SCE, deletions 
Hydroxyurea, 
thymidine Stalled fork HR Gene conversion, SCE 
 
 
Repair of a classical double strand break (DSB) – two-end repair 
 
There are two main pathways for repair of double-ended DSB, homologous 
recombination (HR) and non-homologous end-joining (NHEJ), which are error-free and 
error-prone, respectively. Both pathways are highly conserved throughout eukaryotic 
evolution, but their relative importance differs from one organism to another. In simple 
eukaryotes like yeast, HR is the main pathway, whereas in mammals the NHEJ pathway 
predominates (Cromie et al., 2001). The overlapping roles of HR and NHEJ in 
mammalian cells can be explained by the context in which DSB occurs. HR is favoured 
in S and G2 phase of the cell cycle when a sister chromatid is present and positioned 
close by, while NHEJ is predominant in G0 and G1 phases when the homologous 
chromosome is far away and the homology search would be almost impossible. This 
might also be a crucial factor in deciding whether a DSB is to be repaired by NHEJ or 
HR. Cells respond to exogenous and endogenous DSBs through a cascade of proteins 
ranging from sensors, which recognize the damage, through signal and mediator 
proteins, to a series of downstream effectors that induce cell-cycle arrests, complete 
repair by homologous or nonhomologous mechanisms, or alternatively trigger cell death 
by apoptosis (Jackson, 2002). Defects in almost any step of this response pathway can 
result in measurable alterations of DNA repair by HR and/or NHEJ. Mutations 
upstream in the cascade, before the decision is made whether a lesion is to be repaired by 
HR or NHEJ, can directly affect both principal recombinational repair pathways (Willers 
et al., 2004).  
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1.3.1 Non-homologous end joining (NHEJ) 
 
The NHEJ system repairs DSBs without the requirement for sequence homology 
between the DNA ends and without the need for synapsis of the broken DNA with an 
undamaged partner DNA molecule (Jackson, 2002). It is generally agreed that at least in 
G0/G1 phases, the great majority of DSBs are rejoined by NHEJ (Takata et al., 1998). 
The prevalence of this error-prone mechanism over HR is presumably due to the 
difficulty of matching the damaged sequence to its intact copy on the homologous 
chromosome. Small changes in the sequence of DNA might be tolerated due to the fact 
that only a small proportion of mammalian genome is coding for genes and regulatory 
elements.  
Although one might think that non-homologous end-joining would lead to the random 
joining of any two ends, this does not appear to be the case. Cells lacking crucial 
components of NHEJ undergo numerous chromosome translocations after DNA 
damage, but wild-type cells do not (Ferguson et al., 2000), implying that functional 
NHEJ in wild type cells must preferentially join correct ends of DSB. The components 
of NHEJ pathway are listed in Table 4. The core set of NHEJ proteins is conserved in all 
eukaryotic cells and includes DNA ligase IV, XRCC4, Ku70 and Ku80. Two additional 
proteins are present only in vertebrates, DNA-PKcs and Artemis. They evolved 
presumably to accomplish special functions of NHEJ that are required for V(D)J 
recombination, but are also important for general repair of DSB (Table 5). The basic 
mechanism of NHEJ is described in Figure 11.  
 
Table 5. Genes and proteins important for NHEJ 
Yeast gene Mammalian gene Protein 
LIG4  LIG4  
DNA ligase IV; cooperates with XRCC4 to ligate broken 
dsDNA molecules after their ends have been properly 
processed. 
LIF1  XRCC4  
XRCC4; cooperates with DNA ligase IV to ligate broken 
dsDNA molecules after their ends have been properly 
processed. 
HDF2  XRCC5  Ku80; cooperates with Ku70 to bind DNA ends and recruit other proteins 
HDF1  XRCC6  Ku70; cooperates with Ku80 to bind DNA ends and recruit other proteins 
Not present in yeast  XRCC7  DNA-PKcs; protein kinase; activates Artemis 
Not present in yeast ARTEMIS  Artemis; nuclease regulated by DNA-PKcs; important for preparing DNA ends to make them ligatable 
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Figure 11. Mechanism of non-homologous end joining (NHEJ).  
Recognition of and binding to damaged DNA ends is mediated by the Ku70–Ku80 complex. Thereafter, 
the Ku heterodimer binds to DNA–PKcs, forming the DNA–PK holoenzyme. DNA–PK activates 
XRCC4–ligase IV, which links the broken DNA ends together. Before re-ligation by XRCC4–ligase IV, 
the DNA ends are processed by the MRE11–Rad50–NBS1 complex, presumably involving FEN1 and 
Artemis. Figure adopted from (Christmann et al., 2003) 
 
Central to NHEJ in organisms from yeast to man is the Ku protein, a heterodimer of 
two subunits, Ku70 (~69 kDa in man) (Reeves and Sthoeger, 1989) and Ku80 (~83 kDa 
in man; also known as Ku86) (Jeggo et al., 1992). The first step is the binding of a 
heterodimeric complex to the damaged DNA, thus protecting the DNA from 
exonuclease digestion. Following DNA binding, the Ku heterodimer associates with the 
catalytic subunit of DNA-dependent protein kinase (DNA–PKcs) (Hartley et al., 1995), 
thereby forming the active DNA–PK holoenzyme. DNA-PKcs is an ~465 kDa 
polypeptide, the C-terminal region of which has a homology to the catalytic domains of 
proteins of the phosphatidyl inositol 3-kinase-like (PIKK) family (Smith and Jackson, 
1999). It has affinity for DNA ends and its activation appears to be triggered by its 
interaction with a single-stranded DNA region derived from a DSB (Hammarsten et al., 
2000). Once bound to DNA DSBs, DNA-PK displays protein Ser/Thr kinase activity 
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with preference for the consensus sequence Ser/Thr-Gln (Kim et al., 1999). One of the 
targets of DNA–PKcs is XRCC4, which forms a stable complex with DNA ligase IV 
(Leber et al., 1998). The XRCC4–ligase IV complex binds to the ends of DNA molecules 
and links together duplex DNA molecules with complementary but non-ligatable ends. 
The XRCC4–ligase IV complex cannot directly re-ligate most DSBs generated by 
mutagenic agents—they have to be processed first because DSBs usually result in 
incompatible ends. Therefore, the rejoining typically requires nucleases to remove several 
nucleotides and polymerases to fill in gaps of several nucleotides. Some of these excess 
single-stranded regions require 5' nucleases, and others require 3' nucleases. Processing of 
DSBs is thought to be performed by the MRE11–RAD50–NBS1 complex (Maser et al., 
1997), which displays exonuclease, endonuclease and helicase activity and removes excess 
DNA at 3? flaps (Wu et al., 1999). However, the genetic evidence in mammals calls such 
a proposal into question. V(D)J recombination, which requires intact NHEJ for its 
joining phase, is normal in Nijmegen breakage syndrome (NBS)1-null cells or cells that 
are homozygous for shortened alleles of RAD50 (Harfst et al., 2000). A new gene, 
called Artemis, was identified on the basis of its mutation in patients with human 
severe combined immunodeficiency (SCID) (Moshous et al., 2001). It was shown 
that Artemis is a nuclease with a 5' exonuclease activity. It forms a complex with 
and can be phosphorylated by DNA-PKcs, upon which it acquires an 
endonuclease activity that opens hairpin loops, removes 5’ overhangs and 
shortens 3’ overhangs (Ma et al., 2002). One candidate responsible for removal of 5? 
flaps is the flap endonuclease 1 (FEN1) (Wu et al., 1999). 
After the ends of the DNA have been processed, XRCC4/Ligase IV complex can ligate 
the two duplex termini (Lee et al., 2003). 
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1.3.2 Homologous recombination 
 
In contrast to NHEJ, few details of HR have been elucidated. For many years it was 
generally believed that homologous recombination was only a minor DSB repair pathway 
in mammalian cells, however recent work has shown that HR plays a substantial role in 
the repair of DSBs, especially those arising during replication. In order for this repair 
process to take place, homologous sequences in the form of sister chromatids, 
homologous chromosomes or DNA repeats are required, thus ensuring error-free repair. 
Another difference between NHEJ and HR is that HR is a very slow process, providing 
another explanation why NHEJ prevails in mammalian cells even though it’s error-prone. 
 
Table 6. Proteins involved in homologous recombination.  
Protein Function 
RAD51 Homologous pairing, recombinase 
RAD51B 
(RAD51L1) 
 
RAD51C  Resolvase 
RAD51D (RAD51D) 
XRCC2 
 
XRCC3 
RAD51 homologues 
Resolvase 
RAD52 
RAD54L 
RAD54B 
Accessory factors for recombination 
BRCA1 
Accessory factor for transcription and recombination, 
E3 Ubiquitin ligase 
BRCA2 Cooperation with RAD51, essential function 
DSS1 (SHFM1) BRCA2 associated 
RAD50 ATPase in complex with MRE11A, NBS1 
MRE11 3'→5’ exonuclease 
NBS1 Mutated in Nijmegen breakage syndrome, signalling 
MUS81 A structure-specific DNA nuclease 
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Figure 12. Principal steps and proteins involved in homologous recombination 
 
HRR appears to involve a large number of proteins, including RAD51, RAD52, RAD54, 
BRCA1, BRCA2, the RAD51 paralogs RAD51B, C, D, XRCC2 and XRCC3, and the 
MRN complex (Table 6) (Wood et al., 2005). The first event believed to occur during 
HRR is resection of the DNA to yield single-strand overhangs. Based on analogy to yeast 
models, this resection is assumed to be 5'→3' and to involve the MRN complex; if so, 
other factors must also be involved as the MRE11 subunit itself has ssDNA 
endonuclease and 3'→5' exonuclease, but not 5'→3' exonuclease activity (Trujillo et al., 
1998). The RAD50 subunit of MRN has ATPase activity that is believed to facilitate 
DNA unwinding, whereas the NBS1 subunit appears to be important for nuclear 
  
RAD51B/C/D/XRCC2 
RAD51C/XRCC3 
BRCA2 
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transport and for transmitting signals from DNA damage sensors to MRN (Paull and 
Gellert, 1999). The resulting 3? single-stranded DNA is thereafter bound by a heptameric 
ring complex formed by RAD52 (Stasiak et al., 2000), which protects against 
exonucleolytic digestion. RAD52 competes with the Ku complex for the binding to 
DNA ends. This may determine whether the DSB is repaired via the HR or the NHEJ 
pathway (Van Dyck et al., 1999). RAD52 interacts with RAD51 and RPA, stimulating 
DNA strand exchange activity of RAD51 (New et al., 1998). The human RAD51 protein 
is a homologue of the E. coli recombinase RecA. It forms nucleofilaments, binds single- 
and double-stranded DNA and promotes ATP-dependent interaction with a 
homologous region on an undamaged DNA molecule. RAD51 protein forms 
nucleoprotein complexes on ssDNA tails coated by RPA to initiate strand exchange. It 
catalyzes strand-exchange events with the complementary strand, in which the damaged 
DNA molecule invades the undamaged DNA duplex, displacing one strand as D-loop 
(Baumann and West, 1998). While the RAD52 knockout mice are viable and healthy, a 
knockout of the RAD51 gene is embryonic lethal, as are knockouts in other genes 
involved in HR (RAD51B, RAD51D, XRCC2, RAD50, MRE11, or NBS1), which 
implies that an intact HR pathway is vital (Helleday, 2003 and the references therein).  
For invasion to occur, RAD51 must displace the RPA protein on the 3’ ssDNA 
overhangs. RPA has much higher affinity for ssDNA than RAD51 and its replacement 
with RAD51 may be catalysed by the RAD51 paralogs (Sigurdsson et al., 2001). There 
are 5 paralogs of RAD51 in mammalian cells: RAD51B, RAD51C, RAD51D, XRCC2 
and XRCC3. They form two distinct complexes: BCDX2, composed of RAD51B, 
RAD51C, RAD51D and XRCC2, and CX3, composed of RAD51C and XRCC3 
(Masson et al., 2001). In vertebrate cells, formation of DNA-damage-induced foci of 
RAD51 depends on the presence of RAD51 paralogs (Takata et al., 2001) thus indicating 
that loading of the RAD51 onto ssDNA requires functional paralogs. Interestingly, it was 
shown that the BCDX2 complex of RAD51 paralogs facilitates formation of RAD51 
filaments on gapped DNA sequences (Masson et al., 2001). This is a very interesting 
observation, suggesting that strand invasion can be initiated without a free DNA end.  
The proteins mutated in inherited forms of breast cancer, BRCA1 and BRCA2, are also 
involved at an early point of DSB repair. The BRCA2 protein may also play a role in 
loading RAD51 onto ssDNA (Powell and Kachnic, 2003), as it was shown that it has a 
preference for ss-ds DNA junctions and is required for recruitment of RAD51 and its 
localization to the sites of damage (Esashi et al., 2005). Although considerable indirect 
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evidence suggests that BRCA1 plays a direct role in HRR, the repair effects could be 
indirect through cell cycle control (Deming et al., 2001). Altogether, BRCA1 and BRCA2 
are believed to be important at early points of HRR and perhaps coordinate repair with 
other cellular processes. 
Strand invasion is further stimulated by the RAD54 protein. This protein forms negative 
supercoils in duplex DNA, which may increase accessibility for strand invasion (Tan et 
al., 2003).  
Another group of proteins found mutated in patients with a rare recessive disease, 
Fanconi anaemia, has been implied to play a role in homologous recombination (West, 
2003). It was shown that one of the FANC genes, FANCD1 is in fact BRCA2 (Howlett 
et al., 2002), thus linking the FANC protein complex to DNA repair ( 
Figure 13) 
 
Figure 13. Fanconi anaemia complex. 
The Fanconi anaemia (FA) proteins FANCA, 
FANCC, FANCE, FANCF and FANCG form a 
nuclear complex. In response to DNA damage, 
and during DNA replication, the complex can be 
activated. This results in the monoubiquitylation 
(Ub) of FANCD2 which requires BRCA1. The 
activated FANCD2 protein is then seen to 
colocalize with BRCA1 in nuclear foci, in which 
it might interact with other repair proteins. 
BRCA1 is known to interact with BRCA2 (which 
is also known as FANCD1), which, in turn, 
interacts with the RAD51 recombinase. The 
RAD51 protein has a direct role in DNA repair, 
thus completing the cycle. FANCB, which might 
also be related to BRCA2, is not shown (West, 
2003). 
 
 
Following the RAD51-catalysed invasion of the homologous DNA molecule during HR, 
DNA synthesis is initiated at the 3’ end of the invading strand by a DNA polymerase. 
The synthesis is likely to proceed beyond the site of the original DSB. A Holliday 
Junction (HJ) that arose at the site of invasion, may branch migrate in either direction. If 
the HJ migrates in the direction of replication, it may reverse the invasion, leaving a 
DNA end that has been extended beyond the original DSB. This ssDNA end will share 
homology with the other end and may be repaired by a simple mechanism of Single 
Strand Annealing (SSA). However, synthesis-dependent SSA results in gene conversion, 
which is an error-free repair pathway, although it may result in loss of heterozygosity. 
Alternatively, the extended DNA end may be repaired by NHEJ. This synthesis-
dependent NHEJ will result in tandem duplication at the site of the DSB. Tandem 
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duplications of this sort represent ∼2% of all spontaneous gene mutations in the hprt 
gene in Chinese hamster cells showing that coupling of NHEJ and HR is important in 
the repair of spontaneous DSBs (Richardson and Jasin, 2000) (Figure 14).  
 
Figure 14. First strand invasion in HR. 
Strand invasion of a homologous DNA sequence 
may be initiated by one of the ssDNA ends. The 
invading strand is elongated past the site of 
breakage. Branch migration of the HJ may release 
the invading strand, unveiling homologous DNA 
sequences to the ssDNA overhang on the opposite 
DNA end. Synthesis-dependent SSA may use this 
homology in repair, which causes a gene 
conversion with no deletion. Synthesis-dependent 
NHEJ rejoins the extended DNA end without 
using the sequence homology. This will cause 
tandem duplications, giving a longer product than 
following synthesis-dependent SSA. 
 
As an alternative to the release of the invading end, the second DNA end may invade the 
same homologous DNA molecule. This will result in a double HJ structure that may be 
resolved either by crossing over or non-crossing over (Figure 15).  
 
Figure 15. Second strand invasion in HR 
Strand invasion by the second DNA end may 
occur if the invading strand is not released by 
branch migration; this causes a double HJ. In 
mammalian cells, these HJs are probably not 
resolved by crossing over (filled arrowheads), since 
cross-over products are suppressed in mitotic 
mammalian cells. Instead, the HJs may be resolved 
by non-crossing over (open arrowheads), causing a 
gene conversion event. 
 
 
 
 
Cross-over events are probably rare in mammalian cells, since HRR using a sequence on 
another chromosome does not result in translocation (Richardson et al., 1998) and a SCE 
event has never been observed when analyzing the HR products following repair of an 
induced DSB (Johnson and Jasin, 2000).  
 
Resolution of HJs in mammalian cells has been an enigma for many years. Resolvases 
from other organisms have been identified, like bacteriophage-T4 endonuclease VII, 
bacteriophage-T7 endonuclease I, pox virus A22, E. coli RuvC and RusA, archaeal Hjc 
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and Hje, and Saccharomyces cerevisiae mitochondrial Cce1 (Liu and West, 2004). It was 
shown that the resolvase complex in mammalian cells contains the recombination 
proteins RAD51C and XRCC3 (Liu et al., 2004) although the nuclease component of the 
complex is still not known.  
 
Single-strand annealing in two-end repair 
 
Single strand annealing can be considered as an intermediate pathway between NHEJ 
and HR. It requires a certain number of nucleotides of homology between 3’ ends. If 
repeated sequences are uncovered within the resected 3’ ssDNA overhangs, RAD52 and 
replication protein A (RPA) may initiate single-strand annealing (SSA) repair between the 
repeated sequences. The RAD52 protein binds the 3’ ssDNA ends, whereas the RPA 
protein binds tightly to the 3’ ssDNA overhangs. When these repeats are annealed, the 
regions between the repeats will be flipped out on either side. These are substrates for 
the ERCC1/XPF endonuclease that seems to play a role in SSA (Sargent et al., 2000). It 
has been suggested that SSA is a frequent repair event between repetitive sequences 
(Liang et al., 1998). The product formed by SSA is a deletion, making this pathway error-
prone. Since a large proportion of mammalian genomes consists of repetitive sequences, 
e.g. Alu sequences, SSA may frequently be recruited in the repair of DSBs with two ends. 
 
Recombination in repair of a collapsed replication fork—one end repair 
 
The importance of the homologous recombination repair pathway is highlighted in the 
processes that attempt to repair collapsed replication forks. It has been difficult to 
establish the importance of RAD51 and other HR proteins in replication, as most HR 
knockout mice are embryonic lethal (Lim and Hasty, 1996). However, a conditional 
knockout RAD51-/- chicken cell line has been established. It has been reported to 
accumulate chromosome breaks during the first round of replication and arrests in the 
G2/M phase before entering apoptosis (Sonoda et al., 2001), suggesting that HR is 
involved in the repair of naturally occurring DSBs that arise during the S phase of the cell 
cycle. DSBs may be generated during replication by conversion of SSBs into DSBs, 
resulting in a collapsed replication fork. This collapsed fork may trigger break-induced 
replication (BIR) (Haber, 2000). The most important difference between a classical DSB 
and a replication-associated DSB at collapsed forks is that there is only one end to 
initiate HR (Figure 16). After the single-stranded gap in the template DNA strand has 
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been filled in, the free DNA end may invade this intact DNA molecule and resume 
replication. Following invasion, a single HJ will be left behind the replication fork. Since 
non-cross-over of a HJ is preferred resolution mechanism in mammalian mitotic 
recombination, the outcome of BIR will be a Sister Chromatid Exchange (SCE). The 
SCEs can be visualized since newly synthesised DNA is ligated to template DNA. 
Following a second mitosis, the break site may be clearly scored as a SCE by cytological 
methods (see Materials and Methods). 
 
 
Figure 16. HRR of a collapsed replication fork, i.e. one-end repair.  
(a) A replication fork-associated DSB has one free end to initiate exonuclease resection. (b) The 3’ ssDNA 
overhang is coated with RAD51 and other HR proteins involved in strand invasion. (c) The single-strand 
gap on the template DNA will be filled in advance of (d) strand invasion. Leading strand synthesis may 
continue on the invaded template DNA, and a replication fork is re-established (e). This re-established 
replication fork will have swapped the leading and lagging strands; compare (a) and (e). (f) A single HJ is 
left behind the replication fork, this is probably resolved by non-crossing over since crossing over is an 
unlikely event. Since template DNA and newly synthesised DNA are fused following non-crossing over, 
SCE will be visualised following a second mitosis (g); open arrowheads designate non-crossing over and 
filled arrowheads indicate crossing over (Helleday, 2003). 
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Recombination at stalled replication forks 
 
It’s clear that stalled replication forks are probably the most frequent substrates for 
recombinational repair in mammalian cells (Lundin et al., 2002). In addition to the fact 
that a deficiency in HR is embryonic lethal in mice (Deans et al., 2000; Douglas L. 
Pittman, 2000; Tsuzuki et al., 1996) Chinese hamster cells deficient in HR show delayed 
progress through the cell cycle (Fuller and Painter, 1988), hypersensitivity to agents that 
stall replication (Lundin et al., 2002) and chromosome instability (Cui et al., 1999). 
Furthermore, agents that inhibit replication are potent inducers of HR and RAD51 focus 
formation (Saintigny et al., 2001). RAD51 foci have been shown to form in 
postreplicative DNA and at sites of stalled replication forks (Sengupta et al., 2003). 
Elaborate systems for the repair of broken replication forks exist in all eukaryotic cells. It 
has been suggested that about 10 replication forks collapse or arrest in human cells per 
replication cycle (Cox, 2002; Haber, 1999) 
Emerging evidence from bacteria shows that stalled replication forks may reverse to 
form an intermediate “chicken-foot” structure that may be repaired by trans-lesion 
synthesis or recombination (Michel et al., 2001; Michel et al., 2004). It is possible that 
stalled replication forks may also reverse to form chicken-foot structures in mammalian 
cells, although there is no direct evidence thus far. Some mammalian cell lines treated 
with hydroxyurea accumulate DSBs at or near replication forks (Bianchi et al., 1986; 
Lundin et al., 2002) and in this case both NHEJ and HR participate in the repair of 
broken replication forks. In the case of thymidine, which was reported not to cause 
double strand breaks, HR alone is involved in the repair (Lundin et al., 2002), suggesting 
that NHEJ is only involved in the repair of blocked replication forks that have been 
processed into a DSB. More importantly, it indicates that HR repairs lesions at stalled 
replication forks that do not appear as detectable DSBs. The conclusion from these and 
other experiments is that HR repairs a broader spectrum of lesions that occur at stalled 
replication forks, while NHEJ only repairs DSBs (Lundin et al., 2003).  
 
 
 
Introduction
42
1.4 DNA DAMAGE RESPONSE 
 
The fast response to DNA damage is necessary in order to prevent transmission of 
damaged DNA to daughter cells, thus avoiding dangerous mutations. This fast response 
cannot rely on transcriptional activation, at least not in the time that follows detection of 
the damage. Therefore, two mechanisms may be in play: cascades of posttranslational 
modifications, which change the affinities of proteins for their substrates without the 
need to synthesize new proteins, and/or recruitment of repair proteins to the sites of 
damage, thus creating microenvironment that favours repair. In most instances, these 
two mechanisms are interconnected and sometimes it’s difficult to distinguish effects of 
DNA damage signalling from DNA repair. 
 
1.4.1 DNA damage signalling and checkpoints 
 
DNA damage checkpoints are biochemical pathways that delay or arrest cell cycle 
progression in response to DNA damage. Besides defining the specific time point in the 
cell cycle when the DNA is “checked”, the term has been applied to the entire ensemble 
of cellular responses to DNA damage, including the arrest of cell cycle progression, 
induction of DNA repair genes, and apoptosis. It should be noted though, that DNA 
repair pathways are functional in the absence of damage-induced cell-cycle arrest, and 
that apoptosis can occur independently of the cell-cycle arrest machinery. Generally 
speaking, DNA damage checkpoints are events that slow or arrest cell-cycle progression 
in response to DNA damage in order to provide more time for the repair machinery to 
revert the damage. 
All eukaryotic cells have four phases within the cell cycle, G1, S, G2, and M, and one 
outside, G0. In mammalian somatic cells, the phases are well defined and represent 
stages in the life of a cell in which distinct biochemical reactions take place. In an 
unperturbed cell cycle, the transition points G1/S and G2/M, as well as S-phase 
progression, are tightly controlled, and the same proteins involved in regulating the 
progression through the cell cycle are also involved in checkpoint responses. (Sancar et 
al., 2004). The DNA damage checkpoints, like other signal transduction pathways, 
conceptually have three components: sensors, signal transducers, and effectors (Nyberg 
et al., 2002). Although the G1/S, intra-S, and the G2/M checkpoints are distinct, the 
damage sensor molecules that activate the various checkpoints appear to either be shared 
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by all three pathways or to play a primary sensor role in one pathway and a back-up role 
in the others. Similarly, the signal-transducing molecules, which are protein kinases and 
phosphatases, are shared by the different checkpoints (Zhou and Elledge, 2000). The 
effector components (proteins that inhibit phase transition) of the checkpoints are what 
gives the checkpoints their unique identities. 
Recognition of aberrant DNA is accomplished by a group of phosphatidylinositol-3-
kinase-like kinases. These kinases are ATM (Ataxia Telangiectasia Mutated, (Savitsky et 
al., 1995)), ATR (Ataxia Telangiectasia and Rad3 Related) and the catalytic subunit of 
DNA–PK (Hartley et al., 1995), Rad17-RFC and Rad9-Rad1-Hus1 complexes. 
 
 
Figure 17. Components of the DNA damage checkpoints in human cells. 
The damage is detected by sensors that, with the aid of mediators, transduce the signal to transducers, 
which then, activate or inactivate other proteins (effectors) that directly participate in inhibiting the G1/S 
transition, S-phase progression, or the G2/M transition (Sancar et al., 2004). 
 
ATM is a 350-kDa oligomeric protein found mutated in ATM (ataxia telangiectasia 
mutated), a condition primarily characterized by cerebellar degeneration, 
immunodeficiency, genome instability, clinical radiosensitivity and cancer predisposition 
(Shiloh, 1997). Upon exposure of cells to ionizing radiation, ATM phosphorylates many 
proteins, including Chk2, p53 (Canman et al., 1998), NBS1 (Lim et al., 2000), BRCA1 
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(Cortez et al., 1999) and itself (Bakkenist and Kastan, 2003) at serines and threonines in 
the SQ or TQ sequence context. Autophosphorylation of ATM converts the oligomer 
into monomers, which appear to be the active form of the enzyme for the checkpoint 
response (Bakkenist and Kastan, 2003). 
ATR was discovered in the human genome database as a gene with sequence homology 
to ATM and SpRad3, hence the name ATR (ATM and Rad3 related) (Cimprich et al., 
1996). The gene encodes a protein of 303 kDa with a C-terminal kinase domain and 
regions of homology to other PIKK family members. Knockout of ATR in mice results 
in embryonic lethality and a partial loss of ATR activity in humans has been associated 
with the human autosomal recessive disorder Seckel syndrome, which shares similarities 
with AT (O'Driscoll and Jeggo, 2003). Complete deficiency of ATR is lethal. ATR, like 
ATM, is a protein kinase with specificity for S and T residues in SQ/TQ sequences and it 
phosphorylates essentially all proteins that are phosphorylated by ATM. In contrast to 
ATM however, ATR is activated in vivo by UV light rather than by ionizing radiation, and 
it is the main PIKK family member that initiates signal transduction following UV 
irradiation. Thus, at present it appears that ATM is a sensor and transducer responding 
to double-strand breaks, and ATR serves an analogous role for base damage, at least 
from UV irradiation. 
DNA-PK is a heterotrimer of a 450-kDa catalytic subunit (DNA-PKcs) and a dimer of 
Ku70 and Ku80. The Ku70/Ku80 dimer binds to DNA ends and recruits DNA-PKcs, 
which then becomes activated as a DNA-dependent protein kinase (Gottlieb and 
Jackson, 1993).  
The Rad17-RFC complex is a checkpoint-specific structural homolog of the replication 
factor C (RFC). The replicative form of RFC is a heteropentamer composed of p140, 
p40, p38, p37, and p36. In Rad17-RFC, the p140 subunit is replaced by the 75-kDa 
Rad17 protein (Lindsey-Boltz et al., 2001). The 9-1-1 (Rad9-Rad1-Hus1) complex is the 
checkpoint counterpart of PCNA, a homotrimer with a ring-like structure. Although the 
Rad9, Rad1 and Hus1 proteins have little sequence homology to PCNA, or to one 
another, molecular modelling suggested that they might form a PCNA-like structure 
(Venclovas and Thelen, 2000).  
In humans, there are two kinases, Chk1 and Chk2, with a strictly signal transduction 
function in cell cycle regulation and checkpoint responses (Melo and Toczyski, 2002). 
Both Chk1 and Chk2 are S/T kinases with limited substrate specificities. In mammalian 
cells, the double-strand break signal sensed by ATM is transduced by Chk2 (Matsuoka et 
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al., 2000) and the UV-damage signal sensed by ATR is transduced by Chk1 (Zhao and 
Piwnica-Worms, 2001). However, there is some overlap between the functions of the 
two proteins.  
Three phosphotyrosine phosphatases, Cdc25A, -B, and -C, downstream targets of DNA 
damage transducers, dephosphorylate the cyclin-dependent kinases that act on proteins 
directly involved in cell-cycle transitions. Phosphorylation inactivates the Cdc25 proteins 
by excluding them from the nucleus, by causing proteolytic degradation, or both. 
Unphosphorylated Cdc25 proteins promote the G1/S transition by dephosphorylating 
Cdk2 and promote the G2/M transition by dephosphorylating Cdc2 phosphotyrosine 
(Bartek and Lukas, 2001). 
 
The G1/S checkpoint 
The G1/S checkpoint prevents cells from entering the S phase in the presence of DNA 
damage by inhibiting the initiation of replication. If the DNA damage is double-strand 
breaks caused by ionizing radiation or radiomimetic agents, ATM is activated and 
phosphorylates many target molecules, such as p53 and Chk2. These phosphorylations 
result in the activation of two signal transduction pathways, one to initiate and one to 
maintain the G1/S arrest (Bartek and Lukas, 2001).  
 
 
 
Figure 18. G1/S checkpoint. 
The G1 checkpoint in mammalian cells 
primarily functions to block Cdk2-cyclin E 
activity. This is achieved by stabilizing p53 
and degrading Cdc25A to maintain Cdk2 
inhibitory phosphorylation. 
 
 
 
 
 
 
 
 
The reaction that initiates the G1/S arrest is phosphorylation of Chk2, which in turn 
phosphorylates Cdc25A phosphatase, causing its inactivation by nuclear exclusion and 
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ubiquitin-mediated proteolytic degradation. If the DNA damage is induced by UV light 
or UV-mimetic agents, the signal is sensed by ATR, Rad17-RFC, and the 9-1-1 
complexes, leading to phosphorylation of Chk1 by ATR. The activated Chk1 then 
phosphorylates Cdc25A, leading to a G1 arrest. Whether the initial arrest is caused by the 
ATM-Chk2-Cdc25A pathway or the ATR-Chk1-Cdc25A pathway, this rapid response is 
followed by the p53-mediated maintenance of G1/S arrest, which becomes fully 
operational several hours after the detection of DNA damage (Bartek and Lukas, 2001; 
Nyberg et al., 2002) (Figure 18).  
 
G2/M checkpoint 
The G2/M checkpoint prevents cells from undergoing mitosis in the presence of DNA 
damage. Depending on the type of DNA damage, the ATM-Chk2-Cdc25 signal 
transduction pathway and/or the ATR-Chk1-Cdc25 pathway is activated to arrest the cell 
cycle following DNA damage in G2. These two pathways converge in phosphorylation 
of CDC25C, thus blocking its phosphates activity required to dephosporylate Cdc2 in 
order to make it active and allow entry into mitosis (Figure 19).  
 
 
 
Figure 19. The G2 checkpoint 
In mammalian cells it primarily functions 
to block the Cdc2-cyclin B activity. The 
common means of maintaining Cdc2 
inhibitory phosphorylation is by blocking 
the Cdc25C phosphatase activity, namely 
by promoting its association with 14-3-3-
proteins. 
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1.4.2 Nuclear dynamics of repair proteins 
 
It has been hypothesised that the spatial organisation of chromatin and nuclear protein 
complexes is essential for the proper regulation of processes that take place in the 
nucleus. The nucleus, in this view, consists of a number of immobile protein complexes, 
often referred to as factories in which transcription, replication, repair or RNA 
processing take place (Cardoso et al., 1999). Enzymes required for function are actively 
recruited to these factories, and DNA is reeled through the fixed structures as it is being 
processed. In sharp contrast to this concept of highly compartmentalised nuclear activity 
stands the view that the nucleus is far less organised in a structural sense and that nuclear 
processes are regulated by freely diffusing proteins. Microscopically visible 
protein/DNA/RNA structures are formed, in this view, as a result of protein activity, 
and they do not represent prerequisites for proper function (Lewis and Tollervey, 2000).  
Answers to question of protein mobility and assembly of mutiprotein complexes in the 
nuclei of mammalian cells started to get answered only after GFP technology became 
available and expression of GFP-tagged proteins became possible. It has been shown 
using FRAP (Fluorescence Recovery After Photobleaching), that dextrans up to a 
molecular weight of 500 kDa diffuse freely through the nucleus (Houtsmuller and 
Vermeulen, 2001). In addition, free GFP homogeneously stains the living nucleus and 
nucleotide excision repair proteins diffuse with rates consistent with their molecular 
weight, and show a homogeneous distribution throughout the nucleus (Houtsmuller et 
al., 1999), indicating that most of the proteins find their way through the interchromatin 
compartments easily. It’s possible that those molecules travel through interchromatin 
space only, and that light microscopic resolution is not high enough to reveal this 
because the interchromatin channels are too small. However, it seems unlikely that repair 
factors only have access to the interchromatin space, while DNA damage is distributed 
randomly throughout the entire genome and also in the interior of condensed 
heterochromatin areas. DNA itself could move upon damage induction, bringing lesions 
to the surface of chromatin territories. However, it has been shown with FRAP that 
chromatin itself is quite immobile (Abney et al., 1997).  
 
In vivo studies of DNA repair proteins have shown that in non-damaged cells, most of 
the repair proteins have uniform distribution in the nucleoplasm. Relocalization of the 
proteins and formation of so-called foci has been a hallmark of DNA damage. 
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Formation of foci, or local accumulation of a protein, is also noticed in undamaged cells, 
but is associated with normal DNA metabolism, as shown by PCNA staining of normal 
cycling cells (Essers et al., 2005). Colocalization studies of DNA repair proteins have 
been a useful tool in linking biochemical data and in vivo observations. DNA damaged 
induced foci are thought to be markers of damaged DNA as was shown by experiments 
using local UV irradiation through filter pores and following subsequent recruitment of 
the NER proteins (Volker et al., 2001). With these experiments it became clear that 
proteins engaged in repair of certain lesions are not permanently “trapped” in a position 
inside the nuclear matrix as was thought before, but rather move freely and accumulate at 
the sites of damage. Also, it’s important to notice that once inside the focus, repair 
proteins are not bound permanently but diffuse freely, assumingly as soon as they 
dissociate from the damaged DNA (Schermelleh et al., 2005). 
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3 AIMS AND SCOPE 
 
The principal role of mismatch repair is repairing mismatches that arise during DNA 
replication and escape the proofreading activity of replicative polymerases. Besides this 
well characterized role of MMR, its involvement in other DNA transactions has been 
reported. Studies of the mechanism of MMR have been mostly limited to biochemical 
and in vitro studies due to the fact that induction of mismatches in the genomic DNA is 
experimentally impossible. In order to study the mechanism of MMR in vivo, I used the 
methylating agent N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), whose cytotoxicity 
is known to be mediated by MMR. Activation of MMR after MNNG treatment is 
thought to be due to formation of 6meG residues that are recognized by the polymerase as 
adenine and therefore have tendency to base pair with thymine. Mismatches of this kind 
are permanent, because 6meG persists in the template strand that MMR processing cannot 
affect. But details of the action of MMR proteins are not known and the hypothesis 
trying to explain its role in the cytotoxicity of MNNG failed to be proven. What is the 
mechanism by which MMR addresses MNNG induced damage, and moreover, what are 
the pathways involved in the further processing of the damage, have not been studied so 
far.  
The aim of my study was to characterize the in vivo role of MMR proteins, especially in 
mediating cytotoxicity of MNNG. Consequence of MNNG treatment is activation of 
cell cycle checkpoint on one side, and an attempt to repair the DNA intermediates on 
the other hand. My interest was to characterize DNA repair pathways that are activated 
in MMR dependent manner after MNNG treatment and to elucidate why these repair 
attempts fail. 
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4 RESULTS 
 
 
 
 
 
Short summaries and reprints of publications describing the results 
obtained during my PhD work. 
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4.1 Methylation-induced G2/M arrest requires a full complement of 
the mismatch repair protein hMLH1 
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G, Jiricny J.  
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This publication describes the construction and characterization of the 293T Lα cell line, 
in which expression of hMLH1 can be regulated by doxycycline. Availability of such a 
cell line presents a major achievement in the field, because previous pairs of MMR-
proficient and -deficient cell lines were continuously drifting apart in their genetic 
makeover due to the mutator fenotype of MMR deficiency. Human embryonic kidney 
293T cells expressing high amounts of hMLH1 were MMR-proficient and arrested at the 
G2/M cell cycle checkpoint following treatment with the DNA methylating agent N-
methyl-N'-nitro-N-nitrosoguanidine (MNNG), while cells not expressing hMLH1 
displayed a MMR defect and failed to arrest upon MNNG treatment. Interestingly, MMR 
proficiency was restored even at low hMLH1 concentrations, while checkpoint activation 
required a full complement of hMLH1. The observed defect may be relevant to cellular 
transformation and cancer. 
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The mismatch repair (MMR) gene hMLH1 is mutated
in ~50% of hereditary non-polyposis colon cancers
and transcriptionally silenced in ~25% of sporadic
tumours of the right colon. Cells lacking hMLH1 dis-
play microsatellite instability and resistance to killing
by methylating agents. In an attempt to study the
phenotypic effects of hMLH1 downregulation in
greater detail, we designed an isogenic system, in
which hMLH1 expression is regulated by doxycycline.
We now report that human embryonic kidney 293T
cells expressing high amounts of hMLH1 were MMR-
pro®cient and arrested at the G2/M cell cycle check-
point following treatment with the DNA methylating
agent N-methyl-N¢-nitro-N-nitrosoguanidine (MNNG),
while cells not expressing hMLH1 displayed a MMR
defect and failed to arrest upon MNNG treatment.
Interestingly, MMR pro®ciency was restored even at
low hMLH1 concentrations, while checkpoint activ-
ation required a full complement of hMLH1. In
the MMR-pro®cient cells, activation of the MNNG-
induced G2/M checkpoint was accompanied by phos-
phorylation of p53, but the cell death pathway was
p53 independent, as the latter polypeptide is function-
ally inactivated in these cells by SV40 large T antigen.
Keywords: cell cycle checkpoint/hMLH1/methylating
agent/mismatch repair/TetOff
Introduction
Mutations in mismatch repair (MMR) genes, predomin-
antly hMSH2 and hMLH1, segregate with hereditary non-
polyposis colon cancer (HNPCC). Inheritance of a single
mutated allele of a MMR gene predisposes to precocious
cancers of the colon, endometrium and ovary. Analysis of
HNPCC tumour cells showed that repeated sequence
elements (microsatellites) in their genomic DNA are
frequently mutated (for a review see Peltomaki, 2001). As
microsatellite instability (MSI) is a hallmark of defective
MMR in all organisms tested to date, and has been shown
to be present in all tumour cell lines that have lost both
alleles of hMSH2 or hMLH1 (Boyer et al., 1995), it is
assumed that the wild type alleles of the respective MMR
genes in cells of HNPCC tumours have been lost or
inactivated by mutation. But mutations in MMR genes are
not an absolute prerequisite for MSI. In recent years, a
number of sporadic colon tumours and tumour cell lines
displaying MSI have been described that are MMR-
de®cient due to silencing of the hMLH1 promoter by
hypermethylation (reviewed in Esteller, 2002).
Once both MMR gene alleles have been inactivated, the
cell's propensity towards acquiring mutations increases,
especially in genes carrying microsatellite repeats. Should
the mutated genes be involved in the control of cell
proliferation, the mutator cell in, for example, the colonic
epithelium would be able to divide in an uncontrolled
manner and thus give rise to an adenomatous polyp. As the
cells in this benign growth acquire further mutations with
subsequent cell divisions, the adenoma would rapidly
become transformed into a carcinoma. That such a path to
transformation can be followed in vivo was demonstrated
when numerous HNPCC colon cancers were shown to
carry frameshift mutations in a run of 10 adenines within
the coding sequence of the transforming growth factor b
receptor type II (TGFbRII) gene, as well as in other genes
involved in growth control or apoptosis (reviewed in
Markowitz et al., 2002). Further support for this hypo-
thesis comes from the ®nding that adenomas of HNPCC
kindred transform to carcinomas with a much higher
frequency than those associated with sporadic disease
(Kinzler and Vogelstein, 1998), presumably due to a more
rapid acquisition of transforming mutations.
The above ®ndings help explain how the loss of MMR
might accelerate cellular transformation and tumour
progression. What is unclear to date, however, is whether
the transformation process begins only following the
inactivation of both MMR gene alleles, or whether it
commences already at the stage when only one allele is
affected or when the expression of the given MMR gene is
only attenuated, rather than shut off, such as might be the
case in cells where the hMLH1 promoter is only partially
methylated. The notion that a reduction in MMR protein
levels might promote tumorigenesis originates in studies
with Msh2+/± mice. Although the Msh2+/± embryonic stem
cells were apparently normal in terms of their MMR
capacity as measured by MSI (de Wind et al., 1995), the
heterozygous animals were cancer prone, and presented
with tumours that often still contained the wild-type Msh2
allele (de Wind et al., 1998). The propensity of the MMR
heterozygous cells to transformation would thus appear to
be linked to a process distinct from the correction of
replication errors. What might the nature of these
processes be?
In recent years, MMR defects have been linked to
several other phenomena, such as transcription-coupled
repair and recombinationÐboth mitotic and meiotic
(reviewed in Harfe and Jinks-Robertson, 2000). In
Methylation-induced G2/M arrest requires a full
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addition, the MMR system was implicated in activation
of cell cycle checkpoints and apoptosis, as witnessed by
the increased resistance of MMR-de®cient cells to the
methylating agent N-methyl-N¢-nitro-N-nitrosoguanidine
(MNNG) or cisplatin (reviewed in Bellacosa, 2001).
Thus, while MMR+/± cells, or cells expressing low amounts
of MMR proteins, may not display a mutator phenotype,
they might have at least a partial defect in one of the above
processes, speci®cally in the DNA damage signalling
pathway, which we judged to be of the greatest relevance to
cancer. We wanted to study these processes in detail, but we
lacked isogenic cells expressing varying amounts of MMR
proteins. Cells in which the MMR defect was corrected
either by transfer of a chromosome carrying a single wild-
type copy of the mutated MMR gene (Koi et al., 1994) or its
cDNA (Risinger et al., 1998; Buermeyer et al., 1999;
Lettieri et al., 1999; Claij and Te Riele, 2002) were
unsuitable for our studies, because they express similar or
even higher amounts of the complementing MMR proteins
than MMR-pro®cient controls. Thus, in order to be able to
study the phenotypic consequences associated with reduced
levels of MMR proteins, we had to generate a new line,
preferably of epithelial origin, in which the expression of a
selected MMR gene could be regulated. We now describe
the construction and characterization of a line in which the
expression of hMLH1 can be tightly regulated by
doxycycline with the help of the TetOff system.
Results
Construction of cells with inducible hMLH1
expression
The human embryonic kidney cell line 293T is MMR
de®cient, because the hMLH1 gene in these cells is
epigenetically silenced by promoter hypermethylation
(Trojan et al., 2002). We set out to correct its MMR
defect through the expression of exogenous hMLH1 using
the TetOff expression system, which can be tightly
regulated. We ®rst generated the 293T-TetOff cell line
by stable transfection of the 293T cells with a DNA vector
encoding the tetracycline-controlled transactivator (tTA).
In the second step, we stably transfected the 293T-TetOff
cells with a vector carrying the hMLH1 cDNA under the
control of the tetracycline response element (TRE), thus
creating 293T La cells. In the absence of tetracycline, or
its more stable analogue doxycycline (Dox), the tTA
protein binds to the TRE and activates transcription of
hMLH1; conversely, addition of the drug induces a
conformational change in tTA, which loses its ability to
bind DNA and the transcription of hMLH1 is thus turned
off (Figure 1A). During the initial screening, we used Dox
at a concentration of 2 mg/ml, as recommended by the
manufacturer, but later we found that a concentration of
50 ng/ml was suf®cient to turn off the expression of
hMLH1 below the limit of detection by western blotting
(see below).
In vivo, hMLH1 interacts with hPMS2 to form the
heterodimer hMutLa, which is essential for MMR. Our
previous studies have shown that hPMS2 is unstable in the
absence of its cognate partner (RaÈschle et al., 1999).
Indeed, no hMLH1 could be detected in the extracts of
293T cells, and hPMS2 was hardly detectable (Trojan
et al., 2002). A similar situation also existed in our 293T
La clone grown in the presence of Dox, i.e. under
conditions where the hMLH1 promoter is shut off
(Figure 1B). However, expression of hMLH1 brought
about hPMS2 stabilization through the formation of
hMutLa, such that the levels of the latter protein were
Fig. 1. Inducible hMLH1 expression in 293T La cells. (A) In the Tet-Off system, hMLH1 is expressed in the absence of Dox, because the tTA factor
binds to the promoter of the expression vector and thus activates transcription. Addition of Dox to the culture medium causes a conformational change in
tTA, which leads to its dissociation from the promoter and thus to an inactivation of hMLH1 transcription. (B) Western blot analysis of cytoplasmic (CE)
and nuclear (NE) extracts of cells cultured in the absence (±) or presence (+) of 50 ng/ml Dox. hMLH1 and hPMS2 were visualized using anti-hMLH1 or
anti-hPMS2 antibodies as described in Materials and methods. Total extract (TE) of MMR pro®cient HeLa cells was used as a positive control.
(C) Stability of hMutLa. The cells were cultured without Dox (±) to induce maximal hMLH1 expression. Following the addition of 50 ng/ml Dox (+),
total cell extracts were isolated after 1, 2, 3, 4, 6 and 8 days. Western blot analysis was performed using anti-hMLH1 and anti-hPMS2 antibodies as in (B).
P.Cejka et al.
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comparable to those seen in extracts of MMR-pro®cient
cell lines (Figure 1B).
The expression of hMLH1 in the 293T La cells grown
in the absence of Dox was substantially higher than in any
MMR-pro®cient cell line tested by us to date (Figure 1B;
data not shown). Interestingly, this overexpression did not
appear to be toxic to the cells: we detected no increase in
the rates of apoptosis, as described for cells microinjected
with expression vectors encoding hMSH2 and hMLH1
(Zhang et al., 1999). Moreover, cells grown in the absence
or presence of Dox divided roughly once every 24 h (data
not shown), unlike HCT116 and SNU-1 cells, in which the
stable expression of hMLH1 was reported to result in
substantially slower growth rates (Shin et al., 1998). When
the expression of the transgene was turned off by the
addition of Dox, the hMLH1 and hPMS2 proteins were
present in the cell extracts in a 1:1 ratio only 24 h later
(Figure 1C) and decayed with similar kinetics. This
experiment showed that hMutLa is extremely stable, as
it was detectable in the extracts of 293T La cells even
6 days after the expression of hMLH1 was shut off.
In the following text, cells grown in the presence of
50 ng/ml Dox that do not express hMLH1 and thus lack
hMutLa will be referred to as 293T La± cells. Those
grown in the absence of Dox, which express hMLH1 and
thus contain functional hMutLa, will be referred to as
293T La+ cells.
hMLH1 expression in 293T La cells restores MMR
in vitro
Extracts of the 293T La cells were tested for MMR
activity in vitro using two different MMR assays (see
Materials and methods). No MMR activity was detected in
extracts of 293T La± cells, but as the defect could be
complemented by the addition of the recombinant wild-
type hMutLa, we concluded that this heterodimer was the
only factor missing in these extracts (Figure 2). In contrast,
extracts from 293T La+ cells were MMR pro®cient in both
assays (Figure 2). Importantly, these results showed that
the excess partnerless hMLH1 in the 293T La line does
not inhibit MMR, at least not in our in vitro system. This
differs from the situation in Saccharomyces cerevisiae,
where overexpression of MLH1 gave rise to a mutator
phenotype associated most likely with the inhibition of
MMR through the homodimerization of this polypeptide
(Shcherbakova and Kunkel, 1999; Shcherbakova et al.,
2001). The MMR pro®ciency of the 293T La+ cells in our
in vitro assay was similar irrespective of whether the
extracts were prepared from cells grown in the absence of
Dox, or 24 h after the addition of the drug (data not
shown), at which time point the ratio of hMLH1 to hPMS2
was 1:1 (Figure 1C).
Inducible hMLH1 expression restores sensitivity to
alkylating agents
In order to determine the effect of hMLH1 expression on
the sensitivity of 293T La cells to MNNG, we used
clonogenic assays to quantify the surviving fraction of
293T La± and 293T La+ cells following treatment with
5 mM MNNG. [Note that 293T La cells do not express
MGMT, the enzyme responsible for the detoxi®cation of
methylation damage (G.Marra, unpublished data). For this
reason, the experiments described below were carried out
in the absence of the MGMT inhibitor O6-benzylguanine.]
As shown in Figure 3A, 293T La+ cells were very
sensitive to killing by MNNG, and the surviving fraction
was indistinguishable from that obtained after MNNG
treatment of the related MMR-pro®cient 293 cell line. In
contrast, 293T La± cells were resistant to killing by
MNNG, just like the parental, MMR-de®cient 293T cells.
The presence of Dox in the culture medium had no effect
on the survival of any of the control cell lines used in this
study (Figure 3A).
The sensitivity of 293T La cells to MNNG was further
examined using the MTT assay, which is based on the
cleavage of the yellow tetrazolium salt MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
by the action of mitochondrial dehydrogenases to form a
violet formazan dye. As this reaction takes place only in
living cells, these can be distinguished from non-viable
cells in a simple colorimetric assay. As shown in
Figure 3B, 293T La± cells were 125-fold more resistant
Fig. 2. MMR pro®ciency of 293T La cell extracts. (A) Repair ef®-
ciency of a G/T mismatch in the M13mp2 vector carrying a strand
discrimination signal 3¢ from the mispair, using cytoplasmic extracts of
the 293T La+ and 293T La± cells, supplemented or not with recom-
binant hMutLa (see text for details). Error bars show standard errors.
(B) Correction of a G/T mismatch within a BglII restriction site of a
pGEM vector, following incubation with nuclear extracts of 293T La+
or 293T La± cells, supplemented or not with recombinant hMutLa.
The strand discrimination signal in this heteroduplex substrate was 5¢
from the mispair. Ef®cient repair resulted in the restoration of a BglII
site and in the generation of two DNA fragments that co-migrate with
those observed in the reference digest of the homoduplex molecule
carrying a bona ®de BglII site.
Mismatch repair and methylation-induced G2/M arrest
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to killing by MNNG than the same cells in a MMR-
pro®cient mode (i.e. 293T La+ cells).
Expression of hMLH1 in 293T La cells leads to
activation of a methylation damage induced cell
cycle arrest
To determine whether the increased sensitivity of 293T
La+ cells to MNNG resulted from induction of cell cycle
arrest and cell death, the treated 293T La+ and 293T La±
cell populations were analysed by ¯ow cytometry. As
shown in Figure 3C, 2 days after treatment with 0.2 mM
MNNG, the 293T La+ cells were mostly arrested in the
G2/M phase of the cell cycle. One day later, cells
containing sub-G1 amounts of DNA became detectable,
and this population increased with time. In contrast, no
increase in the population of cells either arrested in G2/M
or with a lower than 2n DNA content was detected in
cultures of treated 293T La± cells.
In order to further characterize the response of cells to
MNNG, we analysed the phosphorylation status of Cdc2.
As shown in Figure 4A, Cdc2 phosphorylated on Tyr15
accumulated exclusively in 293T La+ cells treated with
0.2 mM MNNG. This provides molecular evidence for a
G2/M arrest, because so long as this kinase remains
phosphorylated, entry into mitosis should be blocked. No
difference in Cdc2 phosphorylation was observed in the
extracts of MNNG-treated 293T La± cells (Figure 4A).
The above results thus show that induction of hMLH1
expression in the 293T La cells was necessary and
suf®cient to endow them with a MMR-pro®cient status,
which also enabled them to respond to DNA damage
induced by MNNG. What is presently unclear is the role of
the MMR system in this checkpoint activation. DNA
damage signalling is known to be mediated via several
protein phosphorylation cascades, which involve primarily
the DNA-dependent protein kinase (DNA-PK), or the
ataxia telangiectasia-mutated (ATM) and ATM and
Rad3-related (ATR) kinases. The downstream target of
the latter enzymes is the p53 tumour suppressor protein,
the phosphorylation of which on Ser15 is known to lead to
its stabilization and subsequent activation as a transcrip-
tion factor (Tibbetts et al., 1999). Phosphorylation of p53
has indeed been shown to take place upon MNNG
treatment, and was shown to be dependent on functional
hMutSa and hMutLa (Duckett et al., 1999; Hickman and
Samson, 1999; Adamson et al., 2002). However, as the
latter experiments were carried out with drug concentra-
tions 25- to 125-fold higher than those used in our study,
we wanted to test whether Ser15 phosphorylation also took
place in the 293T La cells treated with 0.2 mM MNNG.
These cells overexpress the SV40 large T antigen and thus
contain large amounts of stabilized p53 polypeptide. This
system is ideally suited for the study of post-translational
modi®cation of p53, as the steady-state levels of the latter
protein remain unaltered during the experiment (Tibbetts
et al., 1999). As anticipated, the p53 steady-state levels in
the 293T La cell extracts were high, irrespective of
whether hMLH1 was expressed or not, or whether extracts
of treated or untreated cells were examined (Figure 4A).
However, following MNNG treatment, phosphorylation of
p53 with a Ser15-speci®c antibody could be detected
exclusively in the MMR-pro®cient 293T La+ cells.
Notably, and in contrast to the study by Adamson et al.
(2002), where the phosphorylation of p53 became detect-
able already just minutes after MNNG treatment, the
MMR-dependent post-translational modi®cation of p53
observed in our cells peaked at 48 h, i.e. at a time point
where most cells were arrested at G2/M (Figure 3C). This
difference is probably linked with the high concentration
of MNNG (25 mM) used in the latter study, which would
be expected to introduce numerous single- and double-
strand breaks into DNA that arise through the spontaneous
loss of methylated purines and the subsequent breakage of
the sugar-phosphate DNA backbone by b-elimination at
the resulting abasic sites (Loeb, 1985). DNA strand breaks
rapidly activate the ATM/ATR kinases that subsequently
phosphorylate a number of downstream targets, one of
which is histone H2AX (Redon et al., 2002). This histone
modi®cation is thought to aid the recruitment of DNA
repair factors to the sites of damage (Paull et al., 2000).
H2AX is phosphorylated in the 293T La cells upon
Fig. 3. Sensitivity of 293T La cells to MNNG. (A) Survival of 293T
La+ and 293T La± cells following treatment with 5 mM MNNG. 293
and 293T cells were used as MMR-pro®cient and -de®cient controls,
respectively. The presence of Dox (+Dox) in the culture medium did
not affect the control cells, but had a dramatic effect on the survival of
the 293T La cell populations. (B) IC50 values of 293T La+ and 293T
La± cells. Each value represents the mean 6 SE. (C) Cell cycle pro®les
of 293T La+ and 293T La± cells treated with 0.2 mM MNNG. Shown
are representative cytometrograms of cells expressing (293T La+) and
not expressing (293T La±) hMLH1. G1, cell population in the G1 phase
of the cell cycle with a 2n DNA content; G2, cells in the G2 and M
stages of the cell cycle with a 4n DNA content; S, cells in various
stages of DNA synthesis with a DNA content between 2n and 4n.
P.Cejka et al.
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treatment with 0.2 mM MNNG, as witnessed by the
formation of phospho-H2AX foci (Figure 4B). However,
these foci arise in both 293T La+ and 293T La± cells soon
after treatment. Thus, damage caused by direct modi®ca-
tions of DNA at low concentrations of MNNG does not
trigger the G2/M checkpoint. The activation of the
checkpoint machinery must take place after H2AX
phosphorylation, in the second cell cycle post-treatment
(Kaina et al., 1997), and must involve the MMR system,
perhaps in conjunction with another pathway of DNA
metabolism that remains to be identi®ed. Thus, the lesions
that trigger the checkpoint machinery are distinct from
those that bring about phosphorylation of H2AX.
MMR pro®ciency and response to MNNG
treatment require different levels of hMLH1
expression
The principal goal of this study was to investigate the
phenotypic effects of reduced expression of MMR
proteins, such as might be encountered when expression
of the gene is attenuated by cytosine methylation. In order
to achieve this goal, we attempted to modulate hMLH1
expression in the 293T La cells. This could be achieved
by varying the Dox concentration in the culture media.
Thus, cells grown in the presence of 0.1, 0.2, 0.4, 0.8 and
1.5 ng/ml Dox contained steadily decreasing amounts of
hMLH1 and hPMS2, as compared with cells grown in the
absence of the drug (Figure 5A).
When we tested how this variation in the amount of
hMutLa affected MMR ef®ciency, we found that extracts
of cells expressing as little as 10% of the amounts found in
cells grown in the absence of Dox were still pro®cient in
the in vitro MMR assays. Cells cultivated with 0.1 and
0.2 ng/ml Dox showed MMR activities comparable to
those of the MMR-positive 293T La+ cells grown in the
absence of Dox, and even extracts of cells cultivated with
0.4 ng/ml Dox were still able to repair mismatches in vitro,
albeit with lower ef®ciency (Figure 5B). MMR pro®ciency
was lost only in cell extracts in which the hMLH1 and
hPMS2 proteins became dif®cult to detect by western
blotting (Figure 5A). To test whether the results of the
in vitro MMR assays were re¯ected also in the MSI
Fig. 4. Post-translational protein modi®cation and strand break process-
ing in MNNG-treated 293T La cells. (A) Phosphorylation status of p53
and cdc2 in 293T La+ and 293T La± cells 1±4 days after treatment
with 0.2 mM MNNG. P-p53, P-cdc2, phosphorylated p53 and cdc2
proteins, respectively; C, untreated control cells; b-tubulin, internal
standard used to ascertain equal gel loading. (B) g-H2AX foci forma-
tion in MNNG-treated 293T La cells. In the control cell population,
<10% of cells displayed H2AX foci. Following MNNG treatment, all
cells contained foci until 24 h post-treatment. See text for details and
Materials and methods for experimental procedures.
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phenotype of the cells, we analysed the BAT26 micro-
satellite marker, which contains a repeat of 26 deoxy-
adenosines, and which is considered to be a reliable
indicator of MSI. Because the 293T La cells are hypo-
triploid, and because this cell line was MMR de®cient for
many generations prior to our intervention, the BAT26
locus was found to be highly heterogeneous. The product
of PCR ampli®cation had on average eight peaks, and we
therefore applied the HNPCC criteria of MSI (Loukola
et al., 2001), whereby only PCR products that differed by
three or more peaks at this locus were considered to be a
sign of MSI. By these criteria, the BAT26 instability in the
cells propagated for 35 generations in 0 or 0.2 ng/ml
Dox was ~1%, whereas cells grown with 50 ng/ml Dox
displayed MSI that was ~5-fold higher (Table I). How-
ever, closer inspection of the data revealed that cells
propagated in 0 or 0.2 ng/ml Dox displayed no alleles
(0/211) that differed by more than 4 bp from the median. In
contrast, two such alleles (two out of 73; 2.7%) were found
in the cells grown with 50 ng/ml Dox (Table I, numbers in
parentheses). This suggests that MSI at the BAT26 locus
in the 293T La± cells is substantially greater than in cells
expressing hMLH1, and thus that expression of even low
amounts of hMutLa are suf®cient to correct the MMR
defect in these cells, both in vitro (Figure 2) and in vivo
(Table I).
We were interested to determine whether the low
amounts of the hMLH1/hPMS2 heterodimer that were
shown to restore MMR pro®ciency were also able to
activate the DNA damage-induced cell cycle arrest in
293T La cells. To this end, we treated the cells with 5 mM
MNNG and calculated the average doubling time over a
period of 5 days. In accordance with our previous
experiments, only cells expressing the highest amounts
of hMLH1 (i.e. 293T La+ cells grown without Dox) ceased
to grow, as suggested by their increased doubling time.
Cells grown in 0.1 ng/ml Dox were only partially affected,
and cells cultivated with 0.2 ng/ml Dox or more grew
similarly to 293T La± cells (Figure 5C). To test whether
this growth retardation was due to checkpoint activation,
we analysed the DNA content of the cells 3 days after
treatment with 0.2 mM MNNG. As shown in Figure 5D,
FACS analysis showed that only cells expressing the
highest amounts of hMLH1 (i.e. cells cultured without
Dox) displayed a strong G2/M arrest (an average of 63% of
the cells were in G2/M). The response of cells cultivated
with 0.1 ng/ml Dox was substantially weaker (~27% cells
in G2/M), and the cell cycle pro®les of cells grown with
0.2 ng/ml Dox or more were indistinguishable from those
of the untreated controls (~22% cells in G2/M). Notably,
whereas cells grown in the absence of Dox activated the
MNNG-induced G2/M checkpoint, while those grown in
Table I. Instability of the BAT26 chromosomal locus in 293T La
cells expressing varying amounts of hMLH1
Dox (ng/ml) MSI+/total % MSI
0 2 (0)/131 1.5
0.2 1 (0)/80 1.3
50 4 (2)/73 5.5 (2.7)
MSI+ clones were de®ned as those displaying more than three extra
peaks in the sequence of the PCR product. Numbers in parentheses
refer to clones with more than four extra peaks.
Fig. 5. Mismatch correction ef®ciency and MNNG-induced G2/M arrest
in cells expressing different amounts of hMLH1. (A) Dependence of
hMLH1 expression on Dox concentration. hMLH1 and hPMS2 were
visualized as described in Materials and methods. b-tubulin, internal
standard used to ascertain equal loading. (B) MMR ef®ciency of a G/T
mispair in an M13mp2 substrate carrying a strand-discrimination signal
3¢ from the mispair. Error bars show standard errors. (C) Variation in
doubling times of 293T La cells grown in the indicated Dox concentra-
tions following treatment with 5 mM MNNG. (D) FACS analysis of
293T La cell populations grown in the indicated Dox concentrations,
either untreated (Control), or 72 h after treatment with 0.2 mM MNNG
(see also Figure 3C). (E) Phosphorylation of p53 and cdc2 48 h after
treatment of cells (grown in the indicated Dox concentrations) with
0.2 mM MNNG. b-tubulin, internal standard used to ascertain equal
loading.
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0.2 ng/ml Dox failed to do so, phosphorylated forms of
p53 and cdc2 could be detected in both cell populations
(Figure 5E). The extent of cdc2 phosphorylation in
particular would predict that a detectable proportion of
the treated cells should be at the G2/M boundary. This was
clearly not the case, as judged by FACS analysis
(Figure 5D; also see Figure 3C).
Taken together, these experiments show that although
only low amounts of hMutLa are required for MMR
pro®ciency, DNA damage-induced G2/M arrest and cell
death in response to MNNG treatment require a full
complement of this heterodimer. The fact that the 293T
La+ cells arrest and die with kinetics and ef®ciency similar
to other MMR-pro®cient cells con®rms that p53, which is
inactive in these cells, is not required for either of
these processes (Hickman and Samson, 1999). Thus, the
molecular pathways controlling the MNNG-induced G2/M
checkpoint in these cells require further study.
Discussion
We show that expression of hMLH1 in 293T La cells
corrected their MMR defect in vitro and in vivo. The 293T
La+ cells were also found to be >100-fold more sensitive
to killing by MNNG than the isogenic cells lacking
hMLH1. MNNG treatment arrested the MMR-pro®cient
cells in the G2/M phase of the cell cycle, and this arrest
was entirely and solely dependent on the function of
hMLH1. This latter statement is supported by the ®nding
that expression of hMLH1 in 293T La+ cells did not affect
the transcriptional activity of other genes, as demonstrated
by Affymetrix GeneChipÔ analysis (data not shown).
This study also showed that the steady-state levels of the
hMLH1/hPMS2 heterodimer required for MMR pro®-
ciency and DNA damage response were signi®cantly
different. In earlier experiments (Lettieri et al., 1999) we
generated a cell line derived from hMSH6-de®cient
HCT15 cells, which expressed low levels (~20%) of
wild-type hMSH6. This line was MMR pro®cient, but
remained as resistant to killing by methylating agents as
the parental cell line. Similarly, a recent study described a
Msh2±/± mouse embryonic stem cell line in which the
MMR defect was largely corrected by the expression of
low levels (10% of control) of exogenous Msh2, but the
response of these cells to methylating agents was
comparable to that observed with the parental Msh2±/±
cells (Claij and Te Riele, 2002). This damage signalling
defect was suggested by the authors to be linked to poor
recognition of MeG/T mispairs, which arise through the
mispairing of O6-methylguanine (MeG) with thymine
during DNA replication (Karran and Bignami, 1996),
and which are bound less ef®ciently than bona ®de
mispairs by the hMSH2/hMSH6 (hMutSa) heterodimer
(Duckett et al., 1996). Constant loading of hMutSa sliding
clamps at MeG/T mispairs was proposed be responsible for
transmission of the DNA damage signal to the checkpoint
machinery in vivo (Fishel, 1999), and it might be expected
that this process is substantially less ef®cient in cells
expressing only low amounts of the mismatch binding
factor hMutSa. However, the amounts of hMutSa in 293T
La+ and 293T La± cells are equal, and similar to those
found in other MMR-pro®cient cells. Our results thus
extend the above hypothesis by showing that the signal
transduction process also requires the hMLH1/hPMS2
heterodimer, thought to act downstream of damage
recognition. Moreover, our result show that the recogni-
tion of MeG/T mispairs per se is insuf®cient to activate the
checkpoint machinery. The G2/M checkpoint is thought to
be controlled by the phosphoinositide-3 (PI3) kinases
ATM/ATR, which are principally responsible for the
phosphorylation of p53 on Ser15 (Osborn et al., 2002).
The MeG/T mispairs arise already during the ®rst round of
replication, yet no p53 phosphorylation is detectable until
24 h after treatment, at which point the cells are beginning
to enter the second S phase (Figure 3C; data not shown).
Notably, the peak of signalling activity coincides with
that of chromosomal rearrangements (sister chromatid
exchanges and recombinations) induced by MNNG (Kaina
et al., 1997). Thus, MMR-dependent processing of the
MeG/T mispairs that arise during the ®rst S phase
apparently does not activate the checkpoint machinery,
but leads instead to the generation of intermediates that
result in aberrant recombination events during the subse-
quent round of DNA replication, which then signal. What
the exact nature of these intermediates may be is currently
the subject of intensive studies.
The evidence presented here shows that cells with lower
than wild-type levels of MMR proteins are not pheno-
typically normal, despite being MMR pro®cient. The
observed defect in DNA damage signalling may be
relevant to cellular transformation and cancer, particularly
in epithelial cells that are rapidly proliferating and that
may be exposed to stress or carcinogens. In the colon, the
epithelial stem cells that are near the bottom of the crypts
give rise to daughter cells that begin to differentiate during
their migration towards the surface of the colon. Upon
reaching the apex of the crypt, these cells undergo
apoptosis and are shed. When the colonic epithelial cells
become damaged, they should undergo apoptosis and thus
give rise to no mutant progeny. In contrast, cells with a
defect in DNA damage signalling, such as those express-
ing suboptimal amounts of MMR proteins, would not
activate cell cycle checkpoints and apoptosis in response
to DNA damage. Instead, they might acquire mutations
that allow them to continue to proliferate and give rise to
an adenoma.
The relevance of this hypothesis to the situation in vivo
hinges on two points. First, there are currently no
experimental data documenting instances where colono-
cytes or other epithelial cells that are prone to transform-
ation express low MMR protein levels. We obtained some
evidence of lower than normal steady-state levels of
hMSH2 and increased resistance to methylating agents in
the immortalized lymphoblasts of HNPCC patients, which
are heterozygous in the hMSH2 locus, but the hMLH1±/±
cells were normal in all assays (Marra et al., 2001). It is not
known whether hMSH2 and hMLH1 levels in hetero-
zygous colonocytes of HNPCC kindred are lower than in
similar cells of normal individuals, even though some
¯uctuations might be expected. However, the recent
characterization of the hMLH1 promoter as a frequent
target of DNA hypermethylation (Esteller, 2002) implies
that there must be cells with only partially methylated
promoters, because de novo methylation of CpG islands is
a gradual process. These cells, such as the 293T La cells
grown in low concentrations of Dox (Figure 5A), would
Mismatch repair and methylation-induced G2/M arrest
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contain decreased levels of hMutLa and would therefore
be likely to also have a defective response to DNA
damage.
The second point concerns the nature of the endogenous
DNA damage that might trigger the transformation
process. It is conceivable that normal colonocytes which
become damaged by endogenous or exogenous DNA
modifying agents would arrest and, in cases where the
extent of the damage is beyond repair, activate cell death
processes, while those expressing reduced levels of
hMutLa would continue to proliferate and thus acquire
mutations. Although human DNA is aberrantly modi®ed
by S-adenosyl methionine and other methyl group donors,
the extent of such modi®cations might be too low to trigger
cell death. However, the deleterious effects of the
checkpoint defect could become evident also in response
to other types of DNA damage; experimental evidence
implicates the MMR system in the processing of DNA
modi®cations ranging from oxidative damage to bulky
moieties such as cisplatin and AAF (reviewed in
Bellacosa, 2001).
We have described a cell line in which the MMR status
can be controlled by the concentration of doxycycline in
the culture medium. Our current results show that the
activation of transcription of exogenous hMLH1 comple-
ments not only the MMR defect of the 293T cells, but also
reactivates their responsiveness to treatment with methyl-
ating agents, providing that the levels of the MMR proteins
are suf®ciently high to activate the DNA damage-induced
checkpoint. This fully isogenic system is clearly open to
further exploitation, and should allow us to study the
involvement of the MMR system in other pathways of
DNA metabolism, such as response to other types of DNA
damaging agents ranging from ionizing radiation to
crosslinking chemotherapeutics, where the involvement
of MMR was found to be only marginal and where it could
not be ruled out that the observed effects (or lack thereof)
were linked to a selection of an atypical clone from the
stably transfected population. The 293T La line could also
be used in the screening for substances that preferentially
kill MMR-de®cient cells. This should prove invaluable in
the treatment of tumours, both hereditary and sporadic,
with defective MMR.
Materials and methods
Cell lines
The 293T cells (a kind gift of K.Ballmer) were grown in Dulbecco's
modi®ed Eagle's medium with Eagle salts (Gibco-BRL, Gaithersburg,
MD), supplemented with 10% Tet System Approved Fetal Bovine Serum
(Clontech, Palo Alto, CA), 2 mM L-glutamine (Gibco-BRL), 100 IU/ml
penicillin and 100 mg/ml streptomycin (Gibco-BRL). For 293T-TetOff or
293T La cells, 100 mg/ml Zeocin (Invitrogen, San Diego, CA) or
100 mg/ml Zeocin and 300 mg/ml Hygromycin B (Roche Molecular
Biochemicals, Mannheim, Germany) were added, respectively.
Plasmid construction
The pTetOff-Zeo plasmid was constructed by ligation of the following
DNA molecules: the ®rst, coding for tTA, was obtained by digestion of
pTetOff (Clontech) with XhoI (New England Biolabs, Beverly, MA)
followed by ®lling-in with dCTP and dTTP using the Klenow fragment of
DNA polymerase I (New England Biolabs). The second, coding for
Zeocin resistance protein, was obtained by digestion of pVgRXR
(Invitrogen) with BamHI (New England Biolabs) followed by ®lling-in
with dGTP and dATP. The pTRE2-hMLH1 plasmid was generated by
subcloning hMLH1 cDNA (a kind gift of R.Michael Liskay) into the
BamHI and NotI sites of pTRE2 (Clontech).
Calcium phosphate transfections
One day before transfection, 250 000 cells were plated in 6-well plates in
3 ml of cell culture medium. The cells reached ~50% con¯uency on the
day of transfection. Three hundred microlitres of solution A (250 mM
CaCl2) was carefully mixed with 15 mg DNA and 300 ml of solution B
(140 mM NaCl, 50 mM HEPES, 1.4 mM Na2HPO4 pH 7) in an Eppendorf
tube. Exactly 1 min after mixing, 300 ml of the precipitation cocktail was
added to the medium. The plates were incubated for 4 h at 37°C. The
medium was then removed, the cells were washed with phosphate-
buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4´7H2O, 1.4 mM KH2PO4) and fresh cell culture medium was
added.
Generation of the 293T La cell line
293T cells were transfected with pTetOff-Zeo using the calcium
phosphate method (see above). The selection of stable cell lines was
initiated 2 days later using 400 mg/ml Zeocin. After 3 weeks, ~50 colonies
were isolated and screened by transient transfection with pTRE2-Luc
(Clontech) for the expression of luciferase in induced and noninduced
cells (with or without 2 mg/ml Dox; Clontech). The clone with the lowest
background and high induction of luciferase (293T-TetOff) was then
transfected with pTRE2-hMLH1 and pTK-Hyg (ratio 15:1). Selection of
stable cell lines was initiated 2 days post-transfection using 400 mg/ml
hygromycin-B. After 3 weeks, ~160 colonies were isolated and their
extracts were screened by western blotting using antibodies against
hMLH1, hPMS2 and b-tubulin. The clone 293T La was selected for
further study, as it displayed the highest induction of hMLH1 in the
absence of Dox, and no background expression with 2 mg/ml Dox.
Regulation of hMLH1 expression
293T La cells were grown in the presence of 50 ng/ml Dox to keep
hMLH1 expression turned off; fresh Dox was added every second day. To
induce hMLH1 expression, the cells were transferred to a Dox-free
medium, and the cells were cultivated for at least 6 more days. To obtain
cells completely free of hMLH1, cells grown in the absence of Dox were
kept for a least 7 days in a medium containing 50 ng/ml Dox. To obtain
intermediate levels of hMLH1, the cells were cultivated with 1.5, 0.8, 0.4,
0.2 or 0.1 ng/ml Dox for at least 7 days.
Preparation of total protein extracts for western blots
Cells were harvested, transferred to a 1.5 ml Eppendorf tube and washed
twice with PBS. Cell lysis was performed on ice in 50 mM Tris±HCl pH 8,
125 mM NaCl, 1% NP-40, 2 mM EDTA, 1 mM phenylmethylsulfonyl
¯uoride, 13 complete protease inhibitory cocktail (Roche Molecular
Biochemicals) for 25 min. Insoluble material was pelleted by
centrifugation at 18 000 g for 3 min at 2°C. Protein concentration was
determined using the Bradford assay (Bio-Rad, Munich, Germany).
Western blot analyses
The primary antibodies used in this study were: anti-hMLH1
[PharMingen, San Diego, CA), 1:2000 in TBST (20 mM Tris±HCl
pH 7.4, 150 mM NaCl, 0.1% Tween-20 with 2.5% non-fat dry milk],
hPMS2 (Calbiochem; 1:500), b-tubulin, p53 (Santa Cruz Biotechnology;
1:1500 and 1:2000, respectively), cdc2 (Upstate Biotechnology;
1:1000) and phospho-p53-Ser15, phospho-cdc2-Tyr15 (Cell Signalling
Technology; 1:1000 and 1:5000, respectively). The proteins (20±50 mg)
were denatured, reduced, separated by SDS±PAGE (7.5±12.5%) and
transferred to Hybond-P PVDF membrane (Amersham Pharmacia
Biotech) according to standard protocols (Sambrook et al., 1989). The
membranes were blocked with 5% non-fat dry milk in TBST for 60 min,
incubated with primary antibodies for 60 min, washed three times with
TBST for 10 min, incubated with the peroxidase-conjugated secondary
antibody (anti-mouse IgG, 1:5000 in TBST with 2.5% non-fat dry milk)
for 60 min and washed three times with TBST for 10 min.
Immunoreactive proteins were detected using enhanced chemilumines-
cence (ECL; Amersham Pharmacia Biotech).
Indirect immuno¯uorescence experiments
Cells grown on coverslips were treated or mock-treated with MNNG
(0.2 mM end concentration) and incubated for 6, 12 and 24 h (Figure 4B).
Foci of phosphorylated histone H2AX were visualized using an anti-
phospho-H2AX rabbit polyclonal antibody (Upstate Biotechnology) at
+4°C, over night, at a dilution of 1:100. The procedure was as described
previously (Kleczkowska et al., 2001). To allow direct comparisons, all
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the cells were treated and processed simultaneously, and all the images
were obtained using the same magni®cation, brightness and contrast
settings.
MMR assays
The cell extracts were prepared as described previously (Marra et al.,
2001; Nystrom-Lahti et al., 2002). Two different in vitro assays were
used. The ®rst, adapted from Holmes et al. (1990), is based on a circular
3¢ 193 bp DNA molecule containing a G/T mismatch within a unique
BglII recognition site, a single-strand nick 369 nucleotide residues 5¢ from
the mismatch in the G-containing strand, and a unique BsaI site. This
molecule is refractory to cleavage with BglII, unless the mispair is
corrected to an A/T. Thus, the unrepaired heteroduplex digested with both
endonucleases gives rise to only a single fragment of 3¢ 193 bp, whereas
the repaired homoduplex is cleaved into two fragments of 1¢ 833 and
1¢ 360 bp (Nystrom-Lahti et al., 2002).
The second method, originally described by Thomas et al. (1991),
makes use of an M13mp2 DNA heteroduplex containing G/T mismatch
within lacZa complementation gene, obtained by hybridizing single-
stranded viral (+) DNA with the replicative form I (±) strand. The repair is
directed to the (±) strand by the presence of a nick. The method was
described in detail elsewhere (Marra et al., 2001). In the complementation
studies, extracts were supplemented with puri®ed recombinant hMutLa
(0.1 mg).
MTT assays
Two thousand cells/well were plated in 96-well plates, treated the next
day with various concentrations of MNNG (Sigma; diluted in dimethyl
sulfoxide and stored at ±20°C in the dark) and incubated for 5 days. Then,
20 ml of MTT solution (5 mg/ml MTT; Sigma; in PBS, sterile ®ltered) was
added, and the plates were incubated for 4±5 h at 37°C. One volume of
lysis solution was then added (20% SDS, 50% dimethylformamide
pH <4.7), and the plates were incubated overnight at 37°C. The
solubilized formazan was quanti®ed at 570 nm, using the Versamax
microplate reader (Molecular Devices, Sunnyvale, CA). The optical
density values were plotted against logarithm of MNNG concentrations
and IC50 values were calculated from the regression curve.
Colony-forming assays
Cells in log phase (50±80% con¯uent) were treated with 5 mM MNNG,
harvested after 2 h, and 200 or 2000 cells per duplicate were plated in
10 cm plates. Colonies were counted after 15±20 days of incubation.
Survival was calculated as the ratio of the number of colonies from
treated versus untreated samples.
Doubling time assessment
Cells (35 000) were plated in 35 mm plates. The cell number was
determined daily for 4 days. The doubling time was calculated from the
numbers of cells between the ®rst and the fourth day after plating.
Cell cycle analyses
Cells (both attached and ¯oating) were harvested, counted, washed with
PBS, ®xed with 70% ethanol and stored up to 1 week at 4°C. The cells
were then washed once with PBS, incubated in PBS containing RNase A
(100 mg/ml, Sigma) for 1 h at 37°C, stained with propidium iodide
(20 mg/ml, Sigma) and incubated on ice in the dark for 30 min. DNA
content was analysed by Coulter Epics Altra Flow Cytometer (Beckman
Coulter, Inc., Fullerton, CA). DNA cell cycle analysis software
(MultiCycle, Phoenix Flow Systems, Inc., San Diego, CA) was used to
quantify cell cycle distribution.
MSI analysis
293 La cells grown with 50, 0.2 and 0 ng/ml Dox were subcloned, and
grown independently for 35 generations. The chromosomal DNA was
extracted using the TRI Reagent (Molecular Research Center, Lucerne,
Switzerland). MSI was assessed at the mononucleotide repeat locus
BAT26. PCRs were carried out in a total volume of 25 ml containing
~100 ng of genomic DNA, as described by Loukola et al. (2001). The
PCR products were diluted 1:4 and 0.5 ml was added to 10 ml deionized
formamide (including 0.5 ml GS size standard 400 ROX), denatured at
95°C for 5 min, chilled on ice and loaded on a 96-capillary ABI PRISM
3700 DNA Analyzer (PE Applied Biosystems). MSI was de®ned as the
occurrence of novel alleles that differed by 63 nucleotides from the
control (Loukola et al., 2001).
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Functional absence of MMR proteins has been linked to defective DNA damaging 
signalling and cell cycle arrest upon MNNG treatment. In order to study the role of 
MMR proteins in activation of signalling cascades, 293T Lα cells were treated with 
MNNG and subsequent activation of DNA damage signalling pathways was assessed. 
Stojic et al. show that MNNG treatment induced a cell cycle arrest that was absolutely 
dependent on functional MMR. Unusually, the cells arrested only in the second G2 phase 
after treatment. Downstream targets of both ATM and ATR kinases were modified, but 
only the ablation of ATR, or the inhibition of CHK1, attenuated the arrest. The 
checkpoint activation was accompanied by the formation of nuclear foci containing the 
signaling and repair proteins ATR, the S*/T*Q substrates, γ-H2AX, and replication 
protein A (RPA). The persistence of these foci implied that they might represent sites of 
irreparable damage. 
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Mismatch repair-dependent G2
checkpoint induced by low doses
of SN1 type methylating agents
requires the ATR kinase
Lovorka Stojic, Nina Mojas, Petr Cejka, Massimiliano di Pietro, Stefano Ferrari, Giancarlo Marra,
and Josef Jiricny1
Institute of Molecular Cancer Research, University of Zurich, CH-8008 Zurich
SN1-type alkylating agents represent an important class of chemotherapeutics, but the molecular mechanisms
underlying their cytotoxicity are unknown. Thus, although these substances modify predominantly purine
nitrogen atoms, their toxicity appears to result from the processing of O6-methylguanine (6MeG)-containing
mispairs by the mismatch repair (MMR) system, because cells with defective MMR are highly resistant to
killing by these agents. In an attempt to understand the role of the MMR system in the molecular
transactions underlying the toxicity of alkylating agents, we studied the response of human MMR-proficient
and MMR-deficient cells to low concentrations of the prototypic methylating agent
N-methyl-N-nitro-N-nitrosoguanidine (MNNG). We now show that MNNG treatment induced a cell cycle
arrest that was absolutely dependent on functional MMR. Unusually, the cells arrested only in the second G2
phase after treatment. Downstream targets of both ATM (Ataxia telangiectasia mutated) and ATR (ATM and
Rad3-related) kinases were modified, but only the ablation of ATR, or the inhibition of CHK1, attenuated the
arrest. The checkpoint activation was accompanied by the formation of nuclear foci containing the signaling
and repair proteins ATR, the S*/T*Q substrate, -H2AX, and replication protein A (RPA). The persistence of
these foci implied that they may represent sites of irreparable damage.
[Keywords: ATM/ATR; cell cycle arrest; DNA damage signaling; G2 check point; methylating agents;
mismatch repair]
Received December 6, 2003; revised version accepted April 6, 2004.
Treatment of cells with clastogenic DNA damaging
agents such as ionizing radiation (IR) generally results in
the rapid activation of damage signaling pathways, cell
cycle arrest and, depending on the extent of damage, ei-
ther recovery or cell death. IR causes predominantly
DNA base modifications (Cooke et al. 2003), which are
rapidly and efficiently processed by the base excision re-
pair (BER) system. Interestingly, this metabolic pathway
does not appear to trigger DNA damage checkpoints. In-
stead, IR-induced signaling events are believed to be as-
sociated exclusively with the detection or processing of
single- and double-strand breaks (DSBs), which rapidly
activate the ATM (Ataxia telangiectasia mutated) ki-
nase (Bakkenist and Kastan 2003) and, later, also ATR
(ATM and Rad3-related; Brown and Baltimore 2003).
DNA damage-induced signaling cascades can be acti-
vated also by DNA replication forks stalled by DNA
damage (e.g., ultraviolet-induced photodimers or cross-
links), nucleotide depletion (e.g., on hydroxyurea treat-
ment), or polymerase arrest (e.g., by aphidicolin). In all
the latter cases, the signaling events are triggered in the
first S phase after treatment and involve primarily the
activation of ATR kinase and its downstream targets
(Abraham 2001; Osborn et al. 2002; Shiloh 2003).
DNA damage signaling induced by SN1-type methyl-
ating agents has to date not been studied in detail. Treat-
ment of cells with N-methyl-N-nitrosourea (MNU) and
N-methyl-N-nitro-N-nitrosoguanidine (MNNG) gives
rise predominantly to N7-methylguanine (7MeG), N3-
methyladenine (3MeA), O4-methylthymine (4MeT), O6-
methylguanine (6MeG), and methyl-phosphotriesters in
their DNA. The major adducts, 7MeG and 3MeA, repre-
sent ∼70% of the damage. However, both these methyl-
ated bases are efficiently removed from DNA by alkyl-
adenine DNA-glycosylase (Scharer and Jiricny 2001), and
the resulting abasic sites are repaired by the BER path-
way (Seeberg et al. 1995), without causing undue cyto-
toxicity at low concentrations. Interestingly, the cyto-
toxicity of the above methylating agents is ascribed to
6MeG, detoxified by methylguanine methyl transferase
(MGMT), which reverts it back to guanine (Sedgwick
1Corresponding author.
E-MAIL: jiricny@imr.unizh.ch; FAX 41-1-634-8904.
Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/
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and Lindahl 2002). 6MeG residues were implicated in cell
killing when cells expressing high levels of MGMT were
shown to be highly resistant to killing by MNU (Karran
2001), but how can persistent 6MeG residues in DNA
lead to cell death?
In 1993, the presence of 6MeG in plasmid DNA was
shown to inhibit DNA replication, but also to stimulate
DNA repair synthesis (Ceccotti et al. 1993). This evi-
dence was extended to show that 6MeG residues did not
inhibit DNA polymerases per se, but that DNA replica-
tion was arrested through a trans-acting signal generated
during the processing of 6MeG residues in DNA (Zhu-
kovskaya et al. 1994). The discovery that cells defective
in both mismatch repair (MMR) and MGMT were resis-
tant to killing by methylating agents implicated the
MMR system in this processing. The MMR substrates
are thought to be 6MeG/T mispairs, which arise during
replication of methylated DNA because of the propen-
sity of 6MeG to preferentially base pair with thymine.
The recognition of the 6MeG/T mispairs by the mis-
match binding factor hMutS (Duckett et al. 1996) is
believed to activate a signal transduction pathway that
results in a G2/M arrest (Aquilina et al. 1999; Cejka et al.
2003). However, how this arrest is activated is currently
unclear. One hypothesis proposes that the repeated load-
ing of the mismatch binding proteins at the mismatch
site may be sufficient to activate a DNA damage-signal-
ing cascade (Fishel 1998). The other suggests that the cell
cycle arrest is activated by nonproductive, repetitive pro-
cessing of 6MeG/T mispairs by the MMR system, or by
intermediates arising as a result of this processing (for
review, see Bellacosa 2001; Karran 2001). We set out to
gain more insights into the molecular transactions un-
derlying the G2/M cell cycle arrest induced by methyl-
ating agents of SN1 type. To this end, we studied the
behavior of proteins involved in DNA damage signaling
and processing in a cell line in which MMR status can be
tightly controlled (Cejka et al. 2003).
Results
MNNG-induced MMR-dependent G2 arrest occurs in
the second cell cycle
The human embryonic kidney cell line 293T is MMR-
deficient and does not convert MeG in its DNA back to
G, as the promoters of the hMLH1 (Trojan et al. 2002)
and MGMT (Cejka et al. 2003) genes are epigenetically
silenced. We used these cells to generate the 293T L
cell line, which carries a stably integrated hMLH1 cDNA
minigene controlled by the TetOff expression system. In
the absence of doxycycline (Dox), these cells, referred to
as 293T L+, express hMLH1, are MMR-proficient, and
are sensitive to killing by MNNG (Cejka et al. 2003; Di
Pietro et al. 2003). In contrast, when the same cells are
grown in the presence of 50 ng/mL Dox (293T L− cells),
they shut off hMLH1 expression, display a MMR defect,
and are 125-fold more resistant to MNNG than 293T L+
cells. Flow cytometric analysis showed that on treat-
ment with 0.2 µM MNNG, the 293T L+ cells arrested
with a DNA content of 4n (Cejka et al. 2003). Interest-
ingly, the arrest did not take place in the first cell cycle,
as synchronized 293T L cells treated with MNNG at
the G1/S-transition progressed through the first G2/M
boundary and mitosis irrespective of their MMR status.
The arrest was activated after the second S phase, and
only in the MMR-proficient 293T L+ cells (Fig. 1A).
However, 293T cells express the SV40 large T antigen, as
well as the adenoviral E1A and E1B proteins, which in-
hibit the functions of the retinoblastoma (Rb) and p53
tumor suppressor proteins in regulating the G1/S transi-
tion on DNA damage (Bartek and Lukas 2001). To en-
sure that the proper functioning of DNA damage re-
sponse in 293T L+ cells was not affected, and to show
that the observed arrest in the second cell cycle was not
limited to this cell line, we repeated this experiment
with synchronized HCT116 (hMLH1-deficient) and
HCT116 + ch3 (hMLH1-proficient) cells that carry both
functional p53 and pRb. As shown in Figure 1B, both
these latter cell lines proceeded through the first cell
cycle in a similar manner. However, 20 h posttreatment,
the MMR-proficient HCT116 + chr3 cells began to accu-
mulate in the second S phase and then proceeded to ar-
rest with a DNA content of 4n (T30), whereas the MMR-
deficient HCT116 cells exited the second S phase nor-
mally and continued to cycle.
We next had to confirm that the cells indeed arrested
in the G2 phase of the cell cycle, rather than stopping
because of a mitotic catastrophe. To this end, we added
nocodazole, an inhibitor of mitotic spindle formation, to
the MNNG-treated cell cultures 24 h before cytological
analysis. If the treated cells were arrested in G2, they
could not traverse to mitosis. Thus, nocodazole should
block only cells that failed to arrest and continued to
cycle. As shown in Figure 1C, the MMR-deficient 293T
L− cells treated first with MNNG and then with noco-
dazole were frequently arrested in mitosis. This indi-
cates that they did not arrest before this phase. In con-
trast, when nocodazole was added to the MNNG-treated
MMR-proficient 293T L+ cells, the number of cells
reaching mitosis was substantially lower, which shows
that more MMR-proficient cells preferentially arrested
in G2 after MNNG treatment. The finding that arrest
took place after the second S phase was further con-
firmed by bromodeoxyuridine (BrdU) labeling experi-
ments, in which synchronized, MNNG-treated 293T L
cells were shown to enter the second S phase between 14
and 24 h after treatment, irrespective of their MMR sta-
tus (Fig. 1D). As shown in the graph, the number of cells
in the second S phase appeared lower than in the first. To
see whether some cells died during the course of this
experiment and were therefore lost, we followed the pro-
liferation of the unsynchronized, MNNG-treated cell
populations. As shown in Figure 1E, no appreciable cell
loss occurred: The MNNG-treated MMR-proficient cells
doubled in number during the first 24 h and then ar-
rested, whereas the treated MMR-deficient cells contin-
ued to proliferate. This showed that the decrease in cell
number in the second S phase (Fig. 1D) was only appar-
ent and was most likely the result of the gradual loss
Stojic et al.
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of synchronization. In summary, the MNNG-induced
checkpoint in MMR-proficient cells is activated after the
second S phase and is absolutely dependent on a func-
tional MMR system.
Caffeine and UCN-01 abrogate the MMR-dependent
G2 arrest
We wanted to check whether the MNNG-induced cell
cycle arrest observed in the 293T L+ cells was brought
about by a physical block to DNA synthesis (e.g., col-
lapsed replication forks, aberrant recombination inter-
mediates) or whether it was caused by the activation of a
DNA damage checkpoint. As the latter process involves
the major DNA damage-signaling protein kinases ATM
and ATR, which are inhibited by caffeine (Sarkaria et al.
1999; Zhou et al. 2000), we decided to test whether the
MNNG-induced arrest was sensitive to this drug. As
shown in Figure 2, this was indeed the case. Fluores-
cence-activated cell sorting (FACS) analysis of cell popu-
lations doubly stained with propidium iodide and an an-
tibody against the phosphorylated form of histone H3
(Xu et al. 2001) allowed us to distinguish between G2-
arrested and mitotic cells, as H3 is phosphorylated on Ser
10 only during mitosis (Crosio et al. 2002). In the initial
set of experiments (data not shown), we pretreated the
cells with caffeine 30 min before adding MNNG and
then incubated the cells for a further 24 or 48 h. Using
this protocol, we failed to observe any differences be-
tween caffeine-treated and untreated cells, as measured
Figure 1. Kinetics of the G2/M arrest in cells
treated with 0.2 µM MNNG. (A) FACS analysis
of 293T L cell cultures synchronized in G1/S
with a double thymidine block and treated
with 0.2 µM MNNG. (T4–T30) FACS analyses
carried out 4–30 h posttreatment. (B) FACS
analysis of MNNG-treated HCT116 and
HCT116 + ch3 cell cultures synchronized in
G1/S with HU. (T4–T30) FACS analyses carried
out 4–30 h posttreatment. The 4n peak in the
unsynchronized and HU-synchronized HCT116
+ chr3 cells is larger than in the HCT116 cells.
This is not the result of a larger fraction of dip-
loid cells in the G2 phase of the cell cycle, but
to a subpopulation of tetraploid cells, which ar-
rest after MNNG treatment with a content of
8n (not shown). (C) Mitotic index of 293T L
cells after MNNG treatment. The cells were
treated with MNNG, and nocodazole was
added 24 or 48 h later. The cells were micro-
scopically examined after an additional 24 h.
As shown, substantially more MMR-deficient
293T L− cells were arrested in mitosis than
were MMR-proficient 293T L+ cells, which in-
dicates that the latter cells were more fre-
quently arrested in G2. (D) Synchronized 293T
L cells (as in A) were pulse-labeled with BrdU,
and the number of cells in S phase was esti-
mated by CELLQuest software. Both 293T L+
() and 293T L− (H17009) cells entered the second S
phase between T14 and T24. (E) Growth curves
of unsynchronized MNNG-treated 293T L
cells. Although the treated 293T L+ cells
doubled their number 24 h after treatment and
then ceased to proliferate, the 293T L− cells
continued to grow.
MMR-dependent G2 arrest requires ATR
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by Western blotting with the phospho-H3 antibody,
probably because the half-life of caffeine is only 4.5 h.
We therefore added the kinase inhibitor some hours after
the MNNG treatment. Using this protocol, MNNG-
treated cells with a DNA content of 4n accumulated as
observed previously (Fig. 1B), but the addition of caffeine
to the treated cells 16 h before harvesting reduced the
number of arrested cells by a substantial amount at the
24- and 48-h time points, as well as causing substantial
cell death (Fig. 2A). That the latter effect was linked to
an increased fraction of cells arriving in mitosis with
unrepaired DNA is witnessed by a greater number of
mitotic cells with phosphorylated histone H3 (Fig. 2B).
The initiation of G2 arrest requires CHK1, the major
transducer of ATR-dependent DNA damage signaling
(Liu et al. 2000). As CHK1 kinase activity can be prefer-
entially inhibited by the staurosporine analog UCN-01
(Busby et al. 2000; Graves et al. 2000), we studied the
response of MNNG-treated cells to this drug in a way
analogous to that deployed for caffeine. FACS analysis
(Fig. 2A) showed that UCN-01 treatment abrogated the
MNNG-induced G2 checkpoint in 293T L
+ cells to an
even greater extent than caffeine. Correspondingly, the
fraction of cells arriving in mitosis, seen in FACS analy-
sis as phospho-H3-positive cells, was higher in the
MNNG- and UCN-01-treated samples than in cells
treated with MNNG and caffeine (Fig. 2B).
Taken together, these results demonstrate that the
MNNG-induced cell cycle arrest was indeed induced by
a DNA damage-signaling cascade. Our data thus help
explain the nature of the in trans inhibition of DNA
replications in cells treated with methylating agents that
was described more than a decade ago (Zhukovskaya et
al. 1994).
Figure 2. The G2 arrest in MMR-proficient 293T L
+
cells is caffeine- and UCN-01-sensitive. (A) 293T L+
cells were treated with MNNG (0.2 µM) for the indi-
cated times, and caffeine (2 mM) or UCN-01 (100 nM)
was added 16 h before harvesting. The cells were
stained with propidium iodide (PI) and phospho-his-
tone H3 antibody (cells in circle) to distinguish mitotic
cells from those in G2. The results show that both
inhibitors attenuated the G2 arrest in MNNG-treated
cells. (B) Quantification of phospho-H3-positive cells
from A. The number of cells entering mitosis in
samples treated with MNNG and caffeine or UCN-01
was higher than in the controls, which shows that
these kinase inhibitors abrogated the G2 arrest and al-
lowed more cells to enter mitosis.
Stojic et al.
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Low-dose MNNG treatment brings
about MMR-dependent phosphorylation
of downstream targets of both ATM and ATR
ATM and ATR are both activated by DNA damage.
However, whereas ATM responds rapidly to clastogenic
damage such as that induced by IR (Bakkenist and Kas-
tan 2003), ATR responds slower and cooperates with
ATM in the later phases of the response (Brown and Bal-
timore 2003). ATR is also known to be preferentially
activated on replication fork arrest induced by ultravio-
let (UV) light, hydroxyurea (HU), or DNA polymerase
inhibitors such as aphidicolin (Abraham 2001; Osborn et
al. 2002). As MNNG treatment is thought to exert its
cytotoxicity through the processing of 6MeG residues
during DNA synthesis (Karran and Bignami 1992), it
might be anticipated that the damage-induced signaling
cascade would initiate in S phase and involve ATR rather
than ATM. Indeed, when the 293T L+ cells were treated
with 0.2 µM MNNG, phosphorylation of the ATR-acti-
vated checkpoint kinase CHK1 on Ser 345 became de-
tectable after 12 h and peaked at 48 h, whereas phos-
phorylation of Thr 68 of CHK2, a preferred target for
ATM, lagged by 12 h and increased steadily until 72 h
(Fig. 3A).
We also examined the posttranslational modification
of the single-stranded DNA-binding protein RPA, re-
ported to redirect its function from replication to repair
(Wang et al. 2001) through recruitment of the ATR/
ATRIP (ATR-interacting protein) complex onto sites of
Figure 3. MMR-dependent DNA damage
signaling in 293T L cells. (A) The 293T L+
cells express hMLH1 and hPMS2 and are
MMR proficient. Treatment with 0.2 µM
MNNG brought about the phosphorylation
of CHK1 and CHK2, as well as that of the
single-strand DNA-binding protein RPA
(p34), while CDC25A was gradually de-
graded. None of these modifications was
observed in the MMR-deficient 293T L−
cells. The phosphorylation status of RPA is
indicated by the slower migration of the
modified polypeptides through polyacryl-
amide gels (48-h time point). TFIIH was
used as loading control. (B) Treatment of
293T L cells with 1 mM HU brought about
a MMR-independent phosphorylation of
CHK1, CHK2, and RPA (p34) and the degra-
dation of CDC25A within 24 h. -tubulin
was used as loading control. (C) Indirect im-
munofluorescence imaging of nuclear foci
formed by protein targets of the ATM/ATR
kinases phosphorylated on serine and threo-
nine residues in the SQ or TQ motifs, RPA
(p34) and ATR. As shown, the foci formed
only in the MMR-proficient 293T L+ cells
and were most numerous 48 h after treat-
ment. (D) Indirect immunofluorescence im-
aging of nuclear foci formed by RPA (p34)
and ATR in HeLa cells treated with 0.2 µM
MNNG. The images were superimposed us-
ing Adobe Photoshop software. (C) Control,
untreated cells.
MMR-dependent G2 arrest requires ATR
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DNA damage, which leads to an ATR-mediated activa-
tion of CHK1 (Zou and Elledge 2003). The p34 subunit of
RPA was indeed phosphorylated after MNNG treatment,
and the timing of its posttranslational modification co-
incided with the appearance of the highest levels of phos-
phorylated CHK1 (Fig. 3A).
The steady-state levels of CDC25A, a cell cycle phos-
phatase that is degraded on phosphorylation by CHK1 or
CHK2 (Falck et al. 2001; Zhao et al. 2002), began to de-
cline 24 h after treatment, at which time point only
CHK1 kinase appeared to be activated. CDC25A con-
trols the activation of CDK1 and CDK2 kinases and is
known to regulate the G1 (Hoffmann et al. 1994), intra-S
(Falck et al. 2001), and G2/M (Mailand et al. 2002) check-
points. Its phosphorylation by CHK1/CHK2 leads to its
destruction by the proteasome and thus also to cell cycle
arrest. Indeed, 24 h after treatment, CDC25A levels were
substantially lower than at the earlier time points.
Taken together, this evidence suggests that ATR down-
stream targets were posttranslationally modified during
the first cell cycle and that CHK2, a target of ATM, be-
came activated later, after the second S phase. Impor-
tantly, none of these phenomena were apparent in the
MMR-deficient 293T L− cells (Fig. 3A), which failed to
arrest following MNNG treatment (Fig. 1A,E).
In a control experiment, we treated the 293T L cells
with HU, which is known to bring about a cell cycle
arrest in the first S phase after treatment. As shown in
Figure 3B, CHK1, CHK2, and RPA-p34 phosphorylation
was detectable already at the 24 h time point and, as
anticipated, no differences were observed between the
MMR-proficient and the MMR-deficient cells. CDC25A
was undetectable in the treated cells at this time point,
again irrespective of the cells’ MMR status. We failed to
observe MMR-dependent differences in phosphorylation
patterns and CDC25A degradation also after 6 and 48 h
(data not shown). These results both confirm that the
293T L− cells do not have defective checkpoint activat-
ing pathways and show that the signals triggering the
HU- and MNNG-dependent G2 checkpoints are differ-
ent.
MNNG treatment induces ATM/ATR activation
in vivo
We set out to seek evidence of the activation of ATM and
ATR protein kinases in living cells. To this end, we em-
ployed the phospho-(Ser/Thr) ATM/ATR substrate (S*/
T*Q) antibody that was raised against peptides carrying
SQ or TQ amino acid motifs known to be posttransla-
tionally modified by these kinases in several different
substrates, and that is an accepted marker of ATM/ATR-
dependent phosphorylation events (DiTullio et al. 2002).
As shown in Figure 3C, foci of phosphorylated polypep-
tides began to appear after 24 h, but they were most
numerous 48 h posttreatment, where they were visible
in 67% of the cells. A similar phenomenon was observed
also for RPA (78% of cells with foci) and ATR (75% of
cells with foci). Again, these changes were observed ex-
clusively in the MMR-proficient 293T L+ cells. In
MNNG-treated MMR-proficient HeLa cells, the ATR
and RPA foci colocalized (Fig. 3D; Zou and Elledge 2003).
Notably, the initial signs of checkpoint activation in the
form of phosphorylation of CHK1 and degradation of
CDC25A in 293T L+ cells (Fig. 3A) preceded the appear-
ance of the foci in both cell types by ∼40 h. This implied
that the ATM/ATR kinases were activated long before
the ATR, RPA, and S*/T*Q proteins formed the foci. As
the appearance of the foci coincides with the formation
of chromosomal aberrations (N. Mojas, L. Stojic, and J.
Jirivny, in prep.), it is possible that the nuclear foci rep-
resent recombination intermediates arising during the
second S phase.
ATM is dispensable for cell cycle arrest induced
by low dose MNNG treatment
As shown above, the MNNG-induced G2 checkpoint
was released by UCN-01, which inhibits preferentially
the CHK1 kinase, the preferred target of ATR. Given
that the latter kinase has been implicated in the control
of S-phase checkpoints triggered by arrested replication
forks (Abraham 2001; Osborn et al. 2002) and that the
nonproductive processing of 6MeG/T mispairs by the
MMR system should also signal during the S phase, it
seemed logical that ATR also should be involved in the
control of the MNNG-induced checkpoint described
above. However, as ATR and ATM display a certain de-
gree of functional redundancy, we wanted to exclude the
involvement of the latter kinase in checkpoint activa-
tion. Under normal conditions, ATM is present in the
nucleus in an inactive, dimeric form, but it can be rap-
idly activated by stress stimuli. This process involves
disruption of the dimer and is accompanied by ATM au-
tophoshorylation of Ser 1981 (Bakkenist and Kastan
2003). Using a specific antibody against this phosphory-
lated isoform, we were able to follow activation of the
ATM kinase in the 293T L cells following treatment
with 0.2 µM MNNG. In a control experiment, ATM was
efficiently activated by IR treatment, irrespective of the
MMR status of the cells, whereas HU treatment was
significantly less effective in activating ATM, as antici-
pated (Fig. 4A). Treatment with MNNG resulted in ATM
activation, although only at the 48- and 72-h time points,
which coincided with the peak of phosphorylation of
CHK2, a known downstream target of ATM (Fig. 3A).
Notably, both these events were observed exclusively in
the MMR-proficient 293T L+ cells.
Although the above experiment demonstrated that
ATM was activated in a MMR-dependent manner by
MNNG treatment in 293T L+ cells, it failed to show
whether this kinase was indispensable for activation of
the cell cycle arrest. This question was answered with
the help of a matched pair of ATM-positive and ATM-
negative fibroblast lines (Ziv et al. 1997), which dis-
played no major differences in G2 arrest efficiency on
MNNG treatment, as assessed by FACS analysis (Fig.
4B).
Consistent with the above evidence, the number and
kinetics of appearance of S*/T*Q foci on treatment with
Stojic et al.
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0.2 µM MNNG was similar in the AT and AT + ATM
cells (Fig. 4C). These foci were not detected in the AT
cells on IR treatment (DiTullio et al. 2002), which
strongly suggested that the lesions generated by the
MMR system during processing of MNNG-induced dam-
age are distinct from IR-induced strand breaks.
Analysis of protein phosphorylation cascades by West-
ern blotting revealed that CHK1 and CHK2 were post-
translationally modified in both cell lines, albeit with
different kinetics (Fig. 4D). In a recent report, Wang and
colleagues (2003) showed that in IR-treated AT-deficient
cells, the ATR kinase compensated for the lack of ATM
through overactivation of CHK1. We now extend these
findings to MNNG treatment, as the phosphorylation of
CHK1 at the 48-h time point was substantially stronger
in the AT cells than in the corrected AT + ATM line.
Taken together, the results presented in Figure 4 dem-
onstrate that although MNNG treatment led to activa-
tion of ATM, this kinase was dispensable for triggering
the protein phosphorylation cascade and the G2 cell
cycle arrest.
The MNNG-induced G2 arrest and DNA
damage-dependent signaling requires ATR
As ATM was not required for the MNNG-induced
checkpoint activation (Fig. 4), we set out to confirm the
involvement of ATR. Unlike in the case of ATM, there
are no stable ATR-defective cell lines, as the loss of this
kinase is lethal, and we therefore had to resort to using
U2OS cells, which overexpress a kinase-dead variant of
ATR (ATR-kd) under the control of the Dox-regulated
TetOn expression system (Nghiem et al. 2002). ATR-kd
overexpression was shown to abrogate the G2 arrest
(Cliby et al. 2002) and to sensitize cells to several DNA
damaging agents (Nghiem et al. 2002), and we wanted to
see how it affected the cellular response to MNNG. The
U2OS cells were substantially more resistant to MNNG
than the 293T L+, AT, and ATM + AT lines (even
though the MGMT activity of all the lines was inhibited
with O6-benzylguanine), and we therefore had to use a
1.5-µM concentration of the drug to obtain cytotoxicity
comparable to that exerted on the latter cells by 0.2 µM
Figure 4. ATM is activated but dispensable
for the MNNG-induced G2 arrest in MMR-
proficient cells. (A) ATM was activated
early in both 293T L+ and 293T L− cells
on ionizing radiation (10 Gy, 1 h) and, to a
lesser degree, after HU treatment (1 mM, 6
h). In contrast, on treatment with MNNG,
ATM was activated late, and only in MMR-
proficient (293T L+) cells. ATM activation
was assessed using an antibody against
phosphorylated Ser 1981. (B) FACS analysis
of unsynchronized cultures of AT and
AT + ATM fibroblasts following treatment
with 0.2 µM MNNG. Both ATM-proficient
(AT + ATM) and ATM-deficient (AT) cells
proceeded through the cell cycle with simi-
lar kinetics and began to accumulate in
G2/M after 2 d. (C) Indirect immunofluores-
cence imaging of nuclear foci formed by pro-
tein targets of the ATM/ATR kinases phos-
phorylated on serine and/or threonine resi-
dues in the SQ or TQ motifs. As shown, the
foci began to form in both ATM-proficient
and ATM-deficient cells after the 24 h time
point. At 48 h, both cell types contained
foci, even though they were less numerous
in the AT cells. However, at 72 h, no sig-
nificant differences in focus number or in-
tensity were observed in the two cell types.
(D) MNNG treatment leads to ATM-inde-
pendent CHK1 and CHK2 activation, albeit
with different kinetics.
MMR-dependent G2 arrest requires ATR
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MNNG. Under these experimental conditions, the un-
induced U2OS cells were largely arrested in the G2 phase
of the cell cycle 48 h after treatment (Fig. 5A, left panel),
similar to the 293T L+ cells (Fig. 1B). However, this
arrest was substantially attenuated when the cells were
induced to overexpress ATR-kd (Fig. 5A, right panel).
Phosphorylation of CHK1, seen in the uninduced cells,
was totally abrogated by overexpression of ATR-kd,
whereas CHK2 phosphorylation remained largely un-
changed (Fig. 5B). Moreover, overexpression of ATR-kd
had a dramatic effect on the formation of S*/T*Q foci
(Fig. 5C,D). The uninduced cells displayed no defect in
focus formation: Both RPA and S*/T*Q foci were abun-
dant 48 h after MNNG treatment, and the fact that they
largely colocalized substantiated recent reports that
demonstrated the requirement for RPA-bound stretches
of single-stranded DNA for the recruitment of ATR and
for focus formation (Zou and Elledge 2003). In ATR-kd
overexpressing cells, the RPA foci formed earlier, but we
failed to observe foci of S*/T*Q. This demonstrated that
the kinase activity of ATR is required for the formation
of the latter foci. This experimental evidence also dem-
onstrated that the formation of RPA foci is ATR inde-
pendent (i.e., that RPA is recruited to sites of damage
before ATR, as discussed by others [Zou and Elledge
2003]).
MNNG treatment induces formation of -H2AX foci
that are not associated with double-strand breaks,
but colocalize with the foci of RPA
We wanted to gain information about the type of damage
generated by the MMR-dependent processing of MNNG-
induced DNA damage. Using alkaline comet assays, we
found evidence of extensive single-stranded DNA degra-
dation in both MMR-deficient and MMR-proficient cells
already 4 h posttreatment. Under these conditions, apu-
rinic sites generated by removal of methylated bases are
cleaved and the strand breaks become detectable as the
double-stranded DNA is denatured. Importantly, the
single-strand breaks completely disappeared with time
in the MMR-deficient cells, whereas in the MMR-profi-
cient cells, a substantial proportion persisted even 48 h
after treatment (Fig. 6A,B). On the basis of this evidence,
we expected to observe no nuclear foci of the phosphory-
lated form of histone H2AX (-H2AX), which was re-
Figure 5. The G2 checkpoint induced by low
MNNG doses is ATR-dependent. (A) FACS
analysis of U2OS cells that overexpress the ki-
nase-dead ATR variant under doxycycline con-
trol. The figure shows that the G2 arrest acti-
vated by MNNG treatment in these cells was
attenuated by overexpression of the ATR-kd
protein. (B) CHK2 phosphorylation was largely
unaffected by overexpression of ATR-kd in the
treated U2OS cells. In contrast, activation of
CHK1 was dependent on the presence of func-
tional ATR. (C) Indirect immunofluorescence
of ATR-kd inducible U2OS cells showing that
formation of S*/T*Q foci and their colocaliza-
tion with RPA (p34) after MNNG treatment is
ATR-dependent. The fraction of foci-displaying
cells on each microscope slide is shown in
panel D.
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ported to associate with DSBs (Rogakou et al. 1999) and
to recruit repair factors to these sites (Paull et al. 2000).
Surprisingly, numerous -H2AX foci appeared soon after
MNNG treatment (Fig. 6C). The lesions associated with
these early foci were apparently not responsible for trig-
gering the signaling cascade, as they appeared in similar
numbers and with similar kinetics in both MMR-profi-
cient and MMR-deficient cells and as no signaling that
could be ascribed to DSBs was detected. Moreover, when
the treated cells were examined by pulse field gel elec-
trophoresis, TUNEL, and neutral pH comet assays, no
DSBs could be detected (data not shown). It is therefore
highly unlikely that the early-appearing -H2AX foci
seen in this study represent sites of DSB formation. A
more likely scenario is that they represent regions in
which chromatin structure is disrupted because of the
processing of modified purines by the BER system.
At later time points, the -H2AX foci gradually disap-
peared from the nuclei of MMR-deficient cells, while in
the MMR-proficient cells they appeared to change mor-
phology and increased in number and intensity. We
wanted to test whether these foci colocalized with those
formed by RPA, given that the single-stranded DNA-
binding protein was seen to colocalize with ATR and the
S*/T*Q substrate (Figs. 3D, 5C, respectively). As shown
in Figure 6C and D, the foci of -H2AX and RPA were
seen to colocalize in ∼60% of the treated cells at the 48-h
time point. At the 72-h time point, the intensity of the
RPA foci diminished and very little colocalization with
the -H2AX foci could be seen.
Discussion
A functional MMR system has been postulated to be
required for the activation of a G2/M cell cycle arrest
(Hawn et al. 1995; Claij and Te Riele 2002; Cejka et al.
2003) and for apoptosis (D’Atri et al. 1998) induced in
mammalian cells by SN1 type methylating agents and
6-thioguanine. Using an isogenic system developed in
our laboratory (Cejka et al. 2003), in which the MMR
status of the 293T L cells can be controlled by Dox, we
show that the MMR-proficient cells treated with 0.2 µM
Figure 6. MMR-dependent processing of
methylation damage. (A) Alkaline comet as-
says showing the appearance and repair of
DNA single-strand breaks in 293T L cells
on 0.2 µM MNNG treatment. The panel
shows representative cells. (B) Quantifica-
tion of the tail moment of 50 randomly se-
lected cells per slide. As shown, the single-
strand breaks (or gaps) were repaired in the
MMR-deficient cells but persisted in the
MMR-proficient ones. (C) Kinetics of his-
tone H2AX phosphorylation and the colo-
calization of -H2AX foci with those of RPA
in MNNG-treated 293T L cells. The
-H2AX foci appeared soon after treatment,
independent of the MMR status of the cells.
They then diminished in number in both
cell types but began to reappear in the
MMR-proficient 293T L+ cells after 24 h.
At the 48-h time point, they largely colocal-
ized with the foci of RPA, but this overlap
diminished by 72 h. In contrast, in the
MMR-deficient 293T L− cells, the -H2AX
foci disappeared completely. The panel
shows representative cells. The fraction of
cells on each microscope slide displaying a
similar phenotype is shown in D.
MMR-dependent G2 arrest requires ATR
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MNNG arrested in the G2 phase of the second cell cycle
(Fig. 1A,B), rather than undergoing a mitotic catastrophe
(Fig. 1C). This was highly unusual, because cells gener-
ally arrest a few hours after DNA damage. We therefore
set out to identify the molecular mechanisms underlying
this phenomenon. In the first series of experiments, we
showed that the accumulation of MNNG-treated cells in
G2 was attenuated by caffeine and UCN-01, which are
known to inhibit preferentially the ATM/ATR and
CHK1 kinases, respectively (Fig. 2). This evidence fur-
ther confirmed that the increase in the number of cells
with a 4n DNA content, as observed by FACS, was the
result of activation of a checkpoint, rather than of a
physical block imposed by the DNA damage. Corre-
spondingly, we could show that MNNG treatment of the
MMR-proficient cells activated a protein phosphoryla-
tion cascade that modified a number of downstream tar-
gets of the ATM/ATR kinases (Fig. 3). It appeared most
likely that these phosphorylation events actually trig-
gered the arrest, as the posttranslational modification of
these targets temporally coincided with its activation.
We were able to rule out the requirement for ATM in the
activation of the MNNG-induced checkpoint: Although
the kinase appeared to be activated at late time points in
the MNNG-treated 293T L+ cells (Fig. 4A), the AT fi-
broblasts lacking this kinase arrested similarly to ATM-
proficient ones (Fig. 4B). This hypothesis is further sup-
ported by earlier findings, which showed that HCT15
cells that lack CHK2, one of the downstream targets of
ATM, arrested normally on treatment with methylating
agents when their MMR defect was corrected (Umar et
al. 1997). In contrast, ATR kinase and its downstream
target CHK1 were shown to be required for the efficient
activation of the MNNG-induced checkpoint, as the
number of cells with a 4n DNA content was dramati-
cally decreased in MNNG-treated U2OS cells overex-
pressing the kinase-dead ATR variant (Fig. 5), or in the
293T L+ cells when the CHK1 activity was inhibited by
UCN-01 (Fig. 2).
Our finding that the ATM kinase is activated only
very late after MNNG treatment seemingly contrasts
with the data of Adamson and colleagues (2002), who
reported that MNNG treatment rapidly activates this
enzyme. These differences are probably the result of the
120-fold higher dose of the reagent used in the latter
study. High concentrations of DNA methylating agents
bring about levels of base damage that are too high to be
effectively processed by the BER system. As a result,
strand breaks arising through incomplete BER appear
soon after treatment and activate damage-signaling path-
ways that are more reminiscent of those induced by
other clastogenic DNA damaging agents. Importantly,
this processing is largely independent of the MMR sys-
tem (L. Stojic, N. Mojas, P. Cejka, and J. Jiricny, in prep.).
The involvement of damage-specific kinases other
than ATM and ATR in the MNNG-induced cell cycle
arrest has not been ruled out. However, it is unlikely
that DNA-dependent protein kinase (DNA-PK) plays a
key role, as it generally does not appear to be required for
DNA damage signaling (Durocher and Jackson 2001).
Moreover, cells mutated in its Ku80 subunit are hyper-
sensitive to IR but appear to respond normally to MNNG
(Jeggo and Kemp 1983).
If ATR is the most upstream DNA damage-signaling
kinase, what is the nature of the MNNG-induced lesions
that trigger its activation? Our results show that the ki-
nase cascade is not activated directly by 6MeG/T mis-
pairs (e.g., through interaction with the mismatch bind-
ing heterodimer hMSH2/hMSH6; Duckett et al. 1996;
Fishel 1999). First, these mispairs should have already
arisen during the first S phase, and even if they were to
activate the signaling cascade directly, there is no reason
why cells should be arrested in the second cell cycle,
when the number of these mispairs is reduced by 50%
because of the semiconservative nature of DNA replica-
tion. (The half-life of MNNG in culture medium is ∼1 h;
it has thus been inactivated long before the onset of the
second cell division.) Second, cells lacking hMLH1/
hPMS2 (e.g., HCT116, 293T, 293T L−) express normal
levels of the hMSH2/hMSH6 heterodimer, yet are also
highly resistant to killing by MNNG and do not arrest in
G2. This would require that the DNA damage signaling
be mediated by the hMSH2/hMSH6/hMLH1/hPMS2
heterotetramer. Although formally possible, the appear-
ance of RPA foci suggests that the signaling was initiated
through processing rather than just detection of the dam-
age—but what is the nature of this processing?
More than 30 years ago, Plant and Roberts (1971) sug-
gested that replication past 6MeG in the template strand
during the first S phase may give rise to single-stranded
gaps, which are converted into DSBs during the second
replication cycle. This was long thought to be unlikely,
as DNA polymerases were expected to repair gaps re-
maining from incomplete replication during the G2
phase. However, it is conceivable that such gaps do in-
deed arise in DNA methylated by SN1-type agents. Dur-
ing DNA replication, the polymerases may incorporate a
T or a C into the newly synthesized strand opposite the
6MeG residues in the template strand, and it has been
suggested that the MMR system will detect these non-
Watson-Crick structures (Duckett et al. 1996) and at-
tempt to repair them. The repair process would exonu-
cleolytically degrade a short stretch of the newly repli-
cated DNA (i.e., the strand containing the pyrimidines).
However, as the 6MeG residues persist in the template
strand, resynthesis of this region would again generate
6MeG/T or 6MeG/C mispairs. The repeated processing of
these mispairs by the MMR system (Karran and Bignami
1996) will likely lead to stalling of the replication fork.
One might pose the question of why these structures
would fail to activate the S-phase checkpoint, when
other polymerase-arresting agents such as HU or aphidi-
colin do so extremely efficiently (Abraham 2001; Osborn
et al. 2002; Shiloh 2003). One possible explanation is
that HU and aphidicolin inhibit all active replicons,
whereas the number of 6MeG residues generated by
MNNG treatment may be too low to trigger an S-phase
arrest. An alternative explanation is that unlike HU,
which brings about a depletion of the purine nucleotide
pool, or aphidicolin, which directly inhibits the replica-
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tive polymerases, 6MeG residues in the template strand
do not prevent a replication restart downstream from the
modified base. Indirect support for the replication restart
hypothesis comes from in vitro experiments carried out
with MNU-modified plasmid DNA; the observed DNA
repair synthesis required nucleoside triphosphates
(NTPs), which would be required by a primase (Ceccotti
et al. 1993, 1996). Furthermore, these experiments dem-
onstrated that the repair synthesis triggered by the pres-
ence of 6MeG residues in the DNA is RPA independent
and that it gives rise to open circular DNA, in contrast to
the in vitro replication reaction of the same, but unmodi-
fied, plasmid, which yielded almost exclusively super-
coiled DNA molecules. These results could be taken as
further evidence of the persistence of unligatable single-
stranded regions or breaks in the plasmid DNA incu-
bated with MMR-proficient cell extracts (Ceccotti et al.
1996). Direct support for the persistence of incompletely
replicated DNA comes from our experiments, in which
the genomic DNA of MNNG-treated MMR-proficient
cells after the first S phase was shown to contain numer-
ous single-strand breaks, as witnessed by the appearance
of DNA tails in alkaline comet assays (Fig. 6A,B). Our
findings are further supported by recent evidence show-
ing that treatment of cells with 6-thioguanine, which is
believed to exert its cytotoxicity via a mechanism analo-
gous to MNNG (Swann et al. 1996), also results in the
accumulation of MMR-dependent single-strand DNA
breaks (Yan et al. 2003).
The latter hypothesis raises two important questions.
First, if genomic DNA containing 6MeG residues does
indeed contain single-strand gaps after the first S phase,
why do such gaps not activate the checkpoint already at
this time? One possibility is that they are too few in
number. Alternatively, the gaps might not stall the repli-
some, or they might be too short to be bound by RPA.
Indeed, the RPA foci began to appear only at 24 h, and
their number peaked at the 48-h time point (Figs. 3C,D,
5C,D). As RPA has been shown to be required for the
efficient recruitment of the ATR/ATRIP complex to the
sites of damage, single-strand gaps that are not RPA
bound would fail to efficiently activate the CHK1 ki-
nase, which has been identified in complexes that asso-
ciate with strand breaks and with single-stranded DNA
(Goudelock et al. 2003) and which was shown to be in-
volved in the MNNG-induced G2 checkpoint (Fig. 2).
Second, assuming that the single-stranded gaps do in-
deed form, how could they persist until the subsequent S
phase as suggested (Plant and Roberts 1971; Kaina et al.
1997)? This could be the result of a combination of fac-
tors. As discussed above, it is possible that, in the ab-
sence of bound RPA, the damage sites may signal too
weakly to effectively activate the checkpoint. The other
reason might be that the filling of a gap opposite a 6MeG
residue may not be trivial. Thus, proliferating cell
nuclear antigen (PCNA)-dependent polymerases tested
to date would generate 6MeG/C or 6MeG/T mispairs
(Reha-Krantz et al. 1996), which would be again ad-
dressed by the MMR system, because of its ability to
interact with the processivity factor (Kleczkowska et al.
2001). Other polymerases might have problems extend-
ing from the non-Watson-Crick 6MeG/C or 6MeG/T
structures, in which case the DNA synthesis would stall
at the mispairs because of the activation of the 3 → 5
proofreading activity (Khare and Eckert 2001).
Persistent single-strand gaps opposite the 6MeG resi-
dues would become DSBs during the second S phase, and
the affected replication forks would collapse unless res-
cued by recombination events such as sister chromatid
exhanges (SCEs). That events of this type indeed arise in
cells treated with methylating agents was suggested by
an increase in SCE frequency in the treated MMR-profi-
cient 293T L+ cells (data not shown; N. Mojas, L.Stojic,
and J. Jiricny, in prep.; see also Galloway et al. 1995;
Kaina et al. 1997). The timing of these events broadly
coincided with the formation of foci containing RPA,
ATR (Fig. 3C,D), and -H2AX (Fig. 6C), which may rep-
resent the sites in chromatin at which processing is tak-
ing place and also from which the signaling events may
be originating.
In conclusion, treatment of mammalian cells with a
low dose of MNNG was shown to bring about a G2 cell
cycle arrest that was absolutely dependent on a func-
tional MMR system and that, to a substantial degree,
was also dependent on the ATR and CHK1 kinases. This
checkpoint was highly atypical, inasmuch as it came
into effect only in the second cell cycle after treatment.
Its activation was accompanied by a number of changes
in the nuclei of the treated cells, possibly indicative of
recombination events. Our present findings thus suggest
that SN1 type methylating agents such as the chemo-
therapeutics procarbazine and temozolomide, which act
similarly to MNNG, kill cells with the help of MMR,
which generates intermediates that cannot be effectively
processed by the cellular repair machinery. The persis-
tence of these lesions into the second cell cycle may kill
cells through the generation of aberrant recombination
intermediates. We are currently attempting to elucidate
the structures of these lesions by biophysical techniques.
Materials and methods
Cell lines
The 293T L cell line was established in our laboratory and
propagated as described (Cejka et al. 2003). HeLa cells were
maintained in DMEM (OmniLab) supplemented with 10% fetal
calf serum (FCS; Life Technologies), penicillin (100 U/mL), and
streptomycin (100 µg/mL). The ATM-deficient (AT) fibroblasts
AT22IJE-T and the matched line complemented with ATM mi-
nigene (AT + ATM) were kindly provided by Yosef Shiloh (Tel
Aviv University, Israel) and were maintained as described (Ziv
et al. 1997). The U2OS cell line conditionally expressing ATR
kinase-dead protein (Paul Nghiem, Harvard University, Cam-
bridge, MA) was maintained in DMEM supplemented with 10%
FCS, 200 µg/mL G418, and 200 µg/mL Hygromycin B. Induction
of ATR-kd was accomplished by supplementing the growth me-
dium with Dox (1 µg/mL) for 48 h, as described (Nghiem et al.
2002). The hMLH1-deficient human colon cancer cell line
HCT116 and its MMR-proficient subline HCT116 + ch3 were
maintained in McCoy’s 5A medium (OmniLab) with 10% FCS.
MMR-dependent G2 arrest requires ATR
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The chromosome-complemented cell line was maintained in
medium containing 400 µg/mL G418. Expression of all MMR
proteins was confirmed in both AT fibroblasts and ATR-induc-
ible cells by immunobloting (data not shown). To inhibit
MGMT activity, HeLa cells, HCT116 and HCT116 + ch3 cells,
AT and AT + ATM fibroblasts, and the ATR-kd-inducible cells
were pretreated with 10 µM O6-benzylguanine 2 h before
MNNG treatment. All cell lines were cultured at 37°C in a 5%
CO2 humidified atmosphere.
Chemicals and irradiations
MNNG (Sigma) was dissolved in DMSO and stored at −20°C in
the dark. O6-benzylguanine (Sigma) was dissolved in ethanol
and stored at −80°C. HU (Sigma) and Dox (Clontech) were dis-
solved in water and stored at −20°C. UCN-01 (Sally Hausman,
Cancer Therapy Evaluation Program, National Cancer Insti-
tute, National Institutes of Health, Rockville, MD) was dis-
solved in DMSO and stored at −20°C. Caffeine (Calbiochem)
was dissolved in water and always prepared fresh. Irradiations
were carried out at the doses indicated, using a Philips PW2184/
00-Monitor SN4.
Mitotic index assays
The 293T L cells were treated with 0.2 µM MNNG and incu-
bated for 24 or 48 h. Nocodazole (0.3 µg/mL, Sigma) was then
added and the cells were incubated for a further 24 h. The float-
ing and attached cells were then harvested and centrifuged at
400g. The pellet was suspended in 3 mL of 75 mM KCl for 10
min, centrifuged again as above, and resuspended in Carnoy’s
fixative (1:3 v/v acetic acid:methanol). This latter step was re-
peated three times. Twenty microliters of the cell suspension
were spotted onto a microscope slide and allowed to air dry.
Once dry, the cells were stained with 0.1 µg/mL 4,6-diami-
dino-2-phenylindole hydrochloride (DAPI; Sigma) for 10 min,
washed with water, and mounted in SlowFade Antifade (Mo-
lecular Probes). Using a fluorescence microscope, cells with bro-
ken nuclei and condensed chromatin were counted as mitotic.
Five hundred cells were counted per sample.
Cell synchronizations
The 293T L cells were grown to 50% confluency in a serum-
rich medium. Thymidine (2 mM, SynGen Inc.) was added, and
the cells were incubated for 18 h, washed three times with PBS,
and released into thymidine-free medium for 9 h. Thymidine (2
mM) was then added for a further 15 h. The cells were then
washed three times with PBS. At this point (G1/S, Fig. 1A), the
cells were treated with 0.2 µM MNNG in a serum-rich medium
without thymidine, and time points were collected 4 (T 4), 8 (T
8), 14 (T 14), 20 (T 20), 24 (T 24), and 30 (T 30) h later. HCT116
and HCT116 + ch3 cells were synchronized in a medium con-
taining 2 mM HU for 14 h. O6-benzylguanine (10 µM) was added
for the last 2 h, when the cells were washed with PBS. The cells
were then incubated in fresh medium containing 0.2 µM
MNNG (G1/S, Fig. 1B) and O
6-benzylguanine. Cells were har-
vested and analyzed by propidium iodide-flow cytometric
analysis as described (Cejka et al. 2003).
Cell cycle analyses
For BrdU labeling, cells were pulse-labeled with 10 µM BrdU
(Sigma) for 30 min before harvesting and fixation in 70% etha-
nol at 4°C. The cells were then processed as described (Cliby et
al. 2002). BrdU incorporation studies and cell cycle distributions
were analyzed by Becton Dickinson CELLQuest software. For
immunofluorescence-based detection of phosphorylated his-
tone H3, the cells were treated with 0.2 µM MNNG. Sixteen
hours before harvesting, the growth medium was supplemented
with caffeine (2 mM) or UCN-01 (100 nM). The cells were col-
lected 24 or 48 h after MNNG treatment. The subsequent steps
were carried out as described (Xu et al. 2001).
Cell doubling assays
Cell doubling assays were carried out as described previously
(Cejka et al. 2003).
Alkaline comet assays
Alkaline comet assays were carried out using Trevigen Comet-
Slides according to the manufacturer’s recommendations. DNA
was stained with ethidium bromide (10 µg/mL) and visualized
using a fluorescence microscope. Fifty comets were analyzed
per slide, using National Institutes of Health images with
Comet macro (Helma and Uhl 2000).
Antibodies and immunoblotting
Anti-MLH1 (554072) and anti-PMS2 (556415) monoclonal anti-
bodies were from BD Pharmingen; anti-CHK1 (611152) was
from BD Transduction Laboratories; and anti--tubulin (D-10),
anti-TFIIH p89 (S-19), anti-CDC25A (F-6), and anti-ATR (FRP1,
N-19) were from Santa Cruz Biotechnology. Anti-RPA p34 (Ab-
3) was from Oncogene. Anti-phospho-CHK1 (Ser 345), anti-
phospho-CHK2 (Thr 68), and anti-phospho-Ser/Thr (S*/T*Q)
ATM/ATR substrate antibodies were from Cell Signaling. Anti-
CHK2 (07-126) and anti--H2AX (Ser 139) antibodies were from
Upstate Biotechnology. The anti-ATM phospho-Ser 1981 anti-
body was obtained from Rockland. The anti-ATM antibody was
kindly provided by Stephen P. Jackson (Wellcome/CRC Insti-
tute, Cambridge, UK). Immunoblotting and total protein extrac-
tions were performed as described previously (Cejka et al. 2003).
Immunofluorescence studies
Cells grown on glass cover slips were treated or mock-treated
with MNNG and incubated for the indicated time periods. Fixa-
tion was done in 3.7% formaldehyde/PBS (15 min, 4°C), fol-
lowed by permeabilization in 0.2% Triton X-100/PBS (5 min,
4°C). In the case of anti--H2AX, the cells were fixed in ice-cold
methanol (20 min, −20°C). The coverslips were blocked with
3% low-fat milk/PBS and incubated with anti-phospho-(Ser/
Thr) ATM/ATR substrate, anti--H2AX (Ser 139), anti-ATR,
and anti-RPA p34 antibodies, all at 1:100 dilution. After wash-
ing, the cells were incubated with FITC-conjugated anti-rabbit
or anti-goat antibodies (Sigma) and TR-conjugated anti-mouse
antibodies (Abcam) for 1 h at 37°C. The nuclei were counter-
stained with DAPI (0.1 µg/mL, Sigma). Images were captured on
a Leica DC 200 fluorescence microscope.
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In order to better understand the mechanism of cell killing by MNNG, I wanted to 
understand what are the pathways required for MMR-dependent processing and how do 
they contribute to cell death or survival. I was able to show that the initial recognition of 
6meG-containing mispairs by MMR happened in the first S phase after treatment and this 
provoked cytologically visible uncoupling of replication and repair foci. Although 
recognized in the first cell cycle, in order to induce cell cycle arrest, presence of 6meG is 
required in both cell cycles after MNNG treatment indicating involvement of another 
pathway. Activation of the MRN complex was MMR dependent, but not necessary for 
the arrest or overall survival. In vivo activation of homologous recombination depended 
on MMR status and the sites of ongoing recombination contained the ssDNA-binding 
protein RPA. Lack of HR repair rendered cells extremely sensitive to MNNG, and 
activated cell cycle arrest already in the first cycle after treatment. This finding suggests 
that progression through the first cell cycle requires homologous recombination, possibly 
to rescue the intermediates created by MMR processing after 6meG mispairing in the first 
replication. 
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Abstract 
 
The cytotoxicity of methylating agents of SN1-type, such as N-methyl-N’-nitro- N 
-nitrosoguanidine (MNNG), has been proposed to be mediated by unsuccessful 
attempts of the mismatch repair (MMR) system to process mispairs between O6-
methylguanine (6meG) and cytosine or thymine, which arise during DNA 
replication. This hypothesis is based on data showing that cells resistant to killing 
by these agents either express high levels of methylguanine methyl tranferase 
(MGMT), an enzyme that selectively reverts 6meG to G, or have defective MMR. 
However, this hypothesis fails to explain why the MNNG-induced cell cycle 
arrest occurs only in the second G2 phase after treatment. In an attempt to 
elucidate this phenomenon, we set out to identify the DNA metabolic pathways 
that transform 6meG-containing mispairs into cytotoxic lesions. We now show that 
the mismatch recognition factor MutSα  localises to replication foci in the first S 
phase after MNNG treatment of MGMT-depleted cells, but that the MutSα  foci 
persist long after replication has ceased. Reactivation of MGMT after the first cell 
cycle abolished the cell cycle arrest, which shows that persistent 6meG residues are 
required for its activation. In contrast, activation of the MRE11/NBS1/RAD50 
(MRN) complex, required in the repair of double-strand breaks, was dispensable 
for cell cycle arrest. Interestingly, cells deficient in homologous recombination 
(HR) were hypersensitive to MNNG and arrested already in the first cell cycle 
after treatment. This implies that HR processes cytotoxic lesions induced by this 
methylating agents so as to allow the treated cells to pass through mitosis. 
However, this processing generates secondary lesions that kill the cells in the 
subsequent cell division. 
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Introduction 
 
Chemotherapeutic methylating agents damage DNA either by methylation or DNA 
interstrand crosslink formation. Procarbazine, dacarbazine and temozolomide contain a 
single methyl group that can form DNA monoadducts at the N7 and O6 atoms of 
guanine, the N1 and N3 atoms of adenine and the N3 atom of cytosine. The majority of 
these adducts are repaired rapidly and efficiently by base excision repair, causing no 
cytotoxicity at doses used in the clinic. The only adduct shown to cause cell death is O-6-
methylguanine (6meG). The methyl group from the 6 position of guanine is usually 
removed by O6-methylguanine methyl transferase (MGMT), a suicide enzyme that is 
targeted to proteosomal degradation after transferring the methyl group to a cysteine 
residue inside its active site. Cells that overexpress MGMT are highly resistant to 
methylating agents, but its activity can be inhibited by a base analogue O6-benzylguanine 
that acts as a high affinity substrate for MGMT (Dolan et al., 1998). 
Treatment of cells with N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) brings about 
cell cycle arrest and cell death in mismatch repair (MMR) dependent manner. As 
hypothesized before, when replicative polymerase encounters 6meG in the template 
strand, it attempts to incorporate a nucleotide that fits Watson-Crick base pairing the 
best. Due to steric reasons, this seems to be T although it was shown that depending on 
the polymerase used, it can be either T or C (Reha-Krantz et al., 1996; Singh et al., 1996). 
Both 6meG-T and 6meG-C are recognized by MutSα (Berardini et al., 2000; Duckett et al., 
1996) and this is thought to initiate the so-called futile cycling of MMR-dependent 
excision and resynthesis by the polymerase. Finally, the polymerase is thought to re-
initiate replication further downstream, leaving a ssDNA gap opposite the 6meG. In the 
subsequent cell cycle, the ssDNA gap will be converted to a double strand break and 
cause cell cycle arrest. 
The surprising thing about MNNG treatment is that the cell cycle arrest is activated only 
in the second S-phase after treatment (Stojic et al., 2004), although processing by MMR 
is expected to occur already in the first replication phase, when the 6meG in the template 
strand mispairs with either T or C. Thus, the delayed mode of action of MNNG may be 
due to formation of secondary lesions that have to be essentially different in the first and 
the second S phase after treatment.  
It has been reported previously that treatment of MMR-proficient cells with MNNG 
causes elevated levels of homologous recombination (Zhang et al., 2000). It could 
 
 
 
Results
89
therefore be assumed that homologous recombination is required for the processing of 
the secondary lesions, as was shown to be the case in yeast (Cejka et al., 2005).  
Besides correcting mismatches that escape the proofreading activity of the polymerase 
during replication, MMR has been implicated also in the processing of recombination 
intermediates. In bacteria and yeast mismatches created during recombination are known 
to be addressed by MMR, which causes abortion of the heteroduplex formation thus 
acting antirecombinogenic (Surtees et al., 2004). The involvement of MMR proteins in 
mammalian recombination processes has been described for meiotic recombination and 
this only for MutL components of the MMR machinery (Baker et al., 1995; Baker et al., 
1996; Edelmann et al., 1996). Possible role of MMR proteins in somatic recombination 
was demonstrated in MSH2-/- mouse ES cell line, which during gene targeting showed as 
efficient integration for nonisogenic construct as for isogenic (de Wind et al., 1995). 
MMR-dependent processing of 6meG adducts has been studied intensively. However, 
although the consequences of the 6meG formation have been described in detail (Cejka et 
al., 2005; Kaina, 2004; Karran, 1995; Stojic et al., 2004), the molecular mechanisms of 
processing of this DNA modification has never been addressed successfully. In this 
work, I set out to identify the DNA metabolic pathways that are involved in the 
cytotoxicity of SN1-type methylating agents such as MNNG in the living cells. 
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 Results and Discussion 
 
Uncoupling of DNA replication and MMR processing after MNNG treatment 
Mismatch repair proteins have predominantly nuclear localization as can be expected by 
the role they play in the cell. MutSα is a heterodimer composed of MSH2 and MSH6 and 
is responsible for recognition of base mismatches and 1-2 nucleotide insertion-deletion 
loops. It was shown that MSH6 interacts with PCNA and is localized to replication foci 
(Kleczkowska et al., 2001). In order to follow the localization of MutSα depending on 
the cell cycle and treatment with MNNG, we synchronized HeLaMR cells (MGMT 
deficient, a kind gift of M. Bignami) with double thymidine block and released them in 
thymidine-free medium without (untreated) or with 0.2 µM MNNG. As shown in Figure 
1A, in untreated cells foci of MutSα appeared in S and G2 phase of the cell cycle and 
followed the localization of PCNA. This is in accordance with previously published data 
(Kleczkowska et al., 2001) as MMR machinery is linked to replication in order to repair 
the mismatched base pairs that have escaped the proofreading activity of the polymerase. 
Also, it can be noticed that foci of MHS6 did not persist throughout the cell cycle but 
were prominent during the S and G2 phases and completely disappeared in G1. The 
pattern of MSH6 localization in cells treated with MNNG after the release from the 
double thymidine block was somewhat different. The number of foci in the first 
replication phase was higher than in untreated cells, but they were still colocalizing with 
PCNA, indicating that MSH6 is part of the replication machinery. After the first S phase, 
the difference between control and treated cells became obvious. The focal pattern of 
PCNA staining disappeared as could be expected, because the cells exit the S phase, but 
MSH6 continued to be localized in the discrete foci. This can be explained by the 
possibility that MutSα complex dissociates from PCNA and replication machinery upon 
mismatch recognition, and continues to stay bound to the mismatch. The same 
phenomenon was observed in in vitro system (Lau and Kolodner, 2003) where MutSα 
dissociated from PCNA upon binding of mismatched DNA.  
In contrast to untreated cells, where foci of MSH6 disappeared after S-G2 phase 
together with those of PCNA, in treated cells MSH6 continued to be localized in very 
clear foci. Although cells continued to cycle as indicated by FACS analysis (Figure 1B) 
and by PCNA staining (big, centrally located foci, indicating late S phase) foci of MSH6 
continued to persist independently of PCNA. Only in the very late time point, when the 
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cells were already arrested in G2 phase, did foci of MSH6 disappear. This indicates that 
MutSα was recruited to the sites of damage during two cell cycles, changing its 
localization already in the first S phase, but still residing on the damaged DNA in the 
second replication phase after MNNG treatment. As can be noted from Figure 1B, the 
progression through the first S phase in control synchronization (Figure 1Ba) and 
MNNG treated cells (1Bc) was identical, that is, the speed of replication fork was not 
influenced by the presence of 6meG. This is contrary to the hypotesis of futile cycling, 
where the progression of the replicative polymerase would be temporarily blocked by the 
cycles of MMR provoked excision and resynthesis by the replicative polymerase. The 
speed of the S phase progression indicates that the polymerase itself is not stalled, but 
can freely continue across and downstream of the 6meG residues in the template. MutSα 
following the replication fork can recognise the mispair, dissociate from PCNA and 
engage in attempts, uncoupled from the replication fork, to remove the mismatch. 
MNNG treatment brings about MMR-dependent cell cycle arrest in the G2 phase of the 
second cell cycle after treatment (Stojic et al., 2004). Presumably, methylation by MNNG 
gives rise to 6meG, which in the subsequent replication phase pairs with T or C. The 
mismatch can then be addressed by MMR and activate the checkpoint. The specificity of 
MNNG treatment is its requirement for two replication cycles in order to arrest the cells. 
6meG residues are normally repaired by MGMT (methyl-guanine methyl transferase), an 
enzyme that catalyses the irreversible transfer of methyl group to an internal cysteine in 
the active site, thus targeting it for degradation. If MGMT reverts the damage before the 
replication fork encounters the 6meG in the template strand, cells continue to replicate 
independently of their MMR status. Therefore, MGMT protects the cells from the 
cytotoxic effect of 6meG. In many tumours, MGMT is not expressed due to 
hypermethylation of its promoter, rendering tumours more sensitive to methylating 
agents. In order to prevent MGMT activity during chemotherapeutic treatments with 
methylating agents, tumours can be pretreated with O-6-benzylguanine (BG), a 
nucleotide analogue that is a substrate for MGMT. Pre-treatment of cells with BG 
depletes MGMT activity, allowing for formation of stable 6meG residues. Although the 
processing of the 6meG-T mispair by MMR is expected to occur during the firs S phase, 
cells are allowed to pass the first mitoses, enter the second cell cycle and arrest only in 
the second G2 phase post treatment. We wanted to examine if the 
6meG residue is 
required for MMR-dependent arrest only in the first replication phase after the treatment 
or in both S phases before the checkpoint arrest. We synchronized HeLa cells with 2 
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mM HU for 16 hours, and released them in HU-free medium. As indicated in the control 
synchronization, levels of MGMT protein do not vary during the cell cycle. When the 
cells were released in the medium containing 0.1 µM MNNG, level of MGMT was high 
enough to revert all 6meG residues back into G. As shown by the levels of MGMT, this 
concentration of MNNG was not high enough to notably lower the amount on MGMT 
in the cells. As expected, cells did not arrest but continued to cycle. Contrary to this, 
when the cells were pretreated with O-6-benzylguanine (BG) for 16 hours, level of 
MGMT was notably reduced, corresponding to the description of MGMT as a suicide 
enzyme that is targeted for proteosomal degradation after the transfer of an alkyl group 
to the active-site cysteine. In this case, 6meG residues were not reverted but enter 
replication where they were addressed by MMR. Consequently, cells arrested in G2/M 
phase of the second cell cycle after release/treatment as indicated at T36 and T60.  
MGMT is a small protein of ∼25kDa and after removal of O-6-benzylguanine from the 
medium is soon re-expressed to the normal levels. To assess if the presence of 6meG is 
required in both the first and the second replication phase in order for the cell to arrest, 
we removed BG from the medium at T10 time point, when the cells have passed the first 
S phase but still did not enter the second cell cycle. The time since removal of BG (T10) 
to the point when the arrest becomes effective (T36) is sufficient to allow for the 
recovery of normal MGMT level (MGMT western blot, Figure 1B - panel 4.). Re-
expression of MGMT allows for the removal of methyl group from guanidine and as a 
result, cells do not arrest but return to a normal cycling profile. From this, we can 
conclude that the presence of 6meG is required in both cell cycles in order for cells to 
activate the checkpoint and arrest. On the other hand, if the BG is removed from the 
medium at T36, when the checkpoint has already been activated, cells continue to be 
arrested and don’t recover from the arrest (Figure 1B, panel 5.). These results correspond 
to localisation pattern of MSH6 in Figure 1A, where MutSα is localised in discrete foci, 
presumably at the sites of damage, during two replication cycles. Foci disappear at the 
point when the arrest is effective (T36, second G2 phase after treatment) and when the 
reactivation of MGMT does not contribute to cell cycle progression. 
Appearance of the cell cycle arrest this late after MNNG treatment suggests that the 
initial damage per se is not triggering the checkpoint activation. This long delay can only 
be explained by the requirement for processing of the initial damage during two cell 
cycles. We wanted to identify the repair pathway activated in MMR-dependent manner 
responsible for the generation of secondary lesions and delayed arrest. 
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 The MRN complex is not required for the repair of MMR-induced intermediates 
after MNNG treatment. 
In order to look for the pathway activated in vivo after MNNG treatment, we carried out 
a series of immunofluorescence studies, using a palette of antibodies that recognize 
proteins involved in different DNA metabolic transactions. Most of the DNA repair 
proteins have a tendency to translocate after damage into so-called DNA damage 
induced foci and colocalization of proteins in the same focus is indicative of their 
engagement in the same repair process. A candidate complex emerged after staining the 
cells with MLH1 and MRE11 antibodies. In untreated culture, a small proportion of cells 
showed foci of MLH1 and MRE11 and, interestingly, these foci were always colocalizing 
(Figure 2A). MRE11 is a component of the so-called MRN (MRE11-NBS1-RAD50) 
complex and is a key player in cellular response to DSBs (Assenmacher and Hopfner, 
2004). The complex is an ATP-stimulated nuclease that degrades DNA in the 3’→5’ 
direction and is involved in the resection of DNA ends during DSB repair, particularly 
by cleaving DNA hairpins formed on ssDNA. Involvement of the MRN complex in 
replication was shown by interaction of its NBS1 component with the E2F transcription 
factor near replication origins (Maser et al., 2001) and colocalisation of MRE11 with 
PCNA in replication foci (Mirzoeva and Petrini, 2003). The role of the MRN complex in 
prevention/repair of collapsed replication forks was shown in cell-free Xenopus egg 
extracts, where the absence of the complex resulted in many DSBs (Costanzo et al., 
2001). Processing of 6meG by the mismatch repair machinery could possibly leave a gap in 
the DNA that would be converted to a DSB in the following cell cycle, where the 
function of the MRN proteins in the stabilization of replication fork could play a key 
role. The possibility that MLH1 and MRE11 participate in the same pathway responsible 
for MNNG sensitivity was not confirmed, because the number of MLH1 or MRE11 foci 
did not increase after MNNG treatment (data not shown). As activation of the repair 
proteins is not always accompanied by their translocation into foci, we set out to check 
the phosphorylation status of NBS1 and MRE11 in 3 matched pairs of MMR-proficient 
and deficient cell lines. 293T Lα+ and Lα- is an isogenic cell pair in which the MMR 
status can be regulated with doxycyclin (Cejka et al., 2003). HCT116+chromosome 3 is a 
MMR proficient cell line derived from MMR deficient cancer cell line HCT116 by 
transfer of chromosome 3. HeLa clone 12 is derived from HeLa by selection with low 
doses of MNNG and is MMR deficient due to the lack of PMS2.  
 
 
 
Results
94
NBS1 is required for ATM autoactivation and phosphorylation (Lee and Paull, 2004) and 
is in turn phosphorylated by ATM on Ser343 (Lim et al., 2000). MRE11 protein is also 
phosphorylated in vivo (Dong et al., 1999), although the phosphorylation site is not yet 
known. As shown in Figure 2B, NBS1 is phosphotylated after MNNG treatment in all 
MMR proficient cell lines, while there is no NBS1 phosphorylation in MMR-deficient 
cells. The same is true for MRE11, whose hyperphosphorylated form is present in MMR 
proficient cells, but is absent from MMR deficient. The lack of the hyperphosphorylated 
form of MRE11 in 293TLα cells is linked to the presence of SV40 Large T-antigen that 
was reported to interfere with the MRN pathway (Digweed et al., 2002; Lanson et al., 
2000; Wu et al., 2004).  
Phosphorylation of NBS1 was apparent already at the 24 hour time point, when cells 
passed through one round of replication with 6meG present in the DNA. Although the 
difference between MMR proficient and deficient cells becomes apparent at this time 
point, this is still not enough for the cells to arrest, indicating that the processing 
intermediates created in the first S-phase can be tolerated.  
In order to assess if activation of the MRN complex is required for the repair of the 
lesions generated by MMR processing, we used two isogenic cell pairs defective in either 
NBS1 (NBS1 cells and NBS1 cells complemented with cDNA of NBS1 (Ito et al., 1999); 
a kind gift of K. Komatsu) or MRE11 (ATLD1 cells and ATLD1 complemented with 
cDNA of MRE11 (Carson et al., 2003); a kind gift of M. Weitzman). The MRN complex 
has been shown to play a crucial role in DNA damage signalling, mainly participating in 
the ATM pathway (Carson et al., 2003). Thus, one of the consequences of the loss of 
MRN function might be incorrect checkpoint activation in response to the damage. As 
we showed before (Stojic et al., 2004), the cell cycle profile of MMR proficient cells 
changes two cell cycles after MNNG treatment. NBS and NBS+NBS1 cells show the 
typical profile of MMR proficient cells with G2/M accumulation two cell cycles after 
treatment, at the 48 hours time point. Although NBS1 was phosphorylated on Ser343 in 
MMR dependent manner (figure 2B), it does not seem to be required for the checkpoint 
activation. The overall survival of the cells after MNNG treatment depends mostly on 
the repair efficiency and not on the signalling pathway activated in response to damage 
(di Pietro et al., 2003). In order to check the involvement of NBS1 in the repair of 
lesions created by MMR processing, clonogenic assays were preformed and, as shown in 
Figure 2D, there were no differences in survival between cells deficient and proficient in 
NBS1. Similar results were confirmed with ATLD-1 cells, where expression of 
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recombinant MRE11 did not influence cell cycle distribution (Figure 2E) or overall 
survival (Figure 2F) after MNNG treatment.  
Interaction of MLH1 and MRE11 has been reported before (Her et al., 2002) and, 
although colocalization of MLH1 and MRE11 in untreated cells (Figure 2A) could 
indicate their involvement in a common pathway, it’s clear from these results that this 
pathway is not necessary for initial checkpoint activation or for overall survival. These 
findings are consistent with the fact that the MMR-dependent cell cycle arrest does not 
require the ATM kinase (Stojic et al., 2004), which participates in the same pathway as 
the MRN complex. Also, the role of the MRN complex in the stabilization of replication 
forks is attributed to linking the free ends of a double strand break formed after the 
collapse of a replication fork (Assenmacher and Hopfner, 2004). In the case of MNNG 
treatment, we could not detect the presence of DSBs at any point after treatment, so the 
need for tethering free DNA ends by the MRN complex is presumably not required. 
 
MMR processing of methylation damage activates homologous recombination. 
 
MMR has been hypothesised to recognize 6meG-T mispairs in the first round of 
replication after MNNG treatment and to attempt to correct them. As it’s capable of 
removing the nucleotide incorporated in the newly-synthesized strand only, it will 
remove the T. This however does not repair the modified nucleotide in the template 
strand, namely 6meG. The replicative polymerase will incorporate again a T opposite, that 
fits the best Watson-Crick pairing. According to this hypothesis, MMR and the 
polymerase will engage in futile cycles of incorporation and degradation of the newly-
synthesised strand opposite of 6meG, and eventually the polymerase will resume the 
replication downstream of 6meG (for review, see (Bignami et al., 2000)). According to this 
model, there will be a gap created in the daughter strand whose filling-in will be blocked 
by 6meG in the template strand. Gaps of this kind are highly susceptible to 
endonucleolytic cleavage in living cells, unless protected by ssDNA binding proteins 
(Wold, 1997). The presence of gaps in the DNA could be detected by the presence of 
damage-induced foci of ssDNA-binding proteins. One of those proteins tested was 
RAD51, a homologue of bacterial RecA, also known as a recombinase, because of its 
role in the initial steps of homologous recombination. Its localization to the sites of 
damage is dependent on BRCA2 with which it interacts through BRC domains 
(Pellegrini et al., 2002). RAD51 displaces RPA from the ssDNA and promotes strand 
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invasion and formation of D-loop in the intact homologous dsDNA (Shin et al., 2004). 
In 293TLα cells, foci of RAD51 became apparent in MMR-proficient cells already at the 
24 hour time point, but peaked 48 hours after MNNG treatment (Figure 3A). The 
highest number of foci corresponded to the time point when the G2 arrest of MMR-
proficient cells was apparent. There were no foci of RAD51 in MMR-deficient cells at 
any time point after treatment indicating that the damage created by MNNG was 
converted to recombination intermediates in MMR-proficient cells only. As we noted 
before, RPA, another ssDNA binding protein, forms MNNG induced foci specifically in 
MMR-dependent manner (Stojic et al., 2004). They were shown to colocalize with γ-
H2AX foci, indicating that they form at the sites of chromatin remodelling in damaged 
DNA. We tested if the RAD51 foci representing sites of ongoing recombination can also 
be localized to the sites of RPA-γH2AX localization. For technical reasons, we used 
MMR-proficient HeLa cells and stained them with both RAD51 and RPA antibodies. As 
shown in Figure 3B, 48 hours after MNNG treatment the number of both RAD51 and 
RPA foci peaked, with majority of the foci colocalizing as indicated by the yellow colour 
of the merged images. Colocalization of RAD51 and RPA at the sites of single-stranded 
DNA regions has been reported previously and is indicative of their common 
involvement in recombination repair (Raderschall et al., 1999).  
From this result, we observed that homologous recombination pathway is activated in a 
MMR-dependent manner. In vivo consequence of repair by homologous recombination 
can be observed at cytological level as sister chromatid exchanges (SCE). They are the 
consequence of homologous recombination associated with stalled or collapsed 
replication forks, while true DSBs in mammalian cells are almost exclusively repaired by 
non-cross-over mechanism (sister chromatid gene conversion) thus not rendering 
cytological phenomenon of SCE (Johnson and Jasin, 2000; Richardson et al., 1998).  
It has been reported previously that MNNG treatment brings about elevated levels of 
SCE and their formation has been specifically attributed to 6meG (Kaina, 2004; Kaina and 
Aurich, 1985). Differential sensitivity of MMR-proficient and -deficient cells to MNNG 
treatment is dependent on the presence of 6meG, as cells expressing high levels of MGMT 
are highly resistant to killing by this agent, irrespective of their MMR status (Kaina et al., 
1997). In order to test the dependence of SCE formation on MMR status, we analyzed 
both MMR-proficient and -deficient 293TLα cells after MNNG treatment. In order to 
distinguish sister chromatids in mitotic chromosomes, the cells have to be grown for two 
cell cycles in the presence of BrdU. Chromosomes of such cells can be distinguished, 
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because one sister chromatid will have both DNA strands labelled with BrdU, while the 
other sister chromatid will have BrdU incorporated in only one strand of DNA. As 
MMR proficient cells needed two replication cycles to activate the checkpint and arrest, 
we assessed the SCE fomation in the presence of MNNG after 48 hours (MNNG added 
together with BrdU) but also after 24 hours, when the cells have passed only one 
replication cycle in the presence of 6meG (MNNG added 24 hours after the addition of 
BrdU). As shown in Figures 3C and 3D, elevated levels of SCE can be observed in 
293TLα+ cells only 48 hours after MNNG treatment. Number of SCE per cell rose 
from average 3.14 to about 4 times higher average level with many cells having around 20 
SCEs. This correlates with previous findings, where it was shown that 6meG needs 
additional processing to be converted into a SCE-inducing lesion (Karran et al., 1993) 
and clearly MMR is a crucial component of the process. 
At this point it has to be noted that SCE are outcomes of recombination-dependent 
processing going on during replication. However, it cannot be concluded that SCE are 
the deleterious structures that finally arrest the cells. Two cell cycles after treatment, a 
large proportion of MMR-proficient cells are arrested in the G2 phase of the cell cycle 
but in order to score SCEs, cells have to pass to mitosis. Therefore, only the cells that 
escaped the arrest can be scored, while those arrested never pass the G2/M boundary 
and their chromosomes cannot be visualized. We can thus assume that the process giving 
rise to SCEs is stalled in the majority of the cells and not efficient enough to repair the 
intermediates and allow the cells to recover from the G2 arrest. Only a small proportion 
of the cells deal with the damage successfully and, as a consequence of this repair 
process, SCEs are visible in their mitotic chromosomes.  
 
Homologous recombination is required for initial bypass and overall survival after 
formation of 6meG 
 
Experiments in which relocalization of RAD51 and RPA proteins was observed in 
MMR-proficient cells and formation of elevated levels of SCEs depended on MMR 
status indicated that homologous recombination pathway is indeed activated in MMR-
dependent manner. Secondary lesions created by MMR processing of 6meG seem to be 
addressed by homology-dependent repair. In order to test the response of MMR-
proficient cells with regard to their ability to carry out recombination repair, we used 
homologous recombination impaired cell lines lacking the RAD51 paralogs XRCC2 and 
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XRCC3. These proteins are members of the RAD51 family (composed of RAD51B, 
RAD51C, RAD51C, XRCC2 and XRCC3) and initial findings suggested that they are 
required for the early steps of homologous recombination. Their ability to repair DSBs is 
almost completely abolished (Johnson et al., 1999; Pierce et al., 1999) and mouse 
knockouts are embryonicly lethal (Deans et al., 2000). Cells lacking XRCC2 or XRCC3 
were shown to be unable to form damage-induced RAD51 foci (Bishop et al., 1998; 
O'Regan et al., 2001) suggesting the requirement for these polypeptides in formation of 
RAD51-ssDNA filaments. Recent results indicate involvement of RAD51 paralogs in 
later steps of homologous recombination. Five members of the family form two distinct 
complexes in living cells: one is composed of RAD51C-XRCC3 and the other comprises 
RAD51B-RAD51C-RAD51D-XRCC2 (Liu et al., 2002; Masson et al., 2001). The 
RAD51C-XRCC3 has been recently identified as a component of the mammalian 
resolvase complex (Liu et al., 2004).  
Irs1 cells are mutated in XRCC2 gene; they fail to form RAD51 foci in response to DNA 
damage and are hypersensitive to a variety of DNA damaging agents such as the 
crosslinking agent Mitomycin C (MMC) (Jones et al., 1987). Introduction of cDNA of 
human XRCC2 restored DNA damage resistance and RAD51 focus formation (O'Regan 
et al., 2001). Irs1SF cells are defective in XRCC3 and, like Irs1, are hypersensitive to 
DNA damaging agents. AA8 is the parental cell line, able to carry out homologous 
recombination.  
In order to assess the influence of functional recombinational repair on survival of 
MNNG-treated cells, we treated two pairs of cell lines: Irs1 and Irs1 complemented with 
cDNA of XRCC2; and Irs1SF and its parental, homologous recombination proficient 
cell line AA8. As indicated in Figure 4A, cell survival after MNNG treatment was highly 
dependent on functional recombination repair. Irs1 and Irs1SF were substantially more 
sensitive to MNNG than their recombination-proficient counterparts. Extreme 
sensitivity of Irs1SF cells might be due to the role of XRCC3 in the resolution of 
Holliday junctions, where in the absence of efficient resolution, recombination 
intermediates signal and eventually arrest the cell cycle. In both cases, it’s clear that 
functional recombinational repair is rescuing some of the intermediates arising after 
MNNG treatment.  
As the lack of recombination efficiency renders cells more sensitive to MNNG 
treatment, we also wanted to know if this influences the cell cycle distribution and arrest 
after treatment. Therefore, we treated the cells and analyzed their DNA content at time 
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points correlating to the length of their cell cycle (approximately 16-18 hours). Figure 4B 
shows that recombination proficient cells, Irs1/XRCC2 and AA8, showed a typical cell 
cycle profile of MMR-proficient cells after MNNG treatment. They required two DNA 
replication cycles to activate the checkpoint and arrested in G2/M phase. Contrary to 
this, the recombination impaired cell lines Irs1 and Irs1SF show accumulation of G2/M 
phase cells already 16 hours after MNNG treatment, during which time the cells were 
able to replicate their DNA only once. The fact that both XRCC2 and XRCC3 deficient 
cell lines behaved the same shows that bypass of the lesions generated after MNNG 
treatment required recombination as a whole rather than merely some of its individual 
components. 
In order to follow the cell cycle of MMR-dependent arrest in recombination proficient 
and -deficient cells in detail, we synchronized the Irs1 and Irs1/XRCC2 cells in G1/S 
phase of the cell cycle and released them in MNNG-containing medium. This pair of 
cells was chosen over Irs1SF and AA8 because they are nearly isogenic (stabile 
transfection of XRCC2 cDNA).  
The cells were synchronized at the G1/S transition with 2 mM hydroxy-urea for 16 
hours (T0) and released in HU-free medium containing MNNG. Control 
synchronization showed that both HR proficient and deficient cells recovered completely 
from the HU-induced arrest. The cells were then collected at the indicated time points 
and processed for cell cycle analysis. Progression of the Irs1/XRCC2 cells followed an 
already known pattern of MMR proficient cells, where they clearly re-entered the second 
cell cycle after treatment as indicated at T10, T12 and T16 time points by an increase in 
the G1 fraction. Contrary to that, the Irs1 cells were still in G2 phase of the cell cycle at 
these time points, with only a very small proportion of the cells re-entering the second 
cycle. The difference was also obvious at the later time point where many more Irs1 cells 
can be detected in the sub-G1 region of the histogram, indicating a larger proportion of 
dead cells.  
A delayed cell cycle arrest, namely the requirement for two replication cycles after 
MNNG treatment in MMR proficient cells, has been a phenomenon observed long time 
ago, but so far there was no mechanistic model given to satisfy the observed results. 
MMR machinery is expected to recognize 6meG-T mispairs already during the first 
replication after MNNG treatment. Unless repaired or bypassed, this processing is 
expected to be recognized by checkpoint proteins that will activate the cell cycle arrest. 
From the cell cycle analysis of recombination deficient cells, we show that during the 
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first cell cycle, MMR indeed recognizes the damage (presumably 6meG) and creates 
secondary lesions. In the absence of homologous recombination, these lesions cannot be 
bypassed and therefore HR-deficient cells arrest already in the first G2 phase after 
treatment. In the presence of HR, secondary lesions can be bypassed during the first 
S/G2 phase, but apparently the DNA still contains structures that will become 
deleterious in the subsequent replication. 
The simplest model that can be drawn from these results is presented in Figure 5A. In 
this model, MMR processing of the 6meG-containing template strand leaves a gap in the 
newly-synthesised strand, because any nucleotide incorporated opposite 6meG will be 
recognized as incorrect and will be removed by the exonuclease component of the 
mismatch repairosome. The role of RAD51 paralogs, XRCC2 and XRCC3 might be to 
bind to the gap and protect it during the subsequent phases of cell division. XRCC2 and 
XRCC3 bind ssDNA and it was reported that two complexes of RAD51 paralogs bind 
DNA gaps and nicks, indicating that gaps per se can be recombinogenic, without the need 
for free 3’ end (Liu et al., 2002). According to this model, RAD51 paralogs would 
prevent access of RPA to the single-stranded fragments; therefore gaps would remain 
“invisible” to the checkpoint machinery, as ssDNA is the substrate for the DNA damage 
sensors only if coated with RPA (Zou and Elledge, 2003). In the subsequent cell cycle, 
the replication fork would encounter the gapped fragment that would result in the 
collapse of the replication fork. In this case, the secondary lesion would be created 
already in the first S-phase but would be covered by ssDNA binding proteins (XRCC2, 
XRCC3) that would protect it till the next replication phase. 
Another possibility is that progression through the first S phase is dependent on 
recombination bypass, something similar to so-called template switching (Figure 5B). 
Polymerase stalling opposite the 6meG would direct the invasion of the 3’ end of the 
newly-synthesised strand to the newly-synthesised strand of the sister chromatid. After 
elongation and formation of the second holiday junction, resolution would occur in 
gene-conversion manner, without cross-over. As shown in Figure 3C, there were no 
sister chromatid exchanges in 293TLα+ cells after the first cell cycle. This is consistent 
with the fact that resolution of double Holliday junctions in mammalian cells results in 
non-cross-over mechanism (Helleday, 2003). Resolution gives rise to nicks in the newly-
synthesised strand, which can be sealed, but it’s possible that these nicks serve as strand 
discrimination signal for MMR initiation that will direct MutSα to recognize 6meG-C pair 
and again remove the C from the daughter strand. 6meG-C pairs are recognized by MutSα 
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with a similar efficiency as 6meG-T mispairs (Duckett et al., 1996) and are repaired 
efficiently in in vitro systems (Franziska Fisher, unpublished data). As the polymerase has 
already moved downstream from the lesion, a gap in the daughter strand is created and 
cannot be refilled due to the persistence of 6meG in the template strand. The consequence 
in the second cell cycle is again a collapse of the replication fork. In both models, a 
collapsed replication fork can induce break-induced replication (BIR), where the 3’ end 
invades the duplex DNA upstream of 6meG and the polymerase tries to extend the 
invading strand. Again, it will encounter 6meG in the template strand and any nucleotide 
incorporated opposite (T or C) will be recognized by MMR, but, in this case, there will 
be no homologous DNA duplex that can serve as template. At this point, the replication 
fork would be blocked and signal strongly to the checkpoint machinery (Figure 5, Major 
product). The collapse of the replication fork in MMR-proficient cells can explain the 
elevated levels of SCE two cell cycles after MNNG treatment. Recombination 
intermediates in break-induced replication are resolved in non-cross over manner, joining 
the template DNA and the newly synthesised DNA at the point of the collapse. It has to 
be noted that a small proportion of cells manage to elongate the daughter strand across 
the 6meG. These are most likely cells that enter mitosis and can be scored for SCEs. On 
the other hand, a majority of the cells cannot elongate the invading strand and arrest in 
the G2 phase, with possible S phase arrest in p53 proficient cells (Stojic et al., 2004). 
Also, this is most likely the moment where point mutations occur. If the polymerase 
manages to elongate the invading strand, it is possible that it will incorporate a T, which 
will cause GC to AT transitions (Figure 5, Minor product).  
The results shown in Figure 1, where the removal of 6meG in the second cell cycle 
prevented the arrest can be explained now. Activation of MGMT allows for removal of 
the methyl group, thus leaving guanine in the template strand. The gap that was 
persistent can now be filled-in before the replication fork in the second S phase 
encounters it. Even if the replication fork progressed past the gap, MGMT could remove 
the methyl group in the template strand and the polymerase could synthesise past it. This 
would leave an unmodified substrate for the repair of the collapsed fork, where the free 
end could invade the sister chromatid and restart the fork. 
The models presented here need additional supporting experiments, but this is the first 
time that distinction between the first and the second replication in the presence of 
MNNG could be made.  
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 Materials and Methods 
 
Cell lines 
The 293T Lα cell line was established in our laboratory and was propagated as described 
(Cejka et al., 2003). HeLa mex- and MRC5 cells were maintained in DMEM (OmniLab) 
supplemented with 10% fetal calf serum (FCS, Life Technologies), penicillin (100 U/ml) 
and streptomycin (100 µg/ml). HeLa mex- cells were a kind gift of Margherita Bignami. 
The hMLH1-deficient human colon cancer cell line HCT116 and its MMR-proficient 
subline HCT116 + ch3 were maintained in McCoy’s 5A medium (OmniLab) with 10% 
FCS. The chromosome-complemented cell line was maintained in medium containing 
400 µg/ml G418. Homologous recombination-impaired Chinese hamster cell line Irs1 is 
mutated in XRCC2 and the Irs1/XRCC2 line was complemented with human cDNA of 
XRCC2. Both cell lines were provided by John Thacker. XRCC3 deficient cells and their 
proficient parental cell line AA8 were a gift from Orlando Schaerer’s group. All four 
Chinese hamster cell lines were maintained in DMEM:F10/1:1 (OmniLab), 10% FCS, 
penicillin (100 U/ml) and streptomycin (100 µg/ml). NBS1 cells and those 
complemented with NBS1 cDNA were produced in the lab of Dr. Kenshi Komatsu and 
provided by Dr. Yosef Shiloh. They were maintained in DMEM supplemented with 10% 
FCS and the complemented cell line with additional 100 µg/ml Hygromycin B. For 
clonogenic assays, the medium was supplemented with 20% FCS. ATLD1-vector and 
ATLD1-MRE11 cells were a kind gift of Dr. Matthew Weitzman and were grown in 
DMEM, 20% FCS with 0.1 µg/ml puromycin. To inhibit MGMT activity, HCT116, 
HCT116+ch3, MRC5, NBS1 and ATLD1 cells were pre-treated with 10 µM O6-
benzylguanine two hours prior to MNNG treatment. All cell lines were cultured at 37°C 
in a 5% CO2 humidified atmosphere. 
 
Chemicals and irradiations  
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG, Sigma) was dissolved in DMSO and 
stored as 1 M solution at -20°C in the dark. O6-benzylguanine (Sigma) was dissolved in 
ethanol and stored at -80 °C. Hydroxyurea (HU, Sigma) and doxycycline (Dox, Clontech) 
were dissolved in water and stored at -20˚C. 
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Cell synchronization  
HeLa (Figure 1) and Irs1 and Irs1/XRCC2 (Figure 4) cells were grown to 30-40% 
confluency and 2 mM HU was added for 16 hours. The cells were washed twice with 
PBS and incubated in fresh medium containing 0.2 or 2 µM MNNG. HeLa cells were 
incubated in the presence of benzyl-guanine as described in the text. The cells were 
harvested at the indicated time points and processed for cell cycle analysis.  
 
Cell Cycle analysis 
The cells were trypsinised, washed once in PBS and resuspended in 70% ethanol. On the 
day of the analysis, the cells were washed again in PBS, incubated for half an hour with 
RNase A (100 µg/ml, Sigma) at 37°C and stained with propidium iodide (20 µg/ml, 
Sigma). Analysis was done using Beckman Coulter FC500 cytometer.  
 
Antibodies and immunoblotting 
Anti-MLH1 (554072) and anti-PMS2 (556415) monoclonal antibodies were from BD 
Pharmingen, anti-β-tubulin (D-10), anti-TFIIH p89 (S-19), anti-PCNA (PC10) and anti 
BRCA1 (D-9) from Santa Cruz Biotechnology, anti-MRE11 (Ab-1) and anti-RPA p34 
(Ab-3) from Oncogene, anti-NBS1 from Novus Bilogicals, anti-phospho-NBS1 (Ser-
343) from Cell Signaling, rabbit polyclonal FBE2 anti-RAD51 was a kind gift of Stephen 
West. The polyclonal rabbit anti-MSH6 antibody was produced and purified in our 
laboratory. Immunoblotting and total protein extractions were performed as described 
previously (Cejka et al., 2003) 
 
Immunofluorescence studies.  
Cells grown on glass cover slips were treated or mock-treated with MNNG and 
incubated for the indicated time periods. Fixation was done in 3.7% formaldehyde/PBS 
(15 min, 4˚C) followed by permeabilization in 0.2% Triton X-100/PBS (5 min, 4˚C). In 
the case of anti-PCNA, the cells were fixed in ice-cold methanol (20 min, -20˚C). The 
coverslips were blocked with 3% Low Fat Milk/PBS and incubated with anti-PCNA, 
anti-MSH6, anti-MRE11, anti-MLH1, anti-RAD51, or anti-RPA p34 antibodies. After 
washing, the cells were incubated with FITC–conjugated anti-rabbit or anti-goat 
antibodies (Sigma), and TR-conjugated anti-mouse antibodies (Abcam) for 1 h at 37˚C. 
The nuclei were counter-stained with DAPI (0.1µg/ml, Sigma). Images were captured on 
a Leica DC 200 fluorescence microscope fitted with a CCD camera. 
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 Sister Chromatid Exchange (SCE) assay 
To differentially label sister chromatids, the cells were incubated for 48 hours with 10µM 
BrdU (two cell cycles). Assessing the effect of MNNG was accomplished by the addition 
of 0.2 µM MNNG 24 or 48 hours before harvesting. To increase the number of mitotic 
cells, 0.1 µg/ml colcemid was added for the last 2 hours. The cells were trypsinized, 
washed once in PBS and resuspended by gentle vortexing in 3 ml of 75mM KCl, 
followed by 10 minutes incubation at 37°C to allow cell swelling. The cells were pelleted 
and resuspended in freshly prepared Carnoy’s fixative (Methanol:Acetic acid/3:1). After 
30 minutes incubation, the cells were spun down and resuspended again in sufficient 
amount of fixative to achieve the desired cell concentration. The cell suspension was 
dropped on ice-cold, wet glass slides and allowed to air dry. After drying, the slides were 
incubated for 15 min in 10 µM aqueous solution of Hoechst 33258 and rinsed twice in 
water only. To differentiate sister chromatids, slides were immersed in 2xSSC solution 
and exposed to strong light for 45 minutes. After washing, the slides were stained in 
3.5% giemsa solution in Soerensen buffer, pH 6.8 for 10 minutes and rinsed 5-6 times in 
tap water. Number of SCE events was counted in 50 metaphases and represented in 
Fig.3D. 
 
Clonogenic survival assay  
The cells were treated with the indicated concentrations of MNNG for 2 hours, 
trypsinized and counted. Serial dilutions of control and treated cells were plated and left 
for 14-20 days, after which colonies were stained with 10% giemsa and counted. 
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Figure legends 
 
Figure 1. 
Mismatch repair is required during two replication cycles for cells to arrest after MNNG 
treatment. (A) Nuclear localization of PCNA and MutSα throughout the cell cycle of 
MNNG-treated and untreated cells. MMR-proficient HeLaMR cells were synchronized 
with double thymidine block, released and treated, and processed for indirect 
immunofluorescence staining as described in Materials and Methods. (B) The presence 
of 6-methylguanine, which is addressed by mismatch repair, is required in both first and 
second replication cycles after treatment. HeLa cells were synchronized in the G1/S 
phase of the cell cycle with 2 mM hydroxy-urea for 16 hours with (Bc, Bd and Be) or 
without (Ba, Bb) 10 µM O-6-benzylguanine (BG). At the point of release, the cells were 
treated with 0.1 µM MNNG and fresh BG was added (Bc, Bd and Be). The cells arrested 
only when BG was present during the two cell cycles after treatment (Bc) or if it was 
removed at T36 (Be) when the checkpoint was already activated. If BG was removed at 
T10 (Bd) and MGMT was resynthesized before the cells enter the second S phase, there 
was no arrest and at T60 the cells had a typical asynchronous profile. 
 
 
Figure 2. 
The MNR complex is activated but not required for MMR-dependent processing of 
MNNG damage. (A) Indirect immunostaining for MLH1 and MRE11 showing 
colocalization of foci in untreated MRC5 cells. Only small percentage of cells was 
showing such foci, but they were colocalizing in each case. (B) NBS1 was activated upon 
MNNG treatment in MMR proficient cells already 24 hours after treatment. Activation 
of NBS1 was assessed by antibody against phosphorylated Ser343. Hyperphosphorylated 
form of MRE11 was present in HeLa and HCT116 + chr3 at later time points, 
represented by the slower-migrating form of the protein. (C) Cell cycle analysis of a 
matched pair of cell lines, one deficient in NBS1, the other complemented with NBS1 
cDNA. The figure shows that the presence or absence of NBS1 does not influence G2 
arrest after treatment with 0.2 µM MNNG. (D) Clonogenic assay of the same pair of cell 
lines, showing that survival after MNNG treatment is not influenced by the NBS1 
protein. (E) FACS analysis of MRE11 mutated ATLD1 cells and a matching line 
complemented with MRE11cDNA after MNNG treatment. Both cell lines showed a 
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similar pattern of arrest, which was not dependent on the presence of functional MRE11. 
(F) Clonogenic assay of the same pair of cell lines showing that survival after MNNG 
treatment is not influenced by the MRE11 protein. 
 
 
Figure 3. 
Mismatch repair dependent processing of methylating damage activates homologous 
recombination. (A) Formation of RAD51 foci in 293T Lα cells upon treatment with 0.2 
µM MNNG. Foci started to appear at the 24 hour time point only in MMR-proficient 
cells and their number peaked 48 hours after treatment. (B) Co-immunostaining of 
MMR-proficient HeLa cells showing colocalisation of RPA and RAD51 foci after 0.2 µM 
MNNG treatment. (C) Representative images of metaphase spreads of 293T La+ cells 
stained to differentiate sister chromatids of individual chromosomes. Only MMR-
proficient cells showed elevated levels of sister chromatid exchanges 48 hours after 
MNNG treatment. (D) Quantification of sister chromatid exchange (SCE) events in 
293T Lα cells after 0.2 µM MNNG treatment showing elevated SCE level in MMR-
proficient cells. 
 
Figure 4. 
Homologous recombination is required for cell survival after MNNG treatment (A) 
Colony survival assay of homologous recombination impaired cell lines after MNNG 
treatment. Cell lines deficient in the RAD51 paralogs XRCC2 (Irs1) and XRCC3 (Irs1SF) 
are hypersensitive to MNNG compared to their recombination-proficient counterparts. 
(B) Cell cycle analysis of cell lines deficient (Irs1 and Irs1SF) and proficient 
(Irs1/XRCC2 and AA8) in homologous recombination after 2 µM MNNG treatment. 
Cells that can carry out recombination repair arrest two cell cycles after the treatment, 
while those defective in such repair start arresting much sooner and show increased 
amount of apoptotic cells correlating with poor survival capability. Cell cycle of these 
cells is approximately 16-18 hours. (C) Homologous recombination is required to bypass 
the first cell cycle after MNNG treatment. Isogenic cell lines (Irs1 and Irs1/XRCC2) 
were synchronized at the G1/S transition with 2 mM hydroxy-urea and treated with 2 
µM MNNG. The cells were collected at the indicated time points and their DNA content 
was analyzed. Homologous recombination-deficient cells (Irs1) show arrest in the first 
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G2 phase after treatment, while the proficient cells (Irs1/XRCC2) went through the first 
cell cycle only to arrest in the second G2 phase after treatment. 
 
Figure 5.  
A possible model for the involvement of homologous recombination repair in MMR-
mediated cytotoxicity of O-6-methylguanine.  
MODEL A. The MMR processing of the 6meG/T or 6meG/C mismatch leaves a gap in 
the newly-synthesised strand. The gap is bound by RAD51 paralogues, thus preventing 
the binding of RPA and activation of the checkpoint. In the subsequent cell cycle, 
replication fork encounters the gap left over from the previous cycle and the fork 
collapses.  
MODEL B. Stalling of the filling-in polymerase or rounds of excision and incorporation 
direct the 3’ end of the newly synthesised strand to invade the sister chromatid and by-
pass the 6meG. The replicative polymerase can continue downstream of the lesion. 
Double Holliday junction will be resolved in a non-cross-over manner, but the nicks 
resulting from the resolvase cleavage can direct the MMR to excise the C opposite 6meG. 
As the gap cannot be filled because of the persistence of 6meG in the template strand, it 
will be converted into a collapsed replication fork in the next replication phase.  
The collapsed replication fork can then be repaired by break-induced replication (BIR) 
but only if the gap in the template chromatid can be filled. As the 6meG persists, neither 
the replicative polymerase, nor the polymerase engaged in the extension of the invading 
strand can bypass the 6meG. Unlike in the first cell cycle, at this moment there is no sister 
chromatid that can be used as non-damaged template. Small persentage of cells that do 
manage to repair such break are very likely to acquire GC to AT transitions because 
incorporation of T opposite of 6meG is less likely to elicit MMR-dependent excision, thus 
allowing for filling-in the gap and providing the substrate for the invading 3’ end of the 
broken chromatid. 
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 4.4 Homologous recombination rescues mismatch-repair-dependent 
cytotoxicity of SN1-type methylating agents in S. cerevisiae 
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MMR is highly conserved, from bacteria to humans and the sensitivity to 6meG –inducing 
agents is one of its hallmarks. The finding that the MMR status did not affect the 
sensitivity of Saccharomyces cerevisiae to MNNG was unexpected. One possible explanation 
for this difference was differential ability of yeast cells to process the secondary lesions 
created by MMR during attempted processing of 6meG residues. As was shown for 
mammalian cells, homologous recombination contributes to cell survival after MNNG 
treatment. Taking into account that recombination efficiency in yeast cells is much higher 
than in mammalian cells, this could be a pathway responsible for MNNG resistance in 
yeast. Indeed, HR inactivation sensitized S. cerevisiae to MNNG and, as in human cells, 
defects in the MMR genes MLH1 and MSH2 rescued this sensitivity. This finding 
suggests the importance of secondary pathways involved in MMR-mediated cytotoxicity. 
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Homologous Recombination Rescues
Mismatch-Repair-Dependent Cytotoxicity
of SN1-Type Methylating Agents in S. cerevisiae
Petr Cejka,1 Nina Mojas,1 Ludovic Gillet,1 cells can be efficiently killed by MNNG without having
to activate the machinery of programmed cell deathPrimo Schär,1,2 and Josef Jiricny1,*
[11] and because even dam− MMR-deficient E. coli are1Institute of Molecular Cancer Research
more resistant to killing by this methylating agent thanUniversity of Zürich
MMR-proficient strains [2]. We therefore reasoned thatAugust Forel-Strasse 7
the different response of yeast and mammalian cells toCH-8008 Zürich
methylating agents might be explained either by differ-Switzerland
ences in DNA-damage recognition or else by differ-
ences in other pathways of methylation-damage pro-
cessing.Summary
The human mismatch binding factor hMSH2/hMSH6
(hMutSα) has been reported to bind oligonucleotideResistance of mammalian cells to SN1-type methylat-
substrates containing MeG/T or MeG/C mispairs [12],ing agents such as N-methyl-N-nitro-N-nitrosogua-
and we wanted to test whether the yeast proteins be-nidine (MNNG) generally arises through increased ex-
haved similarly. To this end, we overexpressed thepression of methylguanine methyltransferase (MGMT),
S. cerevisiae MMR-recognition factor scMsh2p/scMsh6pwhich reverts the cytotoxic O6-methylguanine (MeG) to
(scMutSα) and purified it to near homogeneity (Fig-guanine, or through inactivation of the mismatch re-
ure 1A). Gel-shift assays with increasing amounts ofpair (MMR) system, which triggers cell death through
scMutSα (1.7–67 nM) and a constant amount (6.6 nM)aberrant processing of MeG/T mispairs generated dur-
of MeG/T-, MeG/C-, G/T- and G/C-containing oligonucle-ing DNA replication when MGMT capacity is exceeded
otide duplexes (Figures 1B–1E) revealed that all DNA[1]. Given that MMR and MeG-detoxifying proteins are
substrates formed slowly migrating protein/DNA com-functionally conserved through evolution, and that
plexes at high (>30 nM) scMutSα concentrations. For-MMR-deficient Escherichia coli dam− strains are also
mation of these nonspecific (ns) complexes has beenresistant to MNNG [2], the finding that MMR status did
observed previously [13] and probably results from ag-not affect the sensitivity of Saccharomyces cerevis-
gregation of scMsh2p/scMsh6p heterodimers on theiae to MNNG [3] was unexpected. Because MeG resi-
same oligonucleotide substrate. In contrast, the MeG/Tdues in DNA trigger homologous recombination (HR)
and G/T substrates formed a more rapidly migrating[4–7], we wondered whether the efficient HR in S. cere-
specific (s) complex with the heterodimer; this complexvisiae might alleviate the cytotoxic effects of MeG pro-
already appeared at low protein concentrations andcessing. We now show that HR inactivation sensitizes
represented w90% of the total labeled oligonucleotideS. cerevisiae to MNNG and that, as in human cells,
duplex at 16.4 nM protein concentration (lane with andefects in the MMR genes MLH1 and MSH2 rescue
asterisk in Figures 1B and 1C). In case of the MeG/Cthis sensitivity. Inactivation of the EXO1 gene, which
substrate, only a small amount of the specific complex
encodes the only exonuclease implicated in MMR to
was formed at lower protein concentrations (w35% atdate [8, 9], failed to rescue the hypersensitivity, which
16.4 nM scMutSα, Figure 2E, lane with an asterisk), butimplies that scExo1 is not involved in the processing
this amount was higher than that formed by the G/C
of MeG residues by the S. cerevisiae MMR system. homoduplex substrate (w10%, see Figure 2D, lane with
an asterisk). In both latter cases, the nonspecific band
Results and Discussion was also apparent at the 16.4 nM scMutSα concentra-
tion, indicating a weak recognition of the MeG/C sub-
In the yeast Saccharomyces cerevisiae, the functional strate. These results were confirmed in competition as-
homolog of human MGMT, scMgt1p, has been shown says, in which the labeled G/T heteroduplex (6.6 nM) in
to remove methyl groups from MeG residues and, to a the presence of scMutSα (16.4 nM) was competed with
lesser extent, from O4-methylthymine [10], and to pro- a 10-fold excess of the unlabeled MeG/T, MeG/C, G/T, or
tect the cells from both mutagenesis and killing in- G/C duplexes. In these experiments, the MeG/T oligo-
duced by MNNG [3]. The key players in postreplicative nucleotide appeared to be an even better substrate
MMR are the MutS homologs scMsh2p, scMsh3p, and for scMutSα than G/T (Figure 1F), although it should
scMsh6p and the MutL homologs scMlh1p and scPms1p be pointed out that the affinity of the mismatch bind-
(functional homolog of the human PMS2). These poly- ing heterodimer for the methylated oligonucleotides is
peptides are also functionally highly related to the hu- highly dependent on sequence context, which is gen-
man proteins, yet the MMR status of S. cerevisiae was erally not the case for G/T (our unpublished observa-
reported not to influence the response of mgt1 mutants tions). Differences in DNA-damage recognition thus
to methylating agents [3]. This difference between the cannot explain the difference in phenotype between
lower and higher eukaryotic cells is unlikely to be due yeast and mammalian cells. We therefore argued that
to the lack of apoptosis in yeast because mammalian these differences must lie in the processing of methyla-
tion damage downstream from damage recognition.
Treatment of mammalian and yeast cells with MNNG*Correspondence: jiricny@imcr.unizh.ch
was reported to give rise to elevated levels of homolo-2 Present address: Center for Biomedical and Clinical Sciences,
University of Basel, Mattenstrasse 28, CH-4058 Basel, Switzerland. gous recombination (HR). Furthermore, in human cells,
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HR was elevated specifically in an MMR-dependent
manner [4–7]. Given that the efficiency of HR in S. cere-
visiae is substantially higher than in mammalian cells,
we wondered whether this could be the underlying
cause of the different responses of these organisms to
methylating agents. Inactivation of the RAD52 gene,
which is required for most HR processes in S. cerevis-
iae, rendered the cells hypersensitive to MNNG. Addi-
tional inactivation of the MMR genes MSH2 or MLH1
had no effect on sensitivity, which was not particularly
surprising given that these cells expressed scMgt1p
(Figure 2A). However, when the MGT1 gene was also
inactivated, the mgt1 rad52 double mutant became ex-
quisitely sensitive to MNNG, whereas the mgt1 rad52
msh2 and mgt1 rad52 mlh1 triple mutants were sensi-
tized to a substantially lesser extent (Figure 2B). It
therefore appears that MMR-mediated processing of
MeG residues gives rise to cytotoxic intermediates that
are resolved by homologous recombination. Due to the
high efficiency of HR in yeast, these intermediates are
most likely successfully repaired, which would account
for the substantial resistance of MMR-proficient yeast
cells to MNNG. Interestingly, the survival curve of the
mgt1 rad52 strain appears to be biphasic (Figure 2B).
At low MNNG concentrations (0.5–1.5 M), the inactiva-
tion of MSH2 or MLH1 fully suppresses the sensitivity
of the mgt1 rad52 strain to MNNG, which shows that
the killing is at this concentration range linked almost
exclusively to the processing of MeG residues by the
MMR system. In contrast, cell death at high MNNG
concentrations (>3 M) is also most likely caused by
other types of damage, such as strand breaks arising
through processing of N-methylated purines and aba-
sic sites, which account for more than 90% of the dam-
age caused by these agents. Moreover, overexpression
of scMgt1p in the rad52 strain failed to improve survival
at high MNNG concentrations (data not shown), which
further supports the hypothesis that the cytotoxicity is
in this case linked to DNA modifications distinct from
MeG. A similar situation was also observed in human
cells [14].
It is well established that both scMsh2p and scMlh1p
are absolutely required for MMR, whereas the mecha-
nism and players in the downstream events of the re-
pair process remain enigmatic. We thus decided to
examine the involvement of the EXO1 gene, which en-
chromatography columns. The figure shows aliquots from different
purification steps separated on a denaturing 7.5% polyacrylamide
gel stained with Coomassie Blue.
(B–E) Binding of the scMsh2p/Msh6p heterodimer to different DNA
substrates. Formation of specific (s) and nonspecific (ns) complexes.
The heterodimer (1.7–67 nM) was incubated with 32P-labeled 6.6 nM
G/T, MeG/T, G/C, or MeG/C DNA substrates. The lane with 16.4 nM
protein concentration is indicated by an asterisk. The protein/DNA
complexes were analyzed by a gel-shift assay as described in the
Experimental Procedures and visualized by autoradiography. (E)
Competition binding assay. The Msh6p/Msh2p heterodimer (16.4
Figure 1. Substrate Specificity of the S. cerevisiae Mismatch Bind- nM) was incubated with 6.6 nM 32P-labeled G/T heteroduplex. The
ing Factor Msh2p/Msh6p preformed complexes were then challenged with a 10-fold excess
(A) Overexpression of scMsh2p/Msh6p in E. coli. Uninduced, total of unlabeled G/T, MeG/T, G/C, and MeG/C DNA substrates. The frac-
extract from BL21 codon plus cells; Induced, total extract from tion of the labeled G/T substrate bound by Msh2p/Msh6p was
BL21 codon plus cells overexpressing scMsh2p/Msh6p; SP, Hepa- quantitated by Typhoon 9600 PhosphoImager with ImageQuant
rin and Mono Q, pooled fractions eluted from the respective FPLC software.
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Figure 2. MNNG-Induced Killing of S. cere-
visiae Strains with Different Genetic Back-
grounds
(A) Comparison of MNNG sensitivities of the
MMR-deficient (mlh1 or msh2) and/or recom-
bination-deficient (rad52) strains as mea-
sured by the spot test. Mid-log phase cells
were treated with the indicated concentra-
tions of MNNG, harvested and spotted on
YPD plates at proper serial dilutions as de-
scribed in the Experimental Procedures.
(Wild-type genes are labeled with capitals,
deletion mutants with lowercase letters)
Sensitivity to ultraviolet (UV) light was used
as a control. The upper panel shows a repre-
sentative experiment, and the lower panel
shows a graphic representation of data pooled
from 3–5 independent experiments. Error bars
show standard error of the mean.
(B) Effect of methylguanine methyltransfer-
ase (mgt1) deficiency on the sensitivity of
MMR- and/or recombination-deficient strains
to MNNG. Sensitivity to UV light was used as
a control. The upper panel shows a repre-
sentative experiment, and the lower panel
shows a graphic representation of data
pooled from 3–5 independent experiments.
Error bars show standard error of the mean.
codes the only exonuclease implicated in MMR to date cesses, including mutation-avoidance pathways dis-
tinct from MMR, telomere integrity, and processing of(with the notable exception of the proofreading activity
of polymerase delta [8, 15]) in the processing of methyl- double-strand breaks prior to homologous recombina-
tion, and it is likely that its functions overlap with thoseation damage induced by MNNG. In contrast to MSH2
and MLH1 inactivation, which rescued the hypersensi- of other exonucleases [16]. Although our data provide
evidence that scExo1p is not required for the process-tive phenotype of the mgt1 rad52 mutant strain, dele-
tion of the EXO1 gene brought about a further, albeit ing of methylation damage, they fail to indicate which
exonuclease (if any) fulfills this role in vivo.minor, increase in MNNG sensitivity (Figure 3). These
results suggest that scExo1p helps the cell overcome The interaction between yeast MMR and HR in the
processing of DNA damage has been described pre-the deleterious effects of DNA methylation, rather than
being involved in the MMR-dependent cytotoxic pro- viously [17]. In that study, disruption of MMR genes
conferred a mild but significant (1.5- to 6-fold) resis-cessing of MeG residues. The role of the scExo1p in
MMR has been the subject of some discussion. The tance to cisplatin, carboplatin, and doxorubicin, and
contrary to our results, the resistant phenotype was de-protein plays a role in several other biological pro-
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Figure 3. MNNG Sensitivities of Recombina-
tion- (rad52), Methylguanine Methyltransfer-
ase- (mgt1), and/or Exonuclease 1 (exo1)-Defi-
cient S. cerevisiae
Mid-log phase cells of the indicated strains
were treated with the indicated concentra-
tions of MNNG and spotted at proper serial
dilutions on YPD plates as described in the
Experimental Procedures. The upper panel
shows a representative experiment, and the
lower panel shows a graphic representation
of data pooled from 3–5 independent experi-
ments. Error bars show standard error of the
mean.
pendent on functional scRad52p. This difference can 20-fold more tolerant to killing by MNNG Recombina-
tion-deficient S. cerevisiae thus resemble the methyla-be explained. DNA lesions induced by the above agents
block DNA replication and require recombination for ef- tion-sensitive phenotype of mammalian cells [18]. The
lack of involvement of scExo1p in the processing officient lesion bypass [17]. Because MMR controls the
fidelity of recombination processes, it most likely lowers methylation damage implies that the exonuclease func-
tion is fulfilled by another enzyme(s). Given the amen-recombination frequency in DNA containing these bulky
adducts and thus augments cytotoxicity. In contrast, ability of S. cerevisiae to genetic manipulation and
high-throughput screening, our present results shouldMeG/C pairs arising in methylguanine-methyltransfer-
ase-deficient cells upon methylation do not block DNA help us design assays for identification of these en-
zymes, as well as of other gene products involved insynthesis per se and are well tolerated in the absence
of MMR. Our model for the cytotoxicity of SN1-type the processing of methylation damage. It is hoped that
at least some of these findings will help us understandmethylating agents is outlined in Figure 4. In the ab-
sence of MMR, DNA replication will give rise to one the mode of action of SN1 methylating agents, which
represent an important class of cancer chemothera-unmodified progeny DNA molecule and one that carries
the MeG residue paired either with thymine of cytosine, peutics.
neither of which needs to be resolved by recombina-
Experimental Procedurestion. In the presence of MMR, the MeG/C or MeG/T mis-
pairs arising during replication are detected by the
Production of scMsh2-scMsh6 in E. coli
scMsh2/scMsh6 heterodimer, which triggers a round of The pET11a-scMSH2-scMSH6 plasmid (a kind gift of M. Hingorani)
repair. However, because MMR is directed to the newly was transformed into BL21 DE3 codon plus cells (Strategene). The
synthesized DNA strand, the modified nucleotide per- induction and purification was performed essentially as described
[19], except that ultrasonic treatment was used for cell disruption.sists in the template strand. Because the polymerase
filling the repair patch cannot find a perfect base-pair-
Oligonucleotide Substratesing partner for MeG, it may leave a gap or a similar
The 34-mers 34TopG (AATTCCCGGGGATCCGTCGACCTGCAGCClesion that could be repaired by HR. In the absence of
AAGCT), 34TopMeG (AATTCCCGGGGATCCGTCMeGACCTGCAGC
HR, the gap would be converted during the next repli- CAAGCT), 34BottomT (AGCTTGGCTGCAGGTTGACGGATCCCCG
cation round to a double-strand break that might trig- GGAATT) and 34BottomC (AGCTTGGCTGCAGGTCGACGGATCC
CCGGGAATT) were synthesized by Microsynth (Balgach, Switzer-ger cell-cycle arrest and cell death.
land) and purified by polyacrylamide gel electrophoresis (the sitesIn summary, we show that damage reversal by
of mismatch or base modification are underlined). Despite the factscMgt1p, along with methylation damage processing
that Microsynth strictly adhered to the protocol for MeG incorpora-and repair by HR, mask the sensitivity of MMR-profi-
tion into the oligonucleotide, as recommended by the manufacturer
cient S. cerevisiae cells toward killing by SN1-type of the corresponding phosphoramidite (Glenn Research, USA),
methylating agents. Inactivation of MMR in the mgt1 mass-spectrometric analysis by NanoESI revealed that a substan-
tial part of the MeG-containing oligonucleotide still contained therad52 yeast background rendered cells approximately
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Figure 4. Model of MMR-Induced Killing
upon Treatment with Methylating Agents
See text for details.
isobutyryl protecting group on the exocyclic nitrogen of the methyl- glycerol, 0.33 mg/ml BSA, 25 mM HEPES [pH 8.0], 0.5 mM EDTA,
and 0.5 mM DTT) were incubated for 20 min at room temperatureated guanine. The fully deprotected oligonucleotide had to be sep-
arated from the contaminant by reverse-phase HPLC, for which a in a total volume of 30 l. The reaction products were separated
on 6% polyacrylamide gels (acrylamide:bisacrylamide ratio 19:1) atNucleosil 100Å, C18, 5 m, 250 × 4.0 mm column (BGB Analytik)
eluted with a linear gradient of 5%–20% acetonitrile in 100 mM room temperature at 150V for 85 min. The gels were dried and
scanned with the Typhoon 9400 imager and ImageQuant TL soft-triethylamonium acetate (pH 7) was used. The “bottom” oligonucle-
otides were radioactively labeled with [γ-32P]-ATP (Amersham Bio- ware (both Amersham Biosciences).
sciences) and polynucleotide kinase (New England Biolabs) and
purified on Sephadex G25 columns. Three pmol of the labeled Yeast Media
For unselective growth, YPD medium (2% glucose, 2% bactopep-“bottom” oligonucleotides were then annealed with 4.5 pmol of the
cold top oligonucleotides in 1× polynucleotide kinase buffer by tone, and 1% yeast extract) was used. Clones where the gene of
interest was replaced by the KANMX cassette were selected onbrief heating to 95°C and slow cooling to room temperature. In
this way we obtained the duplex substrates G/C, G/T, MeG/C, and YPD plates supplemented with 200 g/ml G418 (Invitrogen). Where
necessary, the media were solidified by 2% agar (Difco). All yeastMeG /T.
strains were propagated under aerobic conditions at 30°C.
Gel-Shift Experiments
The indicated amounts of purified S. cerevisiae Msh2p/Msh6p pro- Yeast Strains and Transformation
The yeast strains used in this study were all isogenic derivatives oftein (diluted where necessary in 50 mM NaCl, 25 mM Tris.HCl [pH
8.0]) and 6.6 nM of the labeled substrate in binding buffer (10% FF18733 and FF18734 S. cerevisiae strains (a kind gift of F. Fabre)
Table 1. S. cerevisiae Strains Used in This Study
Strain Relevant Genotype Source
FF18733 MATa; leu2-3, 112; ura3-52; his7-2; lys1-1, trp1-289 F. Fabre
ZS30 FF18733 with msh2::KANMX Z. Storchova
EP82 FF18733 with mlh1::KANMX E. Papouli
FPC 45 FF18733 with rad52::URA3 this study
FPC 1-1 FF18733 with mgt1::KANMX this study
FPC 50 FF18733 with exo1::KANMX this study
FPC 32 FF18733 with mgt1::KANMX; rad52::URA3 this study
FPC 24 FF18733 with rad52::URA3; msh2::KANMX this study
FPC 37 FF18733 with rad52::URA3; mlh1::KANMX this study
FPC 3-3b FF18733 with mgt1::KANMX; msh2::KANMX this study
FPC15 FF18733 with mgt1::KANMX; mlh1::KANMX this study
FPC 52 FF18733 with rad52::URA3; exo1::KANMX this study
FPC 55 FF18733 with mgt1::KANMX; exo1::KANMX this study
FPC 21 FF18733 with mgt1::KANMX; rad52::URA3; msh2::KANMX this study
FPC 61 FF18733 with mgt1::KANMX; rad52::URA3; exo1::KANMX this study
FPC 39 FF18733 with mgt1::KANMX; rad52::URA3; mlh1::KANMX this study
FF18734 MATα; leu2-3, 112; ura3-52; his7-2; lys1-1, trp1-289 F. Fabre
ZS30-1d FF18734 with msh2::KANMX this study
EP 85 FF18734 with mlh1::KANMX E. Papouli
FF18743 FF18734 with rad52::URA3 F. Fabre
FPC 2-1 FF18734 with mgt1::KANMX this study
FPC 51 FF18734 with exo1::KANMX this study
FPC 30 FF18734 with mgt1::KANMX; rad52::URA3 this study
FPC 28 FF18734 with rad52::URA3; msh2::KANMX this study
EP 95 FF18734 with rad52::URA3; mlh1::KANMX E. Papouli
FPC 3-2a FF18734 with mgt1::KANMX; msh2::KANMX this study
FPC 16 FF18734 with mgt1::KANMX; mlh1::KANMX this study
FPC 54 FF18734 with rad52::URA3; exo1::KANMX this study
FPC 58 FF18734 with mgt1::KANMX; exo1::KANMX this study
FPC 22 FF18734 with mgt1::KANMX; rad52::URA3; msh2::KANMX this study
FPC 59 FF18734 with mgt1::KANMX; rad52::URA3; exo1::KANMX this study
FPC 43 FF18734 with mgt1::KANMX; rad52::URA3; mlh1::KANMX this study
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and are listed in Table 1. Replacement of the MMR genes was per- 3. Xiao, W., Rathgeber, L., Fontanie, T., and Bawa, S. (1995). DNA
mismatch repair mutants do not increase N-methyl-N#-nitro-N-formed with kanMX4 replacement cassettes with specifically de-
nitrosoguanidine tolerance in O6-methylguanine DNA methyl-signed primers (see below), with pUG6 (MSH2, MGT1, and EXO1)
transferase-deficient yeast cells. Carcinogenesis 16, 1933–or pFA6a-kanMX4 (MLH1) plasmids being used as templates for
1939.polymerase chain reactions (PCR), essentially as described [20].
4. Ryttman, H., and Zetterberg, G. (1976). Induction of mitotic re-The primer sequences for gene disruption were as follows (forward,
combination with N-methyl-N#-nitro-N-nitrosoguanidine (MNNG)reverse primer):
in Saccharomyces cerevisiae. A comparison between treat-
ment in vitro and in the host-mediated assay. Mutat. Res. 34,MSH2, GACACTCTACTCCAATATCAACTGTAAAAAATCTCTTTAT
201–216.CTGCTGGACCTAACATCAAAATCCTCAGATTAAAAGGAGCTGA
5. Zhang, H., Marra, G., Jiricny, J., Maher, V.M., and McCormick,AGCTTCGTACGC, CTTTCCAATGCATATTATATGTACTATTTGTA
J.J. (2000). Mismatch repair is required for O(6)-methylguanine-TCTATATATTATCTATCGATTCTCACTTAAGATGTCGTTGTAATAT
induced homologous recombination in human fibroblasts. Car-TAATTATAACAACGCATAGGCCACTAGTGGATCTG;
cinogenesis 21, 1639–1646.MLH1, ATAGTGATAGTAAATGGAAGGTAAAAATAACATAGACCTA
6. Kaina, B. (2004). Mechanisms and consequences of methylat-TCAATAAGCACAGCTGAAGCTTCGTACGC, AAAGGAAAGGGC
ing agent-induced SCEs and chromosomal aberrations: A longATACACTTTCAAATGAAACACAATCACACTCAGGAAATGCATA
road traveled and still a far way to go. Cytogenet. Genome Res.
GGCCACTAGTGGATCTG;
104, 77–86.
MGT1, TGGCAGGGCATTTAAAATGCGGTGGAAACAAGGAAGAT
7. Fasullo, M., Zeng, L., and Giallanza, P. (2004). Enhanced stimu-
TAATCAAGTAATGATATAGCATCAGCTGAAGCTTCGTACGCTGC lation of chromosomal translocations by radiomimetic DNA
AG, CAATTTACCACATATACATAACTATTTCTTATGTTTATTTTCC damaging agents and camptothecin in Saccharomyces cere-
TAAAATCCTTTATCCAAGCATAGGCCACTAGTGGATCTG; visiae rad9 checkpoint mutants. Mutat. Res. 547, 123–132.
EXO1, TGCTTTTTGGACCACATTAAAATAAAAGGAGCTCGAAAAA 8. Tishkoff, D.X., Boerger, A.L., Bertrand, P., Filosi, N., Gaida,
ACTGAAAGGCGTAGAAAGGACAGCTGAAGCTTCGTACGCTG G.M., Kane, M.F., and Kolodner, R.D. (1997). Identification and
CAG,TTCGACGAGATTTTCATTTGAAAAATATACCTCCGATATG characterization of Saccharomyces cerevisiae EXO1, a gene
AAACGTGCAGTACTTAACTTGCATAGGCCACTAGTGGATCTG. encoding an exonuclease that interacts with MSH2. Proc. Natl.
Acad. Sci. USA 94, 7487–7492.
The transformations were performed by the lithium-acetate 9. Tran, H.T., Gordenin, D.A., and Resnick, M.A. (1999). The
method. The genotypes of all strains used were verified by PCR 3#/5# exonucleases of DNA polymerases delta and epsilon
(primer sequences and details are available on request), Southern and the 5#/3# exonuclease Exo1 have major roles in postrep-
blotting, and tetrad analysis. lication mutation avoidance in Saccharomyces cerevisiae. Mol.
Cell. Biol. 19, 2000–2007.
10. Xiao, W., Derfler, B., Chen, J., and Samson, L. (1991). PrimarySpot Tests
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5 CONCLUSIONS AND PERSPECTIVES 
 
Mismatch repair is highly conserved from bacteria to man. It increases the fidelity of 
DNA replication by ∼1000 fold through correcting the errors that escaped the 
proofreading activity of the replicative polymerases. The importance of functional MMR 
has been highlighted by the discovery that defects in the correction of replication errors 
are linked to hereditary non-polyposes colorectal cancer (HNPCC), as well as significant 
proportion of sporadic colon cancers. Besides maintaining genome stability by correcting 
replication errors, MMR also participates in other DNA transactions such as homologous 
recombination. Of particular interest to clinical applications is the finding that MMR-
deficient cells display resistance to certain types of DNA damaging agents used in 
chemotherapy. The most prominent effect has been observed with SN1-type methylating 
agents, where MMR-deficient cells can tolerate ∼100-fold higher concentrations than 
MMR-proficient ones.  
So far, studies of MMR-dependent DNA metabolism relied on cell lines, which were 
either derived from MMR-deficient tumours or were selected by long-term treatments 
that favoured loss of MMR activity. Such cell lines have high mutation rates and long 
term passaging thus causes a genetic drift from their MMR-proficient counterparts. 
Establishment of a cell line in which expression of a single MMR protein, namely MLH1, 
can be regulated by doxycylin is an important contribution to the field. Cejka et al. 
characterized 293T Lα cells and showed that only a full complementation of MLH1 
brings about G2/M arrest upon MNNG treatment, although MMR proficiency was 
achieved with suboptimal levels of the protein. This finding has important implications 
when considering treatments of MMR-proficient tumours. Absence of cell cycle arrest 
and associated cell death favours tumour progression and accumulation of additional 
mutations. 
Cytotoxicity of SN1-type methylating agents has been attributed to formation of 6-
methyguanine (6meG) residues in the DNA. Under normal conditions, the methyl group 
can be rapidly removed by detoxifying enzyme MGMT. If left unreapired, it is addressed 
by the MMR machinery during subsequent replication. The mechanism that transforms 
6meG into a cytotoxic lesion has been the subject of many studies, but the precise role of 
MMR has been controversial. One hypothesis suggested that MMR proteins have a direct 
signalling role, and that formation of 6meG -containing mispairs can be sensed by the 
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MutSα-MutLα complex, thus transmitting the signal downstream to the checkpoint 
machinery. The nature of the cell cycle arrest after MNNG treatment is contradictory to 
this hypothesis and Stojic et al. showed that additional processing of the initial lesions is 
required in order to activate cell cycle checkpoint responsible for the sustained arrest. 
In vivo activation of ATM was MMR-dependent but not required for the arrest, indicating 
that another kinase, ATR, could play a role in the activation of the checkpoint. Indeed, 
the ATR-CHK1 pathway was shown to be required for the MMR-dependent arrest. The 
late onset of the cell cycle arrest after MNNG treatment indicates that 6-methylguanine 
per se is not sufficient for the checkpoint activation; rather, it requires two cell cycles to 
exert its cytotoxic effect. The lesions created by MMR and the subsequent processing 
were shown to contain ssDNA as indicated by formation of RPA and RAD51 foci, as 
well as sustained persistence of single strand breaks in comet assays.  
Next, we showed that the recognition of MNNG–induced damage by MutSα occurs in 
the first S phase, during which decoupling of replication and repair foci becomes 
apparent. Although MMR recognizes 6meG-containing mispairs already in the first cell 
cycle, persistence of 6meG in the DNA is required throughout the two cell cycles to 
activate the checkpoint. We showed that in order for the cells to pass to the second cell 
cycle, homologous recombination is required for the processing of the lesions generated 
during the first S phase. Absence of efficient homologous recombination arrests cells at 
the first G2/M boundary and has a dramatic influence on overall survival. The finding 
that the cytotoxicity of a single lesion can be attributed to more than one repair 
mechanism highlights the importance of multi-pathway activation. Processing of 6meG 
adducts by MMR creates substrates for homologous recombination, which in turn fails to 
repair the intermediates, thus causing cell death. From the clinical perspective, this 
finding can be of interest, because inactivation of homologous recombination could 
enhance the cytotoxic effect of methylating agents, thus allowing the use of lower doses, 
with less severe side-effects.  
The use of biophysical methods will be of extreme importance in the charcaterisation of 
structures of DNA intermediates that cause cytotoxicity. 
The finding that homologous recombination rescues DNA intermediates created by 
MMR-dependent processing after MNNG treatment was shown to be even more 
pronounced in yeast. Recombination-proficient yeast cells are highly resistant to MNNG 
treatment, even so that the difference between MMR-proficient and deficient cells 
cannot be discovered. This paradigm was explained when recombination-deficient yeast 
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cells were shown to be highly sensitive to killing by MNNG, and that inactivation of 
MMR rescued this sensitivity.  
The establishment of a yeast system provides invaluable tool for further genetic tests, 
with the goal of identifying novel components of both the MMR pathway and the 
recombination machinery. The existence of an analogy with the human mechanism 
offers a solid base for these future studies. 
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MMR status of the cell lines used during the study. Western-blot for MMR proteins in DNA-PK cells (MO59J
and MO59K), FANCD2 cells (PD20 and PD20+FANCD2), NBS cells (NBS and NBS+NBS1) and ATLD1 cells
(ATLD1 and ATLD1+MRE11). All the cell lines were shown to express MMR proteins and were MMR-proficient.
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293T Lα+
293T Lα-
RPA
Control 1 hr 6 hr 12 hr 24 hr 48 hr
IR (10 Gy)
Kinetics of the formation of RPA foci in 293T Lα cells upon ionazing radiation (IR).
Unlike upon MNNG treatment, where relocalisation of RPA into foci was MMR dependent, IR-induced foci formed
independently of MMR status.
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BRCA1
FANCD2
HeLa HeLa-clone 12
c 24 48 72 c 24 48 72
TFIIH
0.2 µM MNNG 0.2 µM MNNG 
MMR-dependent activation of BRCA1 and FANCD2 upon MNNG treatment. HeLa-clone 12, due to the loss
of PMS2, is a MMR-deficient cell line. It was selected from parental HeLa cells through long-term treatment with
MNNG.
Activation of BRCA1 was observed only in MMR-proficient cells, already 24 hours after treatment. The slower
migrating form represents phosphorylated BRCA1 protein. BRCA1 is involved in homologous recombination through
its interaction with RAD51, as well as signalling downstream to the checkpoint machinery.
Monoubiquitylation of FANCD2 is a consequence of activation of Fanconi anaemia pathway and occurs in MMR-
proficient cells upon MNNG treatment. The monoubiquitylated  form of FANCD2 is actively recruited to the
chromatin, where it is thought to be engaged in repair processes, particularly homologous recombination.
Asynchronous
24 hr
48 hr
72 hr
0.2 µM MNNG
PD20
(FANCD2-/-)
PD20 + FANCD2
(FANCD2+)
The Fanconi anaemia pathway is involved in MMR-dependent response upon MNNG treatment.
Cell cycle analysis and survival of FANCD2-proficient and -deficient cell lines upon MNNG treatment. Checkpoint
activation and subsequent arrest is more pronounced in FANCD2-deficient cell line, indicating its requirement for the
processing of DNA intermediates. This requirement is highlighted in cell survival, pointing out that the Fanconi
anaemia pathway is involved in the repair of cytotoxic lesions created by MMR-dependent processing.
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Cell cycle distribution of DNA-PK cells upon MNNG treatment. As a major player in NHEJ pathway, DNA-PK
might be involved in the repair of possible DSB intermediates created by MMR processing of 6meG residues. Cell cycle
arrest was shown to be identical in these two non-isogenic cell lines, indicating the absence of, or a minor role of
DNA-PK in the cell survival upon MNNG treatment.
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